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ABSTRACT 
 
Abnormal folding and hyperphosporylation of tau protein leads to the generation of paired 
helical filaments (PHFs) and neurofibrillary tangles (NFTs), a key neuropathological hallmark of 
Alzheimer’s disease and other tauopathies. Cellular models able to recapitulate tau pathology 
are useful for understanding disease mechanisms and screening and profiling compounds that 
interfere with tau aggregation. We have established a HEK T-REx cell culture model where the 
inducible expression of mutant tau, accompanied by the introduction of aggregated mutant tau 
extracted from transgenic mouse brain, leads to endogenous tau aggregation and filament 
assembly, suggesting a seeding process as a likely mechanism underlying NFT formation. We 
found that substantial aggregation of soluble tau into Triton X-100-insoluble tau can be induced 
by spontaneous uptake of mutant tau aggregates, which are internalised through an endocytic 
mechanism that is temperature-, time- and ATP-dependent, can be potentiated by transfection 
reagents and impaired by pharmacological agents inhibiting macropinocytosis, suggesting a 
potential mechanism for the propagation of tau pathology in tauopathy brains. We also found 
that seed-competent tau species are sarkosly-insoluble, tagged by AT8 and MC1 antibodies, 
and are present in conditioned media from seeded cells. Finally, we established a more 
physiologically relevant model of seeded tau aggregation in rodent neurons. In summary, our 
study establishes cell-based tauopathy models that not only provide mechanistic insights into 
the pathogenesis of tau aggregation, but also offer a robust system for identifying therapeutic 
strategies to prevent propagation and spreading of tau pathology. 
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1. INTRODUCTION 
 
1.1 Tau  
Tau is a microtubule (MT)-binding protein predominantly expressed in neurons, that stabilizes 
and promotes the assembly of MTs (Witman et al. 1976, Drechsel et al. 1992), and whose 
interactions with MTs are negatively regulated by phosphorylation (Biernat et al. 1993, 
Bramblett et al. 1993). Tau is encoded by the MAPT gene on chromosome 17q21 (Lewis et al. 
2001, Neve et al. 1986), and in humans, alternative splicing of the mRNA at exons 2, 3, and 10 
results in 6 tau isoforms (Figure 1.1). These isoforms differ by the presence or absence of none 
(0N), one (1N) or two (2N) 29 aminoacid N-terminal acidic inserts –projection domain- and three 
(3R) or four (4R) repeat domains (RD) at the C-terminal tubulin-binding motif, separated by a 
central proline-rich region. 4R tau has higher affinity for microtubules than 3R tau, and 
consequently higher efficiency at promoting microtubule assembly, but also higher propensity 
for self-aggregation (Goedert, Jakes 1990, Greenberg, Davies 1990, Greenberg et al. 1992, 
Gustke et al. 1994). The various isoforms are differentially expressed during development, 
nevertheless, the 3R and 4R tau isoforms are expressed in a one-to-one ratio in most regions of 
the adult brain, and deviations from this ratio are characteristic of neurodegenerative 
tauopathies (Hong et al. 1998); the 2N isoform is underrepresented compared to the 0N and 1N 
isoforms (~9%, 37%, 54% of total tau, respectively) (Goedert, Jakes 1990). The expression and 
splicing pattern of tau in the human brain also present regional variation, with protein levels two 
times higher in the neocortex than in white matter and cerebellum, and these variations may 
explain the differential vulnerability of brain regions to tau pathology (Trabzuni et al. 2012). A 
“big Tau” isoform with 695 aminoacids is expressed predominantly in the peripheral nervous 
system, likely due to larger diameter of axons, and it is equivalent to 2N4R plus 242 residues 
from exon 4a (Couchie et al. 1992, Goedert, Spillantini & Crowther 1992). Tau is a naturally 
unfolded soluble protein, lacking significant amounts of secondary structure under normal 
conditions, with a preference for adopting a paperclip-like shape in which the N-terminal, C-
terminal and repeat domains are in close proximity (Jeganathan et al. 2006), which may protect 
tau from aggregation, as events that prevent formation of the hairpin structure, i.e. truncation, 
can facilitate tau aggregation (Wang et al. 2007). Tau conformation changes from random coil to 
highly ordered β-pleated sheet structures as it assembles into insoluble, hyperphosphorylated 
paired helical filaments (PHFs) as well as less frequent straight filaments (SFs) that constitute 
neurofibrillary tangles (NFTs) in AD and related tauopathies (Kidd 1963, Berriman et al. 2003). 
In PHFs, the repeat domains constitute the beta-sheet core, whereas the short C-terminal and 
the long N-terminal domain form a “fuzzy coat” which supposedly stabilises the PHFs. Tau is the 
most commonly associated misfolded protein in human neurodegenerative diseases, based on 
the predominance of disorders involving tau neuropathology. 
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Clone Inserts/repeats Number of aminoacids MW (KDa) 
htau40 2N4R 441 45.9 
htau39 2N3R 410 42.6 
htau34 1N4R 412 43.0 
htau37 1N3R 381 39.7 
htau24 0N4R 383 40.0 
htau23 0N3R 352 36.7 
big tau 2N4R + exon 4a 695 72.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Domain structure of the tau isoforms expressed in the adult human brain. Tau 
isoforms differ in the number of tubulin-binding domains (three or four C-terminus repeats, R1-
R4, grey); the presence or absence of none, one or two 29-amino acid long acidic inserts (N-
terminus, blue) and a proline rich region in between these two. Adapted from (Ballatore, Lee & 
Trojanowski 2007). 
 
1.2 Tauopathies 
 
1.2.1 Classification of tauopathies 
Tauopathies are characterized by intracellular aggregation of abnormally phosphorylated tau 
(Kosik, Joachim & Selkoe 1986, Pollock, Mirra & Binder 1986, Goedert et al. 1988, Lee et al. 
1991). They include Alzheimer’s disease (AD), argyrophilic grain disease (AGD), progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease (PiD), primary age-
related tauopathy (PART), formerly known as tangle-only dementia (TD), and frontotemporal 
dementia and parkinsonism linked to chromosome 17 (FTDP-17T), the latter being caused by 
mutations in MAPT (Hutton et al. 1998, Spillantini et al. 1998, Rizzu et al. 1999, Goedert, Jakes 
2005). The causal link between tau abnormality and neuronal dysfunction is underscored by the 
significant correlation between total NFT burden and cognitive decline observed in AD patients 
(Wilcock, Esiri 1982, Arriagada, Marzloff & Hyman 1992) and also by the existence of an 
increasing number of dominantly inherited mutations in the MAPT gene in frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17) (Hutton et al. 1998, Spillantini 
et al. 1998, Rizzu et al. 1999, Goedert, Jakes 2005). For a full up-to-date database, see 
http://www.molgen.vib-ua.be/FTDMutations/. Tauopathies share a common molecular 
 352 
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mechanism and have lesions in common, such as gross brain atrophy, nerve cell loss, gliosis, 
superficial spongiosis and ballooned neurons, but the tau isoforms involved, the morphology of 
the inclusions, the cell type involved, the cellular tau pathology, the selective vulnerability of 
anatomic systems and the clinical presentations significantly vary across disease types 
(Clavaguera et al. 2013, Murray et al. 2014) (Table 1). 
 
Table 1: Neurodegenerative diseases with tau inclusions. Adapted from (Murray et al. 
2014). 
Pathologic diagnosis Histologic tau findings 
Alzheimer’s disease NFTs found in neocortex and limbic regions. Intracellular NFTs 
are found to be both 3R and 4R tau-positive with a preferential 
shift to 3R immunoreactivity in extracellular NFTs. 
Amyotrophic lateral sclerosis 
of Guam 
NFTs positive for 3R and 4R found in neocortex and limbic 
areas with a predilection for cortical layer II. 
Argyrophilic grain disease Spindle-shaped, 4R tau-positive lesions accumulate in neuronal 
processes. Grains are typically found in the neuropil of limbic 
areas, but can be found diffusely deposited in cortex. Coiled 
bodies in oligodendrocytes and tau-positive pretangles can be 
abundantly found. 
Chronic traumatic 
encephalopathy 
Widespread NFTs, tau-immunoreactive astrocytic inclusions, 
and neuritic pathology can be found with a predilection for 
superficial cortical layers and sulcal depths. Irregular, patchy 
tau pathology observed in cortex. 
Corticobasal degeneration 4R tau-positive ballooned neurons, astrocytic plaques, and 
neuropil threads are found in both gray and white matter of 
cortical and striatal regions. Diffuse neurofibrillary tangles with 
calcification NFTs and neuropil threads found diffusely 
deposited in frontal and temporal cortex, as well as limbic 
areas. 
Down’s syndrome NFTs and granulovaculoar degeneration can be found in the 
hippocampus. 
Familial British dementia NFTs and neuropil threads found relatively restricted to limbic 
regions. 
Familial Danish dementia NFTs and neuropil threads found in limbic with abnormal 
neurites limited to amyloid-laden blood vessels and variable 
involvement of cortical regions. 
Frontotemporal dementia and 
parkinsonism linked to 
chromosome 17 (caused by 
MAPT mutations) 
Widespread neuronal and glial cytoplasmic inclusions 
immunopositive for 3R, 3+4R, or 4R tau. Morphology of lesions 
varies with reportedly observed coiled bodies, tufted astrocytes, 
and astrocytic plaques. 
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Frontotemporal lobar 
degeneration (some cases 
caused by C9ORF72 
mutations) 
NFT pathology can be found in a similar Alzheimer’s-like limbic 
and cortical distribution. 
 
Gerstmann–Sträussler–
Scheinker disease 
Tau pathology can be absent, not reported, or inconsistently 
reported as widespread neurofibrillary pathology depending on 
the PRNP mutation. 
 
Guadeloupean parkinsonism 
Widespread neurofibrillary pathology can be found as NFTs, 
neuropil threads, and astrocytic tufts. Myotonic dystrophy NFTs 
in limbic and brainstem regions. 
Neurodegeneration with brain 
iron accumulation 
Diffuse neuritic pathology in cortex, but rare NFT pathology. 
 
Niemann–Pick disease, type 
C 
NFTs, neuropil threads, and oligodendroglial coiled bodies 
range from transentorhinal confinement to widespread limbic 
and cortical involvement. 
Non-Guamanian motor 
neuron disease with 
neurofibrillary tangles 
NFTs can be found in limbic structures, midbrain, and pontine 
nuclei. 
 
Parkinsonism–dementia 
complex of Guam 
NFTs positive for 3R and 4R found in cortical areas with a 
predilection for cortical layers II and III. Tau pathology is also 
found in limbic, basal ganglia, brainstem, and spinal cord. 
Granular hazy tau inclusions are found in motor cortex, 
amygdala, and inferior olivary nucleus. 
Pick’s disease Widespread spherical cytoplasmic 3R tau-positive inclusions 
(Pick bodies) can be found in hippocampus, basal ganglia, 
brainstem nuclei, and especially cortex. 
Postencephalitic 
parkinsonism 
Widespread tau-positive neuronal and glial lesions. Globose 
NFTs are a prominent feature in brainstem nuclei, especially 
substantia nigra and locus coeruleus. NFTs are more common 
in limbic structures than cortex, and have a predilection for 
layers II and III. 
Progressive supranuclear 
palsy 
4R tau-positive globose NFTs, tufted astrocytes, and coiled 
bodies are often found in the subthalamic nucleus, globus 
pallidus, ventral thalamus, cerebellar dentate nucleus, and 
variable involvement of cortex. 
SLC9A6-related mental 
retardation 
Glial tau pathology, resembling coiled bodies, can be found in 
brainstem and cerebellar white matter tracts. Astrocytic plaques 
can also be found in brainstem, thalamus, and cerebral white 
matter. NFT-like inclusions can be found in brainstem and 
thalamic nuclei, hippocampus, and cortex. 
Subacute sclerosing Glial fibrillary tangles can be found in oligodendroglia. NFTs 
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panencephalitis can be found differentially distributed in hippocampus and/or 
cerebral cortex. 
Tangle predominant 
dementia 
4R predominant NFT accumulation relatively combined to 
limbic regions. 
White matter tauopathy with 
globular glial inclusions 
Widespread globular oliogdendroglial inclusions, less so in 
astroglial, immunoreactive for 4R-tau 
 
Thus, the neuronal inclusions found in  AD and TD are composed of both 3R and 4R tau 
isoforms (Goedert et al. 1992, Noda et al. 2006), whereas in PiD tau, isoforms with 3 repeats 
predominate in the neuronal deposits (Delacourte et al. 1996), and PSP, CBD and AGD 
(Flament et al. 1991, Ksiezak-Reding et al. 1994, Togo et al. 2002, Tolnay et al. 2002) are 
characterised by assembly of 4-repeat tau into filaments. PSP and CBD are 4-repeat 
tauopathies, but their tau cleavage products vary in size. Detergent-insoluble cleaved tau from 
PSP migrates as a single band of 33 kDa, whereas that of CBD migrates as a doublet of 37 kDa 
(Arai et al. 2004). FTDP-17T inclusions are composed predominantly of 3 repeats, 4 repeats or 
a mixture of all 6 brain tau isoforms, depending on the underlying MAPT mutations (Ghetti et al. 
2011). The distinct migration of the full length tau species aids the classification of tauopathies: 
in AD, the 6 brain tau isoforms are detected by immunoblotting as a major tau triplet (tau 60, 64 
and 69); in CBD and PSP, mainly 4R tau isoforms form aggregates, and they appear as a major 
tau doublet (tau 64 and 69); in PiD the doublet tau 60 and 64 represents filamentous tau 
deposits predominantly made of 3R isoforms (Tolnay et al. 2002). As regards to the  
morphology of the filaments, in AD and TD tau inclusions occur in the form of neurofibrillary 
tangles (NFTs) located in the somatodendritic compartment, and neuropil threads (NTs) found 
in distal axons and dendrites. In AGD, argyrophilic grains in neuronal processes, pre-tangle 
neurons in limbic areas and glial tau inclusions in astrocytes and oligodendrocytes make up the 
hallmark lesions (Botez et al. 1999, Tolnay, Clavaguera 2004). Neuropathologically, PSP brains 
present neuronal tau inclusions known as globose-type NFTs and NTs (Probst et al. 1988), as 
well as by glial changes in the form of tufted astrocytes and oligodendroglial coiled bodies 
(Nishimura et al. 1992, Yamada, McGeer & McGeer 1992). In CBD brains, intracytoplasmic 
pathological tau in NTs, pre-tangle neurons or small NFTs, as well as astrocytic plaques and 
coiled bodies are found (Feany et al. 1995, Komori et al. 1998, Tolnay, Probst 2002). In PiD, 
Pick bodies are mainly present in neocortical, hippocampal and subcortical nerve cells (Probst 
et al. 1996). FTDP-17T brains are characterised by severe nerve cell loss, astrocytic gliosis and 
spongiosis, with filamentous tau inclusions in nerve cells and/or glial cells. A recent 
breakthrough in understanding the conformation of amyloid fibrils in AD came from cryo-EM 
studies by Fitzpatrick et al., who produced an atomic model of PHFs and SFs from the brain of 
an individual with AD. While the core of both PHFs and SFs consists of two identical C-shaped 
protofilaments comprising tau R3 and R4 domains (residues 306–378), the inter-protofilament 
packing is different between the 2 types of filaments; the rest of the protein forms a “fuzzy coat” 
around the 3R-4R core; the model included a putative binding site for the PET tracer 
AV1451/flortaucipir; this is the first molecular-level structure of tau fibrils from AD brain, and this 
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technique could be applied to unveil the structure of other disease-related amyloid fibrils and 
help inform structure-based drug design (Fitzpatrick et al. 2017). 
 
1.2.2 Pathological tau aggregation 
The process by which MT-bound tau is converted to large aggregate structures such as NFTs is 
suggested to be a multi-step path, which begins with the detachment of tau from the MTs 
(Ballatore, Lee & Trojanowski 2007). The exact mechanism by which this first step occurs 
remains unknown, however, it is thought that phosphorylation and dephosphorylation patterns, 
tau gene mutations and covalent post-translational modifications of tau amongst others trigger 
the disengagement of tau. Under physiological conditions, tau phosphorylation patterns are 
under tight regulation by kinases and phosphatases, so that tau is phosphorylated at multiple 
serine and threonine residues when bound to MTs (Avila et al. 2006). The microtubule binding 
domains of tau contain a number of lysine residues, whose positive charges drive binding to 
negatively charged microtubules (Kolarova et al. 2012). Increased phosphorylation on serine 
and threonine sites on tau disrupts the charge balance and results in reduced tau binding to 
MTs and/or greater propensity for tau to assemble into fibrils (Del et al. 1996, Wagner et al. 
1996, Merrick, Trojanowski & Lee 1997). After dissociation from MTs, higher concentrations of 
free intracellular tau increase the likelihood of pathogenic conformational changes to occur, 
ultimately resulting in aggregation and fibrillization of tau. Further fibrillization is facilitated by 
proteolytic cleavages (Binder et al. 2005, Gamblin et al. 2003, Fasulo et al. 2000), as truncated 
tau assembles much faster than its native form, probably owing to disruption of the paperclip 
structure. Small non fibrillar tau deposits (pre-tangles) grow into paired helical filaments (PHF), 
characterised by β-sheet structure, hyperphosphorylation and cleavage. Finally, PHFs further 
self-assemble into NFTs (Ballatore, Lee & Trojanowski 2007) (Figure 1.2). 
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Figure 1.2: Schematic representation of the stages of pathological tau aggregation 
Adapted from (Ballatore, Lee & Trojanowski 2007). 
a) Tau-mediated neurodegeneration is likely to be initiated by disengagement of tau from 
the MTs, which results in increase of cytosolic tau. Possible causes of detachment of 
tau from the MTs include an imbalance of tau kinases and/or phosphatases, mutations 
of the MAPT gene, covalent modification of tau causing and/or promoting misfolding 
and other post-translational modifications. 
b) Tau misfolding is thought to be a stochastic phenomenon that is more likely to occur at 
higher cytosolic tau concentrations, once tau is unbound from MTs. 
c) Initial deposition of tau forms ‘pretangles’, which are not stained by β-sheet-specific 
dyes like Congo red or thioflavin-T (ThioT), indicating that these early deposits have not 
yet acquired the pleated β-sheet structure typically found in amyloid aggregates.  
d) Pretangles transition into more structurally-organized aggregates (PHFs) which then 
bundle into NFTs (e).  
 
Whatever the pathological conditions that lead to detachment of tau from microtubules, the 
resulting events are toxic: loss of function, gain of function and mislocalisation have been 
identified as the main mechanisms of tau-mediated neurodegeneration.  
 
Mutations in either exonic or intronic regions of human MAPT might cause a loss of function or a 
toxic gain of function and thereby lead to neurodegeneration (Figure 1.3). Missense mutations 
alter the sequence of tau, but may also change the alternative splicing; splicing mutations don’t 
Tau phosphorylation by 
kinases/ dephosphorylation 
by phosphatases 
Tau gene 
mutations 
Tau covalent 
modifications  
Others? 
a) Detachment of tau from the MTs. Increased unbound tau 
b) Misfolded tau 
c) Pretangles 
d) β-sheet-containing 
structures (PHFs) 
e) Filamentous 
inclusions (NFTs) 
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alter the protein sequence but change the relative ratio of different tau isoforms. Most missense 
mutations are within or near the microtubule-binding domain (G272V, N279K, ΔK280, P301L, 
V337M, R406W) and will lead to reduced affinity for microtubules and an increased tendency for 
aggregation (Hong et al. 1998, Barghorn et al. 2000). Mutations away from the microtubule-
binding domain like A152T, R5H may still cause loss of tau function (Magnani et al. 2007, 
Coppola et al. 2012). The FTD/PSP-associated tau mutation A152T still decreases the binding 
of tau to microtubules, causing microtubule disassembly (Coppola et al. 2012), and promotes 
oligomers formation. This mutation is a risk modifier to several neurodegenerative conditions 
including AD, and does not appear to cause autosomal-dominand disease, unlike the majority of 
pathogenic mutations in MAPT (Lee et al. 2013). R5H or R5L are located at the N-terminus, but 
the mechanistic effects of these mutations are poorly understood; it is possible they disrupt the 
binding of tau to the p150 subunit of the dynactin complex — an essential cofactor for the 
microtubule motor dynein, thus interfering with general axonal transport (Magnani et al. 2007). 
Most splicing mutations are within or near intron 10; they usually increase the inclusion of exon 
10 (repeat R2) and consequently the ratio of 4R/3R tau. Other mutations (ΔK280, L266V and 
G272V) inhibit the inclusion of E10 and thus reduce the 4R/3R ratio. The change in the 3R/4R 
tau ratio triggers tau aggregation as the different isoforms may bind to distinct sites on the 
microtubules, and have different microtubule-stabilizing capacities (Goode et al. 1997, Goode, 
Feinstein 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Mutations in the tau gene in FTD and FTDP-17. Adapted from (Goedert 2005). 
Schematic diagram of the 6 tau isoforms (352–441 amino acids) that are expressed in adult 
human brain, with mutations in the coding region indicated using the numbering of the 441 
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amino acid isoform. Twenty missense mutations, two deletion mutations, and three silent 
mutations are shown. 
 
Neurotoxicity from loss of tau function. Loss of normal function of tau induces structural and 
functional impairments of microtubules in axons, leading to an axonal transport deficit. Animal 
models suggest that tau function can only be partly compensated by other, redundant 
microtubule-associated proteins. Aged (~12-month-old) tau KO mice show behavioural 
impairments and structural abnormalities, suggesting that tau is necessary for normal neuronal 
and brain function (Lei et al. 2014) and long-term suppression of tau as a therapy for 
tauopathies might present complications. Loss of tau function is usually attributed to 
aggregation and post-translational modifications that may affect tau aggregation.  
Aggregation decreases levels of soluble unbound tau, which may result in microtubule 
disassembly. The two short hexapeptide motifs VQIINK (PHF6, residues 306-311) and VQIVYK 
(PHF6*, residues 275-280) display propensity for forming β-sheet structures and are required 
for tau aggregation (von Bergen et al. 2000). PHF6 is located at the beginning of the third 
microtubule binding repeat and therefore is present in all tau isoforms, whereas PHF6* is 
located at the beginning of the second microtubule binding repeat and therefore is only present 
in 4R tau isoforms. Abnormal self-assembly of tau will start with dimerization via interactions 
PHF6- PHF6,  PHF6*-PHF6*, or PHF6-PHF6* motif (Peterson et al. 2008); recruitment of tau 
monomer will produce a nucleation “seed” which will then elongate in a dose- and time-
dependent manner into oligomers, and ultimately into tau filaments (Barghorn, Mandelkow 
2002). Disruption of these PHF6 and PHF6* motifs (for example, by amino acid substitutions, 
such as proline residues mutations) render tau incompetent for assembly; by contrast, 
strengthening the β-structure (for instance, by ΔK280 or P301L mutations) promotes tau 
aggregation both in vitro and in vivo (Khlistunova et al. 2006).  
 
Phosphorylation has been assumed to drive tau aggregation because it is observed on 
aggregated tau in patients with a tauopathy or in transgenic mice, but there is now evidence that 
tau phosphorylation alone is not sufficient for its aggregation. Some forms of phospho-tau 
promote aggregation in the brain, and abnormally hyperphosphorylated tau isolated from human 
AD brains can self-assemble into PHFs in vitro (Alonso et al. 2001), but other forms of phospho-
tau (for example, in the repeat domain) protects against aggregation (Schneider et al. 1999). 
Tau aggregation can be induced in vitro efficiently by polyanionic cofactors, regardless of 
phosphorylation (Kampers et al. 1997, Goedert et al. 1996), but it is possible that 
phosphorylation accelerates aggregation indirectly; for example, hyperphosphorylation of tau at 
the repeat domain may reduce its ability to bind microtubules, causing microtubule disassembly, 
leading to axonal transport deficits (Ballatore, Lee & Trojanowski 2007, Wang, Mandelkow 
2012). Intact microtubules, functional motor proteins, correct cargo attachment to motors, and 
sufficient ATP from mitochondria are all necessary for axonal transport; as well as regulating 
microtubule dynamics, tau affects the activity of motor proteins dynein and kinesin; in particular, 
tau reduces dynein and kinesin mobility and binding frequency to microtubules, slowing both 
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anterograde and retrograde axonal transport of cargo (Seitz et al. 2002), ultimately affecting the 
axonal transport of proteins and organelles, including transport of cargo to synapses, leading to 
synapse degeneration; moreover, when untransported organelles such as mitochondria 
accumulate in the neuronal soma, energy deprivation and oxidative stress can occur, 
contributing to the progression of pathology and neuronal loss in tauopathies (Guo, Noble & 
Hanger 2017). Also, axonal and cell body accumulations of organelles and other proteins 
results in axonal swellings and spheroids observed in neurodegenerative diseases (Millecamps, 
Julien 2013). 
 
Truncation may produce tau fragments containing the repeat domain which has a higher 
tendency to aggregate, probably owing to misfolding and disruption of the soluble paperclip 
structure, leading to loss of function. In human AD brains and in the Tg4510 tauopathy mouse 
model, full-length tau is cleaved by caspase 3 at Asp421 to generate tau1–421, which is prone 
to aggregation and colocalises with NFTs, indicating that the generation of this tau fragment 
may be an early event in tangle formation (De Calignon et al. 2010).  Tau truncation at Asn368 
by asparagine endopeptidase has been observed in human AD brains and in a P301S mouse 
model of tauopathy; such truncation abolishes the microtubule assembly function of tau and 
induces its aggregation (Wang et al. 2007, Zhang et al. 2014, Fatouros et al. 2012).  
 
In addition, as tau is involved in multiple novel functions beyond its most well established role of 
stabilising microtubules, including maintaining structural integrity, axonal transport, signalling 
within and between neurons, iron transport, neurogenesis, long-term depression (LTD) and 
neuronal DNA protection (Sultan et al. 2011, Lei et al. 2012, Kimura et al. 2014), its loss of 
function may also impair these processes and lead to neurodegeneration. 
 
Neurotoxicity from gain of function. Gain of function of tau in the form of aggregation leads to 
compromised neuronal function, and possible release into the extracellular space and 
interaction with cell receptors and spreading. As the regional distribution of NFTs in the AD 
brain correlates with the severity of cognitive deficits, NFTs have long been considered the toxic 
tau species, leading to neurodegeneration. However, growing evidence has challenged this 
view, by showing that NFT formation is neither necessary nor sufficient for neurodegeneration 
(Cowan, Mudher 2013). PHFs or NFTs may actually represent a protective response, through 
which cells scavenge the toxic monomeric or oligomeric tau species and thus protect neurons 
from acute assaults (Alonso et al. 2006). In several transgenic mouse models, neuron loss is 
not correlated with tangle formation, but rather most neurons die without forming NFTs, and 
tangle-bearing neurons appear to survive without functional impairments (Andorfer et al. 2005, 
Spires-Jones et al. 2008). In AD brains, tangle-bearing neurons survive for ~20 years (Morsch, 
Simon & Coleman 1999), and neuron loss in the superior temporal sulcus region exceeds the 
number of NFTs more than 7-fold, implying that the majority of neurons have died without 
developing NFTs (Gomez-Isla et al. 1997). Similarly, chimeric mice produced by injecting 
human neuronal precursor cells into newborn APPPS1 mice showed selective death of human 
cells over mouse cells, in absence of tau tangles, contributing to the idea that tangles 
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themselves are not the toxic form of tau. Both mouse and human neurons accumulated 
hyperphosphorylated tau, but only the human cells contained misfolded, MC1-positive tau, 
deemed to be one of the earliest alterations of tau in AD (Espuny-Camacho et al. 2017). Instead 
of being directly toxic, these large tau aggregates may still indirectly cause toxicity by 
sequestering and depleting other functionally significant proteins and cell components, by 
affecting the localization of subcellular organelles and cytoplasm organization, and by physically 
interfering with axonal transport, leading to compromised neuronal function and 
neurodegeneration. Several studies have suggested soluble tau oligomers, rather than NFTs, to 
be the toxic species; levels of SDS-stable tau oligomers are increased in AD and PSP brains 
(Lasagna-Reeves et al. 2012, Maeda et al. 2007). However, the role of tau oligomers in 
tauopathies is controversial due to their poor characterisation: standardisation of oligomer 
preparation and assay methods among different groups will be required to pinpoint the toxic tau 
species; another issue is whether the variety of tau species with differing morphology, solubility, 
and disease-relevant properties present in vivo can actually be generated in vitro.  
 
Neurotoxicity from mislocalization. In normal neurons, only small amounts of tau localize in the 
dendritic compartment. In AD and other tauopathies, hyperphosphorylation, mutations and 
overexpression of tau can cause mislocalization of tau into presynaptic terminals, dendrites and 
postsynaptic spines, resulting in synaptic dysfunction and destabilisation of microtubules, an 
effect that can be rescued by microtubule-stabilising drugs (Hoover et al. 2010, Thies, 
Mandelkow 2007, Tai et al. 2014) as well as abnormal translocation of other proteins and 
enzymes. In fly and rat neurons, mutated tau reduces synaptic transmission by binding to 
synaptic vesicles via its N-terminal domain and interfering with presynaptic functions, including 
synaptic vesicle mobility and release rate (Zhou et al. 2017). Missorted dendritic tau mediates 
Aβ-induced neurotoxicity through various mechanisms. In cultured neurons, dendritic tau 
promotes translocation of tubulin tyrosine ligase-like enzyme 6 (TTLL6) into dendrites, where it 
polyglutamylates the microtubules increasing their susceptibility to severing by spastin, and 
leading to microtubule depolymerisation (Zempel et al. 2013). In addition, dendritic tau can act 
as scaffolding protein to deliver the kinase FYN to postsynaptic sites, where FYN 
phosphorylates subunit 2 of the NMDA receptor (NR2B), resulting in the stabilization of the 
interaction of this receptor  with postsynaptic density protein 95 (PSD95), potentiating 
glutamatergic signalling and rendering neurons susceptible to excitotoxicity mediated by Aβ 
(Roberson et al. 2007, Ittner et al. 2010).  
 
Whether disease-associated changes in tau are pathogenic because they induce a loss of its 
normal function, a novel toxic gain of function, or a combination of both is subject to debate. 
Neurodegeneration from toxic gain of function may have been the prevailing hypothesis, but as 
new results unveil yet-unexplored physiological roles of tau, apart from the well-established 
functions of microtubule stabilization and axonal transport, there is now strong evidence for both 
gain and loss of function effects; both mechanisms may contribute to neurodegeneration to 
different extents, and play separate, though complementary, roles in driving the damage which 
ultimately leads to onset and progression of tauopathies. It will be critical to develop effective 
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tau therapeutic strategies directed at overcoming tau loss of function and/or minimizing gain-of-
function caused by toxic multimeric tau species, depending on which mechanism prevails in 
each tauopathy. For instance, microtubule-stabilising would be a promising approach in 
diseases where a tau mutation causes loss of function but not in phenotypes characterised by a 
novel, microtubule-independent, gain of function, as they don’t address the accumulation of 
toxic tau aggregates. Conversely, tauopathies mainly caused by tau gain of functions could be 
ameliorated by therapeutic strategies reducing tau (i.e. by increasing its proteolysis and 
clearance), whereas such strategies could be deleterious in cases of loss-of function 
mechanisms of tau toxicity, as the sequestration of soluble tau would be exacerbated by the 
treatment; also, a study in transgenic mice with inducible tau expression showed that after 
suppression of transgenic tau expression, memory function recovered and neuronal loss 
ceased, but NFTs continued to accumulate (Santacruz et al. 2005). Therapeutic strategies 
reducing tau would have to be prolonged enough to thoroughly clear any residual seed-
competent tau species from human brains, but this long-term reduction of tau levels may pose 
safety concerns (Guo et al. 2016). 
 
1.2.3 Spreading of tau pathology 
A temporospatial spreading of tau-positive neurofibrillary lesions is observed during the clinical 
course of AD and AGD, suggesting that once tau pathology is initiated it propagates between 
neighbouring neuronal cells, possibly spreading along the axonal network. Braak and Braak 
were the first to propose a 6-tiered system of disease staging based on silver-stained, 
hyperphosphorylated tau aggregates, currently used to stage tau pathology in AD (Braak, Braak 
1991, Braak H et al. 2006, Braak, Del Tredici 2011b) (Figure 1.4). Braak stages I-II correspond 
to the appearance of NFTs in the transentorhinal and entorhinal cortex and are not associated 
with clinical dementia. Braak stages III-IV are characterised by more pronounced involvement of 
these two regions and formation of NFTs in the hippocampus, the fusiform gyrus and temporal 
cortex; these stages may see the appearance of first clinical symptoms, based on the degree of 
neuronal damage. Patients at Braak stages V-VI meet the neuropathological criteria for the 
diagnosis of AD, and present abundant spreading of NFTs to isocortical association areas, 
accompanied by severe dementia. In human brain, tau inclusions appear at a younger age than 
beta-amyloid (Aβ) plaques ((Clavaguera et al. 2013, Braak, Braak 1991, Braak, Del Tredici 
2011a), and sparse tau pathology has been described in the brains of a substantial proportion 
of individuals under the age of 30. Braak and Del Tredici reported silver-negative but AT8-
positive neuronal tau inclusions (first in proximal axons, and thereafter extending to the entire 
somatodendritic compartment) in the locus coeruleus of the majority of children and young 
adults, in the absence of Aβ deposits (Braak, Del Tredici 2011a). Hyperphosphorylated tau 
accumulated first in the locus coeruleus, from where neurons project to the transentorhinal 
cortex suggesting anterograde axonal transport of tau aggregates, followed by their neuron-to-
neuron transmission to other brain regions. In AD in particular, tau pathology initiates in the 
enthorinal cortex and locus coeruleous before becoming symptomatic; this silent tau pathology 
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is present early in life in most healthy people, but does not spread beyond these regions and is 
not associated with clinical symptoms; pathological, clinical and biomarker data indicate that 
following accumulation of a high β-amyloid load in isocortical regions, tau pathology is then 
propagated beyond enthorinal cortex and locus coeruleus with associated symptoms of AD 
(Vasconcelos et al. 2016). In AGD, a similar classification to the one by Braak and Braak for AD 
tau pathology has been proposed (Saito et al. 2004). Here, the earliest changes are restricted to 
the ambient gyrus (stage I), from where the pathological process extends to the anterior and 
posterior medial temporal lobe (stage II), followed by the septum, insular cortex and anterior 
cingulate gyrus (stage III). Stage III is typical of patients with a clinical diagnosis of dementia 
(Saito et al. 2004). 
 
 
 
 
 
 
Figure 1.4: Summary diagram of the 6 stages in the development of AD-associated tau 
pathology. Subcortical pretangle stages are marked in dark red, cortical pretangle stages and 
NFT/NT stages I–II in medium red, NFT/NT stages III–IV in light red, and NFT/NT stages V–VI 
in pink. Stages I–II show alterations that are largely confined to the upper layers of the 
transentorhinal cortex (transentorhinal stages). Stages III–IV are characterized by a severe 
involvement of the transentorhinal and entorhinal regions, with a less severe involvement of the 
hippocampus and several subcortical nuclei (limbic stages). Stages V–VI show the massive 
development of neurofibrillary pathology in neocortical association areas (isocortical stages) and 
a further increase in pathology in the brain regions affected during stages I–IV. Adapted by 
permission from Springer Nature Licence, Springer Nature, Acta Neuropathologica, (Braak, Del 
Tredici 2011b), Copyright 2011. http://www.springer.com/medicine/pathology/journal/401 
 
The molecular mechanisms of tau spreading are the focus of current intense research due to 
the potential therapeutic implications. This process would involve release of tau from a donor 
cell, followed or preceded by aggregation of tau, then uptake of tau aggregates by recipient 
cells and induction of tau aggregation in recipient cells. Some potential mechanisms are 
illustrated in Figure 1.5.  
 
 
 
 
 
Transentorhinal stages 
Braak Stage I-II 
Limbic stages 
III-IV 
Isocortical stages 
V-VI 
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Figure 1.5: Potential mechanisms mediating cell-to-cell transmission of cytosolic protein 
aggregates. Misfolded protein seeds (for example oligomers and protofibrils) first form in the 
cytoplasm of the releasing neuron (left) by seeded fibrillization, where soluble native monomers 
are recruited into large intracellular aggregates (amyloid fibrils) and a positive feedback loop can 
be initiated by generation of more seeds through fragmentation or secondary nucleation. A 
small amount of protein aggregates can be released into the extracellular space in the ‘naked’ 
form (a) or via membrane-bound vesicles such as exosomes (b). Free-floating seeds may 
directly penetrate the plasma membrane of the recipient neuron (1) or enter by fluid-phase 
endocytosis (2) or receptor-mediated endocytosis (3), whereas exosomes containing seeds may 
fuse with the membrane of the recipient neuron (4). Intercellular transfer of seeds may also 
occur by nanotubes that directly connect the cytoplasm of two cells (5). Seeds internalized by 
endocytosis are contained in endosomes (6), from which they exit (by unknown mechanism) to 
then nucleate the fibrillization of native monomers in the cytoplasm of the recipient neuron 
(right). Adapted by permission from Springer Nature Licence, Springer Nature, Nature Medicine, 
(Guo, Lee 2014), Copyright 2014. https://www.nature.com/nm/ 
 
The trans-synaptic spreading of tau has been demonstrated in vivo and in culture models 
(Clavaguera et al. 2014., Ahmed et al. 2014, Calafate et al. 2015) and it is supported by the 
temporal and spatial pattern of spreading observed in tauopathies, but alternative mechanisms 
have been proposed other than direct transfer of tau between synaptically connected neurons 
(Walsh D.M., Selkoe 2016): tau propagation could follow a pattern of selective neuronal 
vulnerability (due to factors like poor myelination (Braak, Braak 1996), high metabolic rates 
(Yan, Wang & Zhu 2013), vulnerability to toxins (Nave, Werner 2014); alternatively, tau 
propagation could follow the progression of neuroinflammation, as microglia has been 
6 
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implicated in tau propagation through phagocytosis and exosome secretion (Maphis et al. 2015, 
Asai et al. 2015). 
 
It is clear that the pathophysiological mechanisms of tauopathies are multifactorial. Several 
hypotheses have been formulated to address them, and in vivo and in vitro models of 
tauopathies have been designed to test these hypotheses. 
 
1.3 Animal models of tau aggregation and propagation 
Cellular and animal models recapitulating features of tauopathies provide a useful tool to 
investigate the causes and consequences of tau aggregation. Several rodent models have been 
developed through modulation of endogenous tau or overexpression of human wild-type tau. A 
nonexhaustive list is given below (Table 2). In addition, rodent models expressing FTDP-17 
mutant forms of tau have been developed following the discovery of the first exonic and intronic 
MAPT mutations (Hutton et al. 1998, Spillantini et al. 1998), which proved that 
neurodegeneration can be caused by genetic defects in tau. A nonexhaustive list is given below 
(Table 3). 
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Table 2. Examples of wild type (murine or human) tau transgenic mice. Adapted from 
(Dujardin, Colin & Buee 2015). 
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Table 3. Examples of mutant rodent transgenic models of tauopathies. Adapted from 
(Dujardin, Colin & Buee 2015). 
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Some sporadic tauopathies display a spatiotemporal progression of neurofibrillary degeneration. 
For example, in AD, neurodegeneration emerges in the trans-entorhinal cortex, spreads to the 
hippocampal formation, anterior temporal cortex, and polymodal and unimodal association 
areas, and eventually affects the whole cerebral cortex (Figure 1.4)(Braak, Braak 1991, 
Duyckaerts et al. 1997, Delacourte et al. 1999). To reproduce this progression, a new class of 
murine models of tauopathy based on trans-synaptic propagation have been developed, and 
recent studies provided in vivo evidence of seeded aggregation of tau in mice (Dujardin, Colin & 
Buee 2015) (Table 4). In the first study, brain extracts from mice transgenic for human mutant 
P301S tau with abundant silver-positive tau inclusions, when injected into the brains of ALZ17 
mice expressing human wild-type tau (lacking tau inclusions), induced the slow assembly of 
wild-type tau into silver-positive, filamentous and hyperphosphorylated tau species several 
months post-injection, detectable at the injection site and in closely connected brain regions, 
suggesting that tau –or a particular species of tau, such as hyperphosphorylated tau, misfolded 
tau, or a fragment of tau—may have been released at the synapses (Clavaguera et al. 2009). A 
similar mechanism was also observed after intraperitoneal injection of TgP301S brain lysates 
(Clavaguera et al. 2014). Similarly, injection of TgP301S tau extracts from the hindbrain of 
symptomatic mice into the hippocampus and overlying cerebral cortex of non-symptomatic mice 
transgenic for human P301S tau, induced the formation of tau inclusions in the hippocampus, 
which spread rapidly (2-4 weeks) to synaptically connected brain regions, showing the 
transmissibility of tau pathology (Ahmed et al. 2014). These studies led to hypotheses about the 
‘prion-like’ behaviour of tau, specifically that individual strains of misfolded tau proteins could 
recruit native tau and show intercellular propagation through the brain.  
 
The induction and spreading of tau pathology through synapses has also been demonstrated 
following the restricted expression of human mutant tau in transgenic mice; two teams 
independently developed a new transgenic model where the neuropsin promoter drives 
overexpression of aggregation-prone P301L truncated tau in the entorhinal cortex, the initial site 
of AD-like tau pathology. From layer II of the entorhinal cortex, the original site of expression, 
trans-synaptic spreading of tau pathology to the hippocampus was detected (de Calignon et al. 
2012, Liu et al. 2012). Another strategy to initiate tau pathology in a defined brain area uses 
lentiviruses (LVs) for local overexpression without diffusion; L.Buée’s team demonstrated that 
wild-type (WT) tau protein is transferred long distances through a trans-synaptic mechanism in 
vivo (Dujardin et al. 2014), whereas the neuron-to-neuron spreading of tau pathology was much 
more limited using mutated P301L tau, possibly due to the mutant protein aggregating more 
readily, leaving fewer soluble species to migrate through axons. Similar data on the mechanism 
of cell-to-cell transfer was produced in a lamprey model of tauopathies (Kim, Lee & Hall 2010b), 
which consists of the microinjection of plasmids in giant anterior bulbar neurons to induce the 
overexpression of WT or mutated human tau (Lee et al. 2009). 
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A further study has shown that intracerebral injection of brain homogenates derived from human 
tauopathies (including AD, PSP, AGD, CBD, PiD and TD) into the brains of mice transgenic for 
human wild-type tau (ALZ17) induced the formation of specific silver-positive tau inclusions 
(Clavaguera et al. 2013). Neurofibrillary tangles, argyrophilic grain and Pick bodies, similar to 
those observed in human brains, were produced upon injection of brain homogenates from AD, 
AGD and PD, respectively. This work revealed the likely existence of distinct conformers 
(strains) of assembled tau, specific for each tauopathy, because following injection of the 
corresponding brain extracts, the light microscopic hallmark lesions of each distinct tauopathy 
were recapitulated. Work in M. Diamond’s group also suggests the existence of different tau 
strains, as they injected various clones of truncated tau recombinant aggregates from HEK293 
cells into hippocampus of young TgP301S mouse brains (Sanders et al. 2014.) and observed 
that the resulting brain depositions were reminiscent of the injected clone. They were also able 
to stably propagate tau species through multiple generations of mice in a prion-like fashion, 
showing that the pathology observed in subsequent generations was not due to residual tau 
seeds from the original inoculum, and that endogenous tau was being templated with high 
fidelity; after showing that tau pathologies induced by these clones were stable through serial 
transmission in TgP301S mice, HEK cells expressing 4 tau repeat domains were seeded with 
homogenates from these brains, and formed identical inclusions to those present in the original 
cells. This is in agreement with the prion hypothesis, where misfolded tau protein strains recruit 
native tau proteins to convert them into pathological species. The same group was able to show 
that antibodies blocking tau aggregate seeding improve cognition in vivo (Yanamandra et al. 
2013b) and that tau strains may explain the diversity of human tauopathies, as they isolated a 
number of tau clones from HEK293 cells, injected into TgP301S (PS19) mouse brains and 
observed strain-specific patterns of tau pathology (Kaufman et al. 2016). 
 
Table 4: Examples of non transgenic animal models of tau propagation (based on local 
delivery). Adapted from (Dujardin, Colin & Buee 2015). 
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As regard to which molecular tau species are responsible for seeding tau pathology, different 
groups have published various hypothesis. Only aggregated tau was able to recruit endogenous 
tau in a WT mice model injected with recombinant fibrils (Holmes et al. 2013), supporting the 
initial work by Clavaguera et al. 2009. Synthetic tau fibrils injected into young mice transgenic 
for human mutant tau were able to convert soluble tau into NFT-like inclusions and induce 
widespread time- and dose-dependent transmission of AD-like pathology from the injection site 
to the interconnected brain regions (Iba et al. 2013), whereas another group showed that upon 
injection of fibrils, oligomers or monomers of tau, only oligomers were able to not only induce 
strong tau pathology at the injection site, with neurodegeneration and behavioural deficits, but 
also transmit transynaptically (Lasagna-Reeves et al. 2012, Lasagna-Reeves et al. 2011, 
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Gerson, Kayed 2013). Also in an vivo model of sporadic tauopathy, soluble/oligomeric forms of 
tau protein appear to drive spreading, rather than aggregates (Dujardin et al. 2014). 
 
All of these studies opened a new and exciting avenue to unravel the pathophysiology of 
tauopathies and expedite the development of therapeutics, but many questions remain to be 
answered about whether protein strains are the cause of different tauopathies in vivo. Cell-
based models, nevertheless, remain an invaluable tool to dissect tau aggregation mechanisms 
in a complex cellular system. 
 
1.4 Cell models of tau aggregation  
Since tau is a highly soluble and naturally unfolded protein, it has been notoriously difficult to 
make it aggregate in cultured cells and produce cell-based models that develop tau aggregates 
similar to those observed in tauopathies. Strategies employed to produce tau tangles in cells are 
summarised in Table 5 (Lim et al. 2014). E. Mandelkow's group generated tau-inducible cell 
lines that overexpressed tau via a doxycycline-inducible system, since tau overexpression was 
toxic in N2a neuroblastoma cells (Khlistunova et al. 2006).  Overexpression of truncated tau, 
that fibrillizes more readily than full-length tau (Wang et al. 2007, Khlistunova et al. 2006), 
produced robust tau aggregation in N2a cells, which was detected by a fluorescence dye, 
Thioflavin-S (ThioS). J. Kuret's group also generated a tetracycline-inducible tau cell line where 
tau aggregation was promoted by the addition of aromatic dyes such as Congo red, a known 
small-molecule aggregation inducer, to overcome the kinetic barrier of fibrillization within cells 
expressing full length tau isoform (Bandyopadhyay et al. 2007). Other groups also used 
overexpression of aggregation-prone tau mutants (Vogelsberg-Ragaglia et al. 2000) or 
treatment conditions such as tau kinases that promote pathological tau phosphorylation, which 
resulted in the formation of short tau fibrils that were detergent-insoluble and Thioflavin-S-
reactive (Sato et al. 2002). It has been reported that tau fibril assembly occurs by a nucleation-
dependent mechanism, whereby oligomeric intermediates form during an initial lag phase 
followed by a relatively rapid elongation phase (Friedhoff et al. 1998b). Therefore, Lee’s group 
used a “seeding” reaction with preformed tau fibrils added to QBI-293 cells to accelerate 
fibrillization of monomeric tau and bypass the rate-limiting nucleation step (Guo, Lee 2011); they 
demonstrated that the formation of intracellular tau tangles can be accelerated by using mutant 
tau seeds and expressing mutant tau carrying FTDP-17 associated mutations that were shown 
previously to increase the fibrillization propensity and/or reduce the MT-binding affinity of tau 
(Hong et al. 1998, Hasegawa, Smith & Goedert 1998, Nacharaju et al. 1999, von Bergen et al. 
2001). P301L, the most aggressive FTDP-17 mutation among the ones tested by Guo and Lee 
(ΔK280, P301L and R406W), dramatically promoted aggregation in a mammalian cell-based 
model, particularly when used in both exogenous seeds and cellular tau. In addition, Nonaka's 
group also introduced the treatment of exogenous tau fibrils to facilitate intracellular tau 
aggregation. In their study, full-length tau was expressed in SHSY5Y cells and tau aggregation 
was induced by the treatment of preformed tau fibrils, which act as a seed for intracellular tau 
aggregation (Nonaka et al. 2010). Other publications that showed induction of intracellular 
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aggregates by exogenously derived amyloid fibrils from tau and other proteins involved in 
neurodegenerative disorders include (Ferrari et al. 2003) (addition of pre-aggregated amyloid-β 
fibrils in SHSY5Y cells) and (Frost, Jacks & Diamond 2009) (addition of pre-aggregated 
microtubule-binding region of tau (K18) in C17.2 and HEK293 cells). Recently, modelling tau 
aggregation in human iPSC-derived neurons, whose biology resembles human neurons more 
closely than mammalian cell lines, has shown promise. One group used iPSC-derived neurons 
transduced with P301L tau seeded by heparin-aggregated P301L-K18 to detect aggregation 
measured by AlphaLisa and western blot, which could be reduced by autophagy inducers 
(Verheyen et al. 2015). Another publication claimed that their 3D human neural cell culture 
system recapitulated both Aβ and tau pathology, as they showed that 3D-differentiated neuronal 
cells expressing FAD mutations exhibited high levels of Aβ deposits, as well as detergent-
resistant, silver-positive tau filaments; β- or γ-secretase inhibitors not only decreased Aβ 
pathology, but also attenuated tauopathy, supporting the idea that accumulation of Aβ drives 
tauopathy (Choi et al. 2014). By introducing the tau repeat domain (RD) carrying the P301L and 
V337M mutations into human iPSC-derived neurons, Reilly et al. could detect endogenous 
aggregation without the addition of recombinant tau fibrils, and spreading of tau pathology 
between neurons via conditioned media (Reilly et al. 2017). 
 
Standard approaches to monitor intracellular tau aggregation require secondary methods such 
as Thioflavin-S or immuno-stains against phosphorylated tau; to directly measure intracellular 
tau aggregation, several fluorescence labels (GFP, CFP, and YFP) were introduced and 
showed tau aggregation in living cells (Nonaka et al. 2010, Lu & Kosik 2001). In addition, 
fluorescence protein technologies such as fluorescence resonance energy transfer (FRET) or 
bimolecular fluorescence complementation (BiFC) have been employed to investigate tau–tau 
interaction in living cells. During FRET, energy is transferred from a donor fluorophore (CFP) to 
an acceptor fluorophore (YFP), both tagged to the proteins of interest (Rizzo et al. 2004), only 
when those proteins in are close proximity (typically 2–6 nm), allowing differentiation of 
aggregated species from non-aggregated species in living cells. G.V. Johnson’s group co-
expressed full-length tau-CFP and caspase-cleaved tau-YFP in HEK293 cells (Chun W, 
Johnson GV 2007); when tau aggregation was induced by GSK3β, the two different tau 
isoforms bound to each other, thereby enabling the quantitation of tau aggregation. M.  
Diamond's group used a FRET technique to demonstrate trans-cellular propagation of tau 
aggregates (Kfoury et al. 2012); when they expressed K18(ΔK280)-CFP and K18(ΔK280)-YFP 
in separate cells populations, they observed a FRET signal derived from trans-cellular 
movement and co-aggregation of tau aggregates moving between cells, that was abrogated if 
either one of the constructs contained a double proline mutation to block β-sheet formation. 
More recently, the group improved the FRET assay to detect seeding activity with ultrahigh 
sensitivity and specificity; they engineered a monoclonal FRET biosensor HEK293T cell line 
(“tau biosensor cells”) to stably express the tau repeat domain (RD) with the disease-associated 
P301S mutation fused to either CFP or YFP. After application of exogenous seeds, the 
nucleated aggregation of the tau FRET reporter proteins is detected by flow cytometry, rather 
than a FRET plate reader, with a reported sensitivity in the femtomolar range; in a P301S 
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mouse model of human tauopathy, the detection of proteopathic seeding by tau biosensor cells 
preceded the detection of  standard histopathological markers, suggesting that seeding plays an 
early role in the pathology of tauopathies (Holmes et al. 2014). Although FRET is clearly an 
outstanding method to quantify protein–protein interactions in living cells, the use of a bulky 
fluorescence protein tag adds an artificial manipulation to the system and might interfere with 
the interaction between the proteins of interest. Also, the FRET-based tau aggregation sensor 
needs fine-tuning to measure tau aggregation, rendering it not suitable for high-throughput drug 
screening that needs a robust screening platform. The BiFC technique reduces the size of 
tagging by using a fluorescence protein split into 2 non-fluorescent fragments, subsequently 
tagged to the proteins of interest. Only when those proteins of interest are associated together 
is fluorescence measured (Outeiro et al. 2008, Kerppola 2006, Chen et al. 2006). Johnson's 
group applied a split green fluorescent protein (GFP) complementation technique to quantify tau 
aggregation by BiFC in situ (Chun, Waldo & Johnson 2011, Chun, Waldo & Johnson 2007); full-
length tau protein was directly fused to a smaller GFP fragment (GFP11), and co-expressed in 
cells with a larger GFP fragment (GFP1–10). Only tau monomers or low degree aggregates 
allow the large GFP fragment to access the small fragment fused to tau, leading to the 
association of the fluorescently active GFP. Tau aggregation prevents the reconstitution of 
active GFP, leading to reduced GFP fluorescence in cells. An intrinsic shortcoming of this 
fluorescence “turn-off” approach is the fact that it detects early processes of tau aggregation, 
such as soluble tau intermediates. On the other hand, in Venus-based “turn-on” BiFC systems, 
only when tau assembles together is fluorescence produced; Venus fluorescence protein is split 
into two non-fluorescent N- and C-terminal fragments (VN173 and VC155), used to label tau 
(Tak et al. 2013); there is little fluorescence background in basal conditions, but Tau–BiFC 
fluorescence turned on dramatically when tau aggregation was stimulated by treatment with 
small molecules inducing tau phosphorylation.  
 
Table 5: Induction of tau aggregation in cells. Adapted from (Lim et al. 2014). 
K18 = truncated tau containing only the four MT-binding repeats 
Tau37 = 1N3R tau 
Tau39 = 2N3R tau 
Tau40 = 2N4R tau 
 
Tau 
isoform 
Mutants Host cell Expression Aggregation 
inducer 
Detection Reference 
K18 ΔK280 
ΔK280/PP 
(I277P/I308P) 
N2a Stable 
doxyclicin 
inducible 
- ThS  (Khlistunova et 
al. 2006) 
Tau40 - HEK293 Stable 
tetracyclin 
inducible 
Congo red Antibody (Bandyopadhyay 
et al. 2007) 
Tau40 N279K 
ΔK280 
CHO Stable 
expression 
- Antibody (Vogelsberg-
Ragaglia et al. 
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P301L 
S305N 
V337M 
R406W 
2000) 
Tau40 - COS-7 Transient 
expression 
GSK3β, 
JNK3 
ThioS (Sato et al. 
2002) 
Tau40 - 
ΔK280 
P301L 
R406W 
QBI-293 Transient 
expression 
Exogenous 
tau 
Antibody (Guo, Lee 2011) 
Tau40 
Tau37 
- SHSY5Y Transient 
expression 
Exogenous 
tau 
Antibody 
GFP 
(Nonaka et al. 
2010) 
Tau40 - 
P301L 
SHSY5Y Stable 
expression 
Exogenous 
Aβ 
Antibody (Ferrari et al. 
2003) 
Tau40 - C17.2 
HEK293 
Transient 
expression 
Exogenous 
tau 
YFP 
Alexafluor 
Antibody 
(Frost, Jacks & 
Diamond 2009) 
Tau40 
Tau39 
P301L 
V337M 
R406W 
NIH 3T3 Stable 
expression 
- GFP 
CFP 
YFP 
(Lu M, Kosik KS 
2001) 
Tau40 
Tau (1-
421) 
- HEK293 Transient 
expression 
GSK3β FRET 
(CFP, 
YFP) 
(Chun W, 
Johnson GV 
2007) 
K18 ΔK280 
P301L 
V337M 
I277P 
I308P 
HEK293 Transient 
expression 
K18 FRET 
(CFP, 
YFP) 
(Kfoury et al. 
2012) 
Tau40 
K18 
ΔK280 
I277P 
I308P 
HEK293 Transient 
expression 
GSK3β BiFC 
(GFP11, 
GFP1-10) 
(Chun, Waldo & 
Johnson 2007) 
Tau40 - HEK293 Stable 
expression 
Forskolin 
okadaic acid 
BiFC 
(VN173, 
VC155) 
(Tak et al. 2013) 
K18 P301S HEK293 Stable 
expression 
- FRET 
(CFP, 
YFP) 
(Holmes et al. 
2014 
3-
repeats 
and 4-
repeats 
tau 
- 3D-
differentiated 
neurons 
expressing 
FAD 
mutations  
Stable 
expression 
- Antibody (Choi et al. 
2014) 
3-
repeats 
and 4-
P301L hiPSC-
derived 
neurons 
Transient 
expression 
K18 Antibody (Verheyen et al. 
2015) 
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repeats 
tau 
K18 P301L 
V337M 
hiPSC-
derived 
neurons 
Transient 
expression 
- ThioT, 
antibody 
(Reilly et al. 
2017) 
 
These studies successfully demonstrated that overexpressed tau could be aggregated in cells. 
These cellular systems enabled the spatial and temporal resolution of tau aggregation and also 
the investigation of pathological mechanism of tau aggregation. Several models for tau 
aggregation exist but none are currently available that have all the ideal features for allowing 
screening of compounds that affect tau aggregation.  
 
1.5 Thesis aims 
Cellular and animal models recapitulating features of tauopathies provide a useful tool to study 
the causes and consequences of tau aggregation.  Some key questions in the field include 
which species of tau are competent to act as pathological seeds, and what are the molecular 
mechanisms controlling their uptake and release. In order to answer these critical questions, we 
developed a novel cell model for tau aggregation. 
The specific aims of this project are:  
1.     To develop a robust and reproducible cell model of tau aggregation. 
2.     To extensively characterise this cell model in term of tau uptake and release: which tau 
species are transferred between cell to cell, which mechanisms are involved in the 
transfer, and which tau species constitute a seed. 
3.     To confirm the findings in a neuronal cell model and determine whether the 
mammalian cell model is a good surrogate for neurons. 
For these purposes, our lab initially developed a seeded transient cell model of HEK293T cells 
transiently transfected with P301S 1N4R tau, with the aim of understanding mechanisms of tau 
aggregation and cell-to-cell propagation and also allowing screening of tool molecules. We 
chose to express P301S mutated tau, among the dominantly inherited tau mutations in FTDP-
17, because of the high propensity of induced aggregation (Clavaguera et al. 2009, Allen et al. 
2002, Bellucci et al. 2004, Scattoni et al. 2010). Also, the P301S mutation was chosen to match 
with the sarkosyl-insoluble TgP301S mouse-derived tau extract used for seeding (TgP301S 
seed), as it has been demonstrated that template-based seeding requires homotypic 
interactions between seed and substrate, consistent with the existence of seeding barriers 
(Sanders et al. 2014., Collinge, Clarke 2007). Subsequently, the transient system was migrated 
to an inducible model which is less labour intensive as no tau transfection is required, more 
reproducible as tau expression is regulated by tetracyline induction and is not dependent on 
transfection efficiency, more robust and more amenable to higher throughput assays. An 
inducible HEK T-REx cell line stably expressing P301S 1N4R tau (Falcon et al. 2015) was 
therefore used to further investigate the seeding process. The migration from transient to 
inducible system involved a change of cell line, but did not change the seeding process, which 
consisted of adding sarkosyl-insoluble TgP301S mouse-derived tau extract (TgP301S seed). 
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Our cell model differs from the existing ones by being inducible, hence more robust, by using 
sarkosyl-insoluble tau extracts from transgenic mice instead of recombinant tau as seeding 
agent, and by expressing full length tau and not the MB domain fragment, thus providing a more 
biologically relevant mechanism of nucleation and propagation of tau aggregation. 
 
First, to investigate whether endocytosis is the main mechanism of tau uptake in this model, we 
explored the effect of different endocytosis modulators during seeding. Then, we explored the 
effect of temperature and transfection reagents on seed uptake. Next, we investigated 
colocalization between tau seed and endocytic markers (dextran, early endosome antigen 1 
(EEA1), CD63) by immunofluorescence. Finally, following the incidental observation of 
tunnelling nanotubes (TNTs) in our cell model, we characterised them by confocal microscopy 
and explored the effect of the F-actin-depolymerising compound latrunculin A on tau 
intercellular propagation.   
 
We then focused on tau release by characterising the  tau species in conditioned media from  
unseeded vs seeded HEK T-REx P301S tau inducible cells, to investigate the presence of post-
translational modifications (phosphorylation, truncation,..) aggregation state, size and 
encapsulation in vesicles of extracellular tau. 
 
Next, to better investigate the molecular mechanisms of tau malfunction, we created a neuronal 
model recapitulating the main features of seeded tau pathology, using hippocampal neurons 
from TgP301S mice expressing 0N4R P301S tau, or rat cortical neurons expressing 1N4R 
P301S tau. Employing a neuronal cell model is of importance not only to confirm the findings 
obtained in the mammalian inducible model of tau aggregation, but also to be able to observe 
mechanisms that may be neuron-specific. 
 
Some of the work described below has been included in recent publications. In Falcon et al. 
2015 we described the development of a cell model to understand the relationship between tau 
conformation, phosphorylation state and seeding ability. Using both recombinant and native tau 
aggregates, we provided evidence that despite being taken up by cells to the same degree, 
native tau aggregates have a higher seeding potency than recombinant tau aggregates; the 
latter though can acquire the conformation and seeding potency of the former by templated 
assembly, demonstrating for the first time that conformation and not phosphorylation determines 
the seeding potency of tau aggregates (Falcon et al. 2015). In Jackson et al. 2016 we 
characterized by sucrose gradient and immunodepletion the native tau species responsible for 
seeding and pathology spreading in TgP301S mice. Tau species that were aggregated, AT8-, 
and nY29-positive with structure ranging from ring-like to small fibrils of 179–250 nm were able 
to seed tau aggregation in our inducible cell model and initiate trans-synaptic spreading in 
TgP301S mice in vivo, indicating that short fibrils are the most potent species capable of 
seeding tau pathology (Jackson et al. 2016).   
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Not only do our cell-based tauopathy models provide a tool for investigating the pathogenesis of 
tau aggregation, but also offer an invaluable system for identifying therapeutic strategies against 
neurodegenerative tauopathies, such as small molecules inhibiting tau fibrillization or antibodies 
blocking the spontaneous cellular uptake of tau. 
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2. EXPERIMENTAL PROCEDURES 
 
2.1 Reagents and antibodies   
For endocytosis modulation studies, Earle Balanced Salt Solution #14155 was purchased from 
Invitrogen; sodium azide NaN3 #S8032, Latrunculin A #L5163, 5-(N-ethyl-N-isopropyl)amyloride 
(EIPA) #A3085 and 2-deoxy-D-glucose #D6134 were obtained from Sigma. Transfection 
reagent Fugene was purchased from Roche and Lipofectamine 2000 from Invitrogen. For 
cellular fractionation, N-laurosarkosine #L9150 was obtained from Sigma. TgP301S transgenic 
mice over-expressing the shortest 4R form (0N4R) of human tau bearing an FTDP-17 mutation 
(P301S) under the mouse Thy1 promoter (Allen et al. 2002) were licensed from M. Goedert, 
Cambridge. 
 
Table 6: Antibodies 
 
Antibody Target Host Supplier Catalogue 
number 
Dilution 
for WB 
Dilution 
for IF 
DA9 Total tau mouse P. Davies  2000 1000 
TG5 Total tau mouse P. Davies  - - 
PG5 pS409-tau mouse P. Davies  - 1000 
MC6 pS235-tau mouse P. Davies  - - 
PHF1 pS396-tau mouse P. Davies  - - 
MC1 Conformationally 
changed tau 
mouse P. Davies  - 8000 
CP27 Total human tau mouse P. Davies  - 1500 
AT8 pS202/pT205-tau mouse In-house  35,000 16,000 
nY29 nY29-tau mouse Covance sig-339349-
500 
- 1000 
1N 1N tau mouse Covance #MMS-
5066 
 100 
GAPDH GAPDH mouse Ambion #AM4300 6000  
EEA1 EEA1 mouse BD 
Biosciences 
#610457  500 
CD63 CD63 mouse Iowa DSHB #H5C6  400 
 
2.2 Sarkosyl-insoluble tau extraction from P301S and WT mice 
A68 buffer composed of 10 mM Tris-HCl (SAFC #RES3094T-B102X) pH 7.4, 0.8 M sodium 
chloride (NaCl, Sigma), 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA, Sigma), 5 mM ethylenediaminetetraacetic acid (EDTA, Sigma), 10% sucrose (Sigma), 
Complete (Roche cat# 11697498001) protease Inhibitor tablet, 1 mM phenylmethylsulphonyl 
fluoride (PMSF, Sigma, #93482), was used to prepare 0N4R tau sarkosyl-insoluble extract 
(“seed”) by sarkosyl extraction of TgP301S mice brains as previously described (Falcon et al. 
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2015). Briefly, homozygous mice transgenic for 0N4R tau with the P301S mutation showing 
severe paraparesis (~4.5 months) were killed by cervical dislocation. Whole brains were 
homogenised in Dulbecco's phosphate-buffered saline (DPBS, Invitrogen) by needle extrusion 
and brain homogenates were pooled; the pool was diluted with A68 buffer to 5 mg/ml of protein, 
measured by Bradford assay (Thermo Scientific #23236), and centrifuged twice at 13,000g for 
20 min. Combined supernatants were made to final concentration of 1% sarkosyl from a 10% 
sarkosyl stock solution in dH2O and incubated at room temperature for 1 hour under agitation; 
following sarkosyl extraction, the mixture was centrifuged at 100,000g for 1 hour at 4°C. The 
resulting pellet, named TgP301S seed, was washed once with A68 buffer, resuspended in 50 
mM Tris-HCl pH 7.4, sonicated and frozen as single-use aliquots at −80 °C. WT seed was 
prepared according to the same protocol from aged C57BL/6S mice. 
 
2.3 Transient cell line culture and seed inoculation 
HEK293T cells (ECACC) were transiently transfected with pcDNA3.1 constructs encoding 
human tau using Lipofectamine-2000. The cells were split the following day and grown 
overnight. They were then seeded with sarkosyl-insoluble tau (at the concentrations stated in 
the figure legends) diluted in OptiMEM (Gibco 31985-070). After 3 hours the seed/OptiMEM mix 
was removed and replaced with fresh complete medium [Dulbecco's Modified Eagle's medium 
(DMEM, Gibco #11960-044) plus 10% foetal calf serum (FCS)] supplemented with 
penicillin/streptomycin (Gibco 10378), blasticidin (Calbiochem 203350) and hygromycin (Roche 
10843555001). Cells were then incubated for 3 days. Cells were passaged once weekly in T175 
flasks, washed with Hank's balanced salt solution (HBSS, Gibco 14170-088), detached with 
0.05% trypsin (#L11-003 PAA, GE Healthcare) in HBSS and typically split at a 1:40/1:50 
dilutions into new flasks. 
 
2.4 Inducible cell line culture and seed inoculation  
To produce a stable inducible cell line, HEK293 T-REx cells (Invitrogen) were transfected with 
human 1N4R P301S tau/pcDNA 4T/O using FuGene 6. Clones were selected in the growth 
media containing 5 µg/ml blasticidin (Calbiochem #203350) and 200 µg/ml zeocin (Sigma 
#R25001). Following clone selection, expression of tau was induced in medium containing 1 
µg/ml of tetracycline (T7660, Sigma) for 24/48 hours and expression levels were evaluated by 
western blotting with DA9 antibody. HEK T-REx inducible cells expressing human 1N4R tau 
bearing the P301S mutation were grown in full media (DMEM, 10% foetal bovine serum (FBS) 
supplemented with penicillin/streptomycin, blasticidin and zeocin (Sigma #R25001). Cells were 
passaged once weekly in T175 flasks, washed with HBSS, detached with 0.05% trypsin in 
HBSS and typically split at a 1:40/1:50 dilutions into new flasks. 
 
Cells were plated in 6-well tissue culture plates (Corning) (for biochemical analysis) or 96-well 
poly-d-lysine coated imaging plates (Becton Dickinson #359271) (for imaging analysis) and 
induced with 1 µg/ml tetracycline. 24 hours later the TgP301S sarkosyl-insoluble tau seed 
diluted in OptiMEM was added to the cells for 3 hours at tau concentrations of 50-500 ng/ml. 
Cells were then treated with 0.0125% trypsin for 1 minute at room temperature to digest 
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extracellular seed (unless otherwise stated), and placed on induction medium (containing 1 
µg/ml tetracycline) for 24 hours, after which the induction was stopped by replacing the media. 3 
days after seeding, cells were harvested and fractionated for biochemical analysis, or fixed with 
4% paraformaldehyde (PFA, Affimetrix, #19943)/1% Triton X-100 (Sigma, #X100) (unless 
otherwise stated) and prepared for immunofluorescence and imaging analysis. 
 
For the time course profile of the seeding phase, cells were seeded for 10 or 30 or 60 minutes, 
followed by a 3-day post-seeding phase. For the time course profile of the post-seeding phase, 
cells were seeded for 3 hours followed by 0, 1, 2 or 3 days growth. For studying the effect of 
temperature on seed uptake, cells were seeded for 3 hours at 37˚C or 4˚C, followed by a 3-day 
propagation phase. For studying the effect of ATP depletion on seed uptake, medium was 
replaced by Earle’s Balanced Salt Solution containing 10 mM sodium azide and 10 mM 2-
deoxy-D-glucose for 2.5 h before inoculation with TgP301S sarkosyl-insoluble seed for 2 hours. 
For endocytosis modulation studies, cells were pre-incubated with compounds for 30 minutes 
prior and during inoculation with seed for 3 hours. Cells were subsequently grown for further 3 
days and fixed with PFA 4%/Triton X-100 1% before aggregate uptake was monitored by high 
content imaging, or were fixed immediately after seeding and imaged by confocal microscopy. 
For actin depolymerisation experiments, cells were inoculated with seed for 3 hours, then seed 
was removed and replaced with media containing 300-0.4nM latrunculin A for 1, 2, or 3 days 
before fixation with PFA 4%/Triton X-100 1% and confocal and high content imaging analysis. 
 
2.5 Sequential extraction and biochemical analysis 
Sample fractionation for biochemical analysis was performed as previously described (Falcon et 
al. 2015) to produce total lysate and soluble and insoluble fractions from cell lysate samples. 
Briefly, cells were washed once with PBS before being scraped into 1 ml/well of DPBS; cells 
from 2 duplicate wells of a 6-well plate were combined and pelleted at 1000g for 5 minutes. Cell 
pellets were resuspended in 500 ul of fractionation buffer composed of 50 mM sodium 
phosphate (Sigma), pH 7.0, 10 mM sodium pyrophosphate (Sigma), 0.5 mM 
phenylmethylsulphonyl fluoride (PMSF), 2 mM sodium ortho-vanadate (Sigma), 2 mM EGTA, 2 
mM EDTA, 20 mM sodium fluoride (Sigma), 1 mM dithiothreitol (DTT, Sigma #D0632), 
phosphatase inhibitor cocktail 1 (Sigma cat# P2850), phosphatase inhibitor cocktail 2 (Sigma 
cat# P5726), Complete protease inhibitor cocktail tablet. Following sonication, lysates were 
centrifuged at 10,000g for 10 min to clear cell debris. Supernatants were protein-matched using 
the Bradford assay and aliquots were kept as “TL Total lysates”. When indicated, the remaining 
total lysates were incubated with 1% sarkosyl (from a 10% sarkosyl solution in dH2O) at room 
temperature for 1 hour on a flat rotating shaker. After centrifugation of the total lysates at 
100,000g for 30 min at 4°C, supernatants were saved as “soluble fraction” whereas pellets 
(“insoluble fractions”) were washed twice in fractionation buffer, resuspended in 50 mM Tris-HCl 
ph 7.4 and sonicated. Aliquots of all the fractions were stored at -80°C. 
 
For sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by western blot (SDS-
PAGE-WB), total lysates, soluble fractions and insoluble fractions were mixed with 4X loading 
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buffer (Invitrogen, NP0007) containing 5% β-mercaptoethanol (Sigma, M7164), boiled 10 
minutes at 95˚C and resolved on 8% SDS-polyacrylamide gels, transferred to nitrocellulose 
membranes, and blocked in 5% milk in Tris buffer saline (TBS) before probing with DA9 
(1:2000, from P. Davies, Manhasset, NY), AT8 (1:1000, Thermo Scientific), GAPDH (1:6000, 
#AM4300 Ambion). Proteins were detected using Supersignal West Femto or West Dura 
detection systems (Thermo Scientific). 
 
Alphascreen (AS) assays (Perkin Elmer) were performed according to the manufacturer’s 
guidelines using tau specific antibodies. The Alphascreen technology is a sandwich assay for 
detection of molecules of interest in biological fluids in a sensitive, quantitative, reproducible 
manner. Essentially, a biotinylated anti-analyte antibody binds to streptavidin-Donor beads while 
another anti-analyte antibody is conjugated to Acceptor beads. In the presence of the analyte, 
the beads come into close proximity. The excitation of the Donor beads provokes the release of 
singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, 
resulting in light emission. Optimised Alphascreen assays were set up using biotinylated tau 
antibodies paired with acceptor beads-conjugated tau antibodies (DA9, MC1, TG5, PG5, from 
P. Davies, Manhasset, NY; AT8, from Thermo Scientific). 10 µl/well of antibody mix of acceptor-
conjugated and biotinylated antibodies were added to 384 well assay plates (#784075, Greiner) 
together with 5 µl/well of total lysate, soluble fraction, insoluble fraction sample or standard 
diluted in assay buffer (0.1% casein (Sigma) in DPBS). After overnight incubation at 4
˚
C, 5 
µl/well of streptavidin-coated donor beads diluted in assay buffer were added to each well and 
plates incubated in the dark with gentle agitation at room temperature for 4 hours. Plates were 
read at excitation 680 nm and emission 520-620 nm using an Envision plate reader (Perkin 
Elmer).  Two-tailed paired Student's t test or one-way Anova were used for all the comparisons 
in the study, and differences with p values less than 0.05 were considered significant. 
Alphascreen data was expressed as “Relative Alphascreen units” because the magnitude of the 
signal is dependent on the aggregation state of tau, therefore an absolute quantitation cannot 
be made. 
 
2.6 Immunofluorescence 
Cells were washed twice with DPBS and fixed with 4% PFA/1% Triton X-100 for 15 min to 
remove soluble proteins (Guo, Lee 2011). After blocking with 5% fat-free milk in TBS for 1 hour 
at room temperature, cells were incubated with primary antibodies overnight at 4°C followed by 
staining with appropriate Alexa Fluor-conjugated secondary antibodies for 1 hour at room 
temperature. Hoechst 33342 (Invitrogen) diluted 1:1000 in TBS was added for 30 minutes to 
label cell nuclei. PG5 and CP27 tau antibodies were obtained from P. Davies, Manhasset, NY. 
EEA1 antibody was from BD Biosciences #610457. CD63 antibody developed by Dr. David R. 
Soll was obtained from the Developmental Studies Hybridoma Bank developed under the 
auspices of the NICHD and maintained at The University of Iowa, Department of Biology, Iowa 
City, IA 52242. Lysosomal-associated membrane protein 1 (LAMP1) antibody was from BD 
Biosciences #555798.  Alexa Fluor-labelled phalloidin for labelling F-actin was obtained from 
Invitrogen. Epifluorescence images were acquired using BD Bioscience Pathway, TTP Labtech 
45 
 
Acumen bioimaging systems (high content imaging assay, HCI) and an Olympus Fluoview 1000 
inverted confocal microscope was used for confocal imaging with a 40X or 60X oil objective. 
Images were typically 1024 × 1024 pixels. For quantifying the percentage of cells carrying tau 
aggregates, 9 random-field images were taken per well at 20X magnification, and at least 6 
replicate wells were used in each experiment, which was repeated at least twice (n=2). Two-
tailed paired Student's t test or one-way Anova were used for all the comparisons in the study, 
and differences with p values less than 0.05 were considered significant. 
 
2.7 Expression and purification of recombinant tau  
The nucleotide sequences encoding untagged full-length human P301S mutants of 0N4R Tau 
(NP_058518.1) and 1N4R Tau (NP_001116539.1) were inserted into pET21d (Novagen) vector.  
Bacterial BL21(DE3) (Novagen) was used as an expression host, and the induction of protein 
expression was carried out in 2xTY media with 1 mM IPTG at 18⁰C overnight.  Cells were 
harvested, and the fresh cell pellets were lysed by stir-boiling in lysis buffer (20 mM MES, pH 
7.3, 5 mM DTT, 0.2% Triton X-100, 1 mM PMSF) for 30 min followed by cooling on ice with 
stirring for 30 min.  All subsequent purification steps were conducted at 4⁰C.  Cell lysates were 
clarified by centrifugation in a Beckman JA-18 rotor at 40,000g for 20 min.  The supernatant 
was incubated with SP Sepharose Fast Flow (GE Healthcare) for 2 h.  Proteins were eluted with 
0-1 M NaCl gradient in buffer A (25 mM MES, pH 7.3, 2 mM DTT, 0.5 mM PMSF).  Tau-
containing fractions were pooled, concentrated and loaded onto a HiLoad 26/600 Superdex 200 
column (GE Healthcare) and eluted in either buffer A (PBS, pH 7.4, 1 mM DTT, 5% glycerol) for 
0N4R Tau or buffer B (10 mM HEPES, pH 7.4, 100 mM NaCl, 0.1 mM PMSF) for 1N4R.  
Fractions containing tau were pooled and protein concentration determined by UV280.  The 
purified protein was aliquoted and stored at -80⁰C. To obtain monomeric tau, purified 
recombinant tau was centrifuged at 100,000g at 4°C for 1 h and the supernatant used. 
 
2.8 In vitro seeded assembly of recombinant tau 
Recombinant 0N4R P301S tau was diluted to 135 μg/mL in PBS/1 mM DTT and incubated at 37 
°C in an 800μL reaction volume with or without 5% (v/v) TgP301S tau sarkosyl-insoluble brain 
extract. An aliquot of the samples was added to 15 μM Thioflavin T (ThioT, Sigma, #T3516) in a 
384-well plate (Corning #4514) and ThT fluorescence monitored over time with excitation and 
emission filters set to 444 and 485 nm, respectively, in an Envision (Perkin Elmer) plate reader. 
Fluorescence readings were taken every 20 min, with agitation in between each reading. The 
aggregation reaction was stopped, by snap-freezing the samples, when the ThioT signal 
reached a plateau. Samples were sarkosyl-extracted, as described below, and the pellets 
washed and resuspended in 50 mM Tris-HCl, pH 7.4. Samples were run on SDS-PAGE and 
probed with total tau antibody DA9. Equal amounts of tau protein were then added to HEK T-
REx P301S 1N4R tau inducible cells following the seeding paradigm described above. 
 
2.9 Conditioned media and cells collection 
HEK-T-REx-293 P301S inducible cells were plated in triple layered flasks (Thermo Scientific 
Nunc #132913, Nunclon Delta surface), induced with 1 ug/ml tetracycline and 24 hours later 
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seeded with P301S mice derived brain extract diluted in OptiMEM for 3 hours as described 
above, in presence or absence of Lipofectamine. Cells were treated with 0.0125% trypsin for 1 
min at RT to remove residual seed and placed again on induction medium containing 1ug/ml 
tetracycline. Phenol-red free DMEM (Gibco #21063-029) was used in the medium in order to 
diminish the interference with Alphascreen assay. Conditioned medium from these cells was 
collected at different time points post-seeding (0-1-2-3 days post seeding), spun 5 minutes at 
200g and concentrated using Amicon Ultra-15 Centrifugal filter units with Ultracel 10K 
membrane or Centricon Plus-70 device, 10K, #UFC701008. Protein concentration in media 
samples was measured by Bradford assay and samples were normalised to the lowest protein 
concentration with DPBS. Tau concentration was measured by Alphascreen assay to normalise 
tau levels, then media samples were then used to seed naïve HEK-T-REx-293 P301S inducible 
cells, according to the seeding paradigm previously described (3 hours exposure to seed 
followed by 3 days of growth). Cells were also washed and collected at different time points 
post-seeding (0-1-2-3 days post seeding). After pelleting, the cells were lysed by sonication in 
tau fractionation buffer (50 mM sodium phosphate pH 7.4, 10 mM sodium pyrophosphate, 2 mM 
EGTA, 2 mM EDTA, 20 mM sodium fluoride, 1 mM dithiothreitol, supplemented with 
phosphatase inhibitor cocktail 2, phosphatase inhibitor cocktail 3, 0.5 mM PMSF, 2 mM sodium 
orthovanadate (NaVO3) and Complete protease inhibitor cocktail tablets. The cell lysate was 
then spun at 13,000g for 5 minutes to pellet cell debris and the protein concentration was 
determined in the supernatant by Bradford assay, normalising all the samples to the lowest 
protein concentration in tau fractionation buffer. This supernatant was the cell total lysate (TL).  
 
2.10 Cytotoxicity assays 
The presence of cell death was measured by Trypan blue cell count and LDH assay (Roche) in 
the media. HEK T-REx P301S tau inducible cells, uninduced, unseeded and treated 4 hours 
with 1% Triton X-100 were used as “high control” (100% cytotoxicity); HEK T-REx P301S tau 
inducible cells, uninduced, unseeded were used as “low control”; sample from  unconditioned 
media was used as “background control”. The samples’ cytotoxicity was calculated as follow: 
Cytotoxicity (%) = (Exp value - Low Control)/(High Control - Low Control) x 100. 
 
2.11 Sarkosyl extraction of conditioned media and total lysate samples 
Conditioned media and total lysate samples were incubated with 1% sarkosyl (from a 10% 
solution of sodium lauryl sarcosinate in water) for 1 hour, shaking, at room temperature. At the 
end of the incubation, the samples were spun for 1 hour at 235,400g at 4°C. 
The resulting supernatants were collected and frozen as “sarkosyl-soluble fractions”, while the 
pellet was washed by adding A68 buffer (10 mM Tris-HCl pH 7.4, 0.8 M NaCl, 1 mM EGTA, 5 
mM EDTA, 10% sucrose, protease inhibitor tablet, 1 mM PMSF) and centrifuged 10 minutes at 
235,400g at 4°C. All the remaining supernatant was discarded, pellets were dried and then 
sonicated 5 x 1 s pulses in 1/10
th
 of the volume spun of 50 mM Tris-HCl pH 7.4, supplemented 
with Complete protease inhibitor tablet and 1 mM PMSF and frozen as “sarksosyl-insoluble 
fractions”. 
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2.12 Immunodepletion 
Activated sepharose 4 Fast Flow (GE Healthcare) was conjugated to the antibody of choice at 5 
mg/ml, as per manufacturer’s instructions, and stored in PBS containing 0.01% sodium azide. 
Following washing, 250 ul beads were incubated with 5 mg TgP301S tau brain lysate and 
rotated overnight at 4°C. Sepharose was removed through centrifugation at 1000g and depleted 
lysates stored at -80°C until further analysis. 
 
2.13 TgP301S primary neuronal cultures  
Primary neuronal cultures were prepared from E17 embryos from time-mated TgP301S and 
C57BL/6S female mice (Charles River, UK). Dissociated hippocampal/cortical neurons were 
plated onto poly-D-lysine coated 96-well plates. Media was made with Neurobasal medium 
(Invitrogen 21103-049) supplemented with MACS Neurobrew-21 (Miltenyl Biotec 130-093-566) 
and L-glutamine (Life Technologies 25030-024). Seeding was performed at day-in-vitro 7 
(DIV7), when sarkosyl-insoluble TgP301S 0N4R tau seed was diluted in medium before being 
added to neurons. Neurons were fixed for immunocytochemistry at DIV14 in 4% PFA containing 
2% sucrose and 1% Triton X-100 for 15 min to remove soluble proteins, as previously described 
(Guo, Lee 2013). After blocking with 0.5% BSA/0.1% Triton X-100/TBS for 1 h at RT, neurons 
were incubated with specific primary antibodies overnight at 4ºC followed by staining with 
appropriate AlexaFluor-conjugated secondary antibodies (Invitrogen) and Hoechst for 1 h at RT. 
Epifluorescence images were acquired using BD Bioscience Pathway, TTP Labtech Acumen 
bioimaging systems (high content imaging assay, HCI) and an Olympus Fluoview 1000 inverted 
confocal microscope was used for confocal imaging with a 40X or 60X oil objective.  
 
2.14 Rat primary neuronal cultures  
Primary neuronal cultures (rat cortical neurons, RCNs) were prepared from E12 embryos from 
time-mated CR rats. Dissociated cortical neurons were plated onto poly-D-lysine coated 96-well 
or 6-well plates. Media was made with Neurobasal medium supplemented with MACS 
Neurobrew-21 and L-glutamine. Cultures were transduced at DIV0 with P301S 1N4R tau 
vectors (Vector Biolabs). Plasmids were subcloned into AAV vector with synapsin promoter and 
WPRE transcrptional enhancer, and packaged into AAV virus particles. The vector used was 
the P2A fusion eGFP-P2A-MAPT(P301S), which is subjected to cleavage by endogenous 
proteases. The P2A peptide sequence is GSGATNFSLLKQAGDVEENPGP. After cleavage, the 
red sequence remains with eGFP, and green sequence remains with tau, resulting in GFP-
labelled cells but unlabelled tau protein.  
 
 
 
 
 
 
 
eGFP Tau 
P2A 
eGFP Tau 
Protease 
cleavage 
GSGATNFSLLKQAGDVEENPGP 
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Seeding was performed at DIV8, when sarkosyl-insoluble TgP301S 0N4R tau seed was diluted 
in medium before being added to neurons. Neurons were collected for analysis at DIV15.  For 
immunocytochemistry, neurons were fixed in 4% PFA containing 2% sucrose and 1% Triton X-
100 for 15 min to remove soluble proteins, as previously described (Guo, Lee 2013). After 
blocking with 0.5% BSA/0.1% Triton X-100/TBS for 1 h at RT, neurons were incubated with 
specific primary antibodies overnight at 4C followed by staining with appropriate AlexaFluor-
conjugated secondary antibodies (Invitrogen) and Hoechst for 1 h at RT. Epifluorescence 
images were acquired using BD Bioscience Pathway, TTP Labtech Acumen bioimaging 
systems (high content imaging assay, HCI) and an Olympus Fluoview 1000 inverted confocal 
microscope was used for confocal imaging with a 40X or 60X oil objective. For biochemical 
analysis, cells were collected as above for HEK T-REx P301S inducible cells. 
 
2.15 Statistical analysis 
Statistical analysis was carried out using Prism statistical analysis software (GraphPad Software 
Inc.). Differences between two groups were compared using a two-tailed paired Student’s t test. 
Differences between multiple groups were compared using one-way ANOVA and then groups 
compared using a post-hoc Dunnet test.  
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RESULTS 
 
3. DEVELOPMENT OF TRANSIENT AND INDUCIBLE CELL MODELS OF SEEDED 
TAU AGGREGATION 
 
Our lab initially developed a seeded transient cell model of HEK293T cells transiently 
transfected with P301S 1N4R tau, with the aim of understanding mechanisms of tau 
aggregation and cell-to-cell propagation and also allowing screening of tool molecules. We 
chose to express P301S mutated tau, among the dominantly inherited tau mutations in FTDP-
17, because of the high propensity of induced aggregation (Clavaguera et al. 2009, Allen et al. 
2002, Bellucci et al. 2004, Scattoni et al. 2010). Also, the P301S mutation was chosen to match 
with the sarkosyl-insoluble TgP301S mouse-derived tau extract used for seeding (TgP301S 
seed), as it has been demonstrated that template-based seeding requires homotypic 
interactions between seed and substrate, consistent with the existence of seeding barriers 
(Sanders et al. 2014., Collinge, Clarke 2007). The first aim of this thesis was to migrate this 
transient system to an inducible model which is less labour intensive as no tau transfection is 
required, more reproducible as tau expression is regulated by tetracyline induction and is not 
dependent on transfection efficiency, more robust and more amenable to higher throughput 
assays. This chapter will present the characterisation of the transient model, followed by the 
development and characterisation of seeded tau aggregation assays in the inducible cell model. 
 
3.1 Spontaneous uptake of seed without transfection reagent induces endogenous tau 
aggregation in HEK293T cells 
To explore the capability of TgP301S sarkosyl-insoluble tau seed to nucleate intracellular 
fibrillization of soluble tau, HEK293T cells transiently transfected with the 1N4R human tau 
isoform bearing the P301S mutation were treated for 3 hours with sarkosyl-insoluble 0N4R tau 
extract generated from TgP301S transgenic mice, in absence of transfection reagent, and 
cultured for a further 3 days. Sequential extraction (fractionation) of cell lysates performed in 
presence of 1% sarkosyl produced a pellet named “sarkosyl-insoluble fraction” and a 
supernatant named “sarkosyl-soluble fraction”. Total lysates recovered in fractionation buffer, 
sarkosyl-soluble and sarkosyl-insoluble fractions were resolved by SDS-PAGE. Immunoblotting 
with AT8 (pS202/pT205-tau) and DA9 (total tau) antibodies revealed accumulation of abundant 
sarkosyl-insoluble tau in seed-treated cells (Figure 3.1). Since the endogenous tau isoform 
being used was 1N4R and exogenous seeding tau 0N4R, the two isoforms could be 
distinguished by size in WB, as well as by isoform-specific antibodies (see Figure 3.6). 
Therefore AT8 immunoreactivity in seed-treated cells can be entirely attributed to the transiently 
expressed 1N4R P301S tau, and not to exogenously supplied tau seed. The insoluble 1N4R tau 
separated at a higher molecular weight than the input 0N4R tau, suggesting that the 0N4R tau 
inocula entered cells and recruited 1N4R tau into sarkosyl-insoluble hyperphosphorylated tau 
species. In the absence of tau expression, seeding with sarkosyl-insoluble native tau did not 
result in any insoluble, aggregated tau. In addition, cells that were not treated with TgP301S 
sarkosyl-insoluble native tau, but expressed tau, did not form sarkosyl insoluble tau. 
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Figure 3.1:  Accumulation of sarkosyl-insoluble tau in seed-treated cells. Western blot with 
anti-tau antibodies DA9 (phosphorylation-independent) and AT8 (pS202/pT205) of the total 
lysate, sarkosyl-soluble and sarkosyl-insoluble fractions from HEK293T cells transiently 
transfected with or without P301S 1N4R tau DNA. Cells were exposed for 3 h to increasing 
amounts of sarkosyl-insoluble material from TgP301S 0N4R tau mice brains, followed by 3 days 
of incubation.  A total lysate loading control for GAPDH is also shown. Data shown is 
representative of 2 independent experiments. 
 
An Alphascreen was used to measure the levels of different tau species (Figure 3.2). In the 
absence of seed, sarkosyl-soluble tau was phosphorylated at the MC6 (pS235) epitope. 
Following treatment with TgP301S tau seed, there was a dose-dependent reduction in sarkosyl-
soluble total tau (Figure 3.2 i) and sarkosyl-soluble tau phosphorylated at the MC6 epitope 
(Figure 3.2 iii) and a parallel increase in sarkosyl-insoluble total (Figure 3.2 v) and sarkosyl-
insoluble MC6-positive tau (Figure 3.2 vii), suggesting that soluble tau was being converted into 
insoluble tau aggregates. In the sarkosyl-soluble fraction, a small amount of tau was MC1 
(conformationally changed)-positive, and it increased dose-dependently following seed 
treatment for 3 h and growth for 3 days (Figure 3.2 ii). Sarkosyl-soluble tau was also AT8-
positive, but only following seed treatment (Figure 3.2 iv). We cannot completely exclude the 
possibility of an incomplete separation between sarkosyl-soluble and sarkosyl–insoluble 
material, although no differences in the amounts of MC1- and AT8-positive tau in the sarkosyl-
soluble fractions were observed following 100,000g centrifugations at 30 min, 1 h and 24 h 
(data not shown).  Following incubation with TgP301S tau seed, a dose-dependent increase in 
the levels of MC1- and AT8-positive sarkosyl-insoluble tau was observed (Figure 3.2 vi and viii) 
(Falcon et al. 2015). 
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Figure 3.2:  Accumulation of sarkosyl-insoluble tau in seed-treated cells. Alphascreen 
showing levels of total tau (DA9) (i and v), conformationally changed tau (MC1) (ii and vi), tau 
phosphorylated at S235 (MC6) (iii and vii) or S202/T205 (AT8) (iv and viii) in HEK 293T cells 
transiently transfected with or without human P301S 1N4R tau, exposed for 3 h to increasing 
amounts of sarkosyl-insoluble material from the brains of P301S 0N4R tau mice, followed by 3 
days of incubation. The results are the means ± SEM (n=3).  Absolute quantification of the 
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levels of sarkosyl-soluble (upper panel) and sarkosyl-insoluble (lower panel) tau cannot be 
made, because the magnitude of the signal is dependent on the aggregation state of tau.  
 
3.2 Trypsin digestion of inocula 
In agreement with what had been shown by other groups for tau (Frost, Jacks & Diamond 2009) 
and SOD1 (Munch, O'Brien & Bertolotti 2011) we found that TgP301S sarkosyl-insoluble tau 
seed was completely digested when treated with 0.0125% trypsin for 1 min at room temperature 
(Figure 3.3). This is 4-fold lower than the level of trypsin routinely used to re-plate cells in tissue 
culture (0.05% for 3 min at 37C); this relative sensitivity of the extracellular aggregates to 
proteolysis allowed us to incorporate a trypsin treatment following seeding in our model, without 
the need to re-plate the cells. 
 
 
 
 
 
 
 
 
Figure 3.3: Aggregated tau is sensitive to trypsin digestion. TgP301S mouse sarkosyl-
insoluble extract treated with up to 0.05% trypsin in HBSS for 1 minute at room temperature and 
resolved by SDS-PAGE, followed by immunoblotting with DA9 (total tau) antibody and GAPDH 
(loading control). 0.0125% trypsin is sufficient to completely digest the seed. 
 
3.3 Development and characterisation of a seeded tau aggregation: biochemical assay in 
HEK T-REx P301S tau inducible cells 
An inducible HEK T-REx cell line stably expressing P301S 1N4R tau was produced by S. 
Glover, Eli Lilly, Windlesham, and used in all subsequent experiments to further investigate tau 
seeded assembly and seed uptake. 
HEK T-REx inducible cells that had been expressing the 1N4R human tau isoform bearing the 
P301S mutation for 24 hours, were treated for 3 hours with sarkosyl-insoluble 0N4R tau extract 
generated from TgP301S transgenic mice, in absence of transfection reagent, and cultured for a 
further 3 days. 
Sequential extraction (fractionation) of cell lysates performed in presence of 1% sarkosyl 
produced a pellet named “sarkosyl-insoluble fraction” and a supernatant named “sarkosyl-
soluble fraction”; sequential extraction performed without 1% sarkosyl produced a pellet named 
“insoluble fraction” and a supernatant named “soluble fraction”. Samples were resolved by SDS-
PAGE. When sarkosyl-extraction was performed, similarly to what we observed in the transient 
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cell model, immunoblotting with AT8 antibody revealed accumulation of abundant insoluble tau 
in seed-treated cells (Figure 3.4 A). The sarkosyl-insoluble 1N4R tau separated at a higher 
molecular weight than the input seed (0N4R tau) suggesting that the 0N4R tau inocula entered 
cells and recruited the endogenous 1N4R tau into sarkosyl-insoluble hyperphosphorylated tau 
species. When the total lysate extraction was performed in absence of 1% sarkosyl, again a 
dose dependent increase in levels of insoluble AT8-positive tau was observed upon seed 
treatment; however, cells treated with Optimem alone as controls showed low levels of insoluble 
tau recognised by DA9 antibody, which was not AT8-immunoreactive (Figure 3.4 B). Unseeded 
cells extracted in presence of 1% sarkosyl did not retain any tau species recognised by AT8 or 
DA9 antibody by WB, whereas the same cells extracted in absence of sarkosyl showed basal 
level of tau recognised by DA9 but not AT8 antibody; this means that AT8-positive sarkosyl-
insoluble tau species are only formed upon seed addition.                 
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Figure 3.4: Dose-dependent accumulation of aggregated tau 3 days post-seeding. 
Western blot with total tau antibody (DA9) and pS202/pT205 tau antibody (AT8) of fractions 
extracted of HEK T-REx P301S 1N4R tau inducible cells fractionated in presence (A) and 
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absence (B) of 1% sarkosyl. Quantifications of the blots are shown in the graphs. Cells were 
treated with increasing concentration of TgP301S mouse sarkosyl-insoluble extract for 3 hours, 
followed by 3 days of growth. Data shown are mean ± SEM (n=2).  
 
Similarly, Alphascreen assays showed a dose-dependent accumulation of hyperphosphorylated 
tau aggregates, upon treatment with TgP301S seed, in the insoluble fraction, detected by 
antibody AT8 (Figure 3.5). 
  
Figure 3.5: Dose-dependent accumulation of aggregated tau 3 days post-seeding. 
Alphascreen assays showing levels of total tau (DA9-TG5 antibodies) or hyperphosphorylated 
tau (AT8-DA9 antibodies) in the insoluble fractions following 3 hour inoculation with increasing 
concentrations of TgP301S mouse sarkosyl-insoluble extract and 3 days growth. Data shown 
are mean ± SEM (n=2).  
 
An anti-1N tau antibody was also employed to confirm the endogenous nature of tau 
aggregates by WB (Figure 3.6). 
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Figure 3.6:  Accumulation of endogenous aggregated tau 3 days post-seeding. Western 
blot with 1N tau antibody and total tau antibody (DA9) in different fractions of HEK T-REx 
P301S 1N4R tau inducible cells treated with TgP301S mouse sarkosyl-insoluble extract, 
followed by trypsinisation, reveals accumulation of abundant insoluble endogenous 1N4R tau in 
seeded cells. Sequential extraction (fractionation) was performed; total lysates (cellular fraction 
recovered in fractionation buffer), soluble and insoluble fractions were loaded on SDS-PAGE. 
Input seed (expected to contain 0N4R P301S tau, and no 1N-tau) was loaded as negative 
control for the 1N-tau antibody. PHF from AD brain (expected to contain 0N-, 1N-, 2N-tau) was 
loaded as positive control for the 1N-tau antibody. Data shown is representative of 2 
independent experiments. 
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3.4 Development and characterisation of seeded tau aggregation: imaging assays in HEK 
T-REx P301S 1N4R tau inducible cells 
Abundant Triton X-100-insoluble phospho-tau aggregates were detected by 
immunofluorescence using anti-phosphoS409-tau antibody PG5 after 1% Triton X-100 
extraction during fixation to remove soluble proteins (Figure 3.7 A). Quantification of the % of 
aggregate-bearing cells induced by TgP301S seed inoculation was performed by BD pathway 
high-content imaging: treatment of 1N4R P301S tau-expressing cells with 0N4R seed for 3 
hours followed by 3 days of growth yielded aggregates in up to ~12% of cells, in a dose-
dependent fashion (Figure 3.7 B). 
 
 
 
 
 
 
 
 
B 
 
Figure 3.7: High-content imaging (HCI) assay shows dose-dependent accumulation of 
aggregated tau 3 days post-seeding. (A) After incubation of HEK T-REx P301S 1N4R tau 
cells with tau seed for 3 hours, followed by 3 days of growth, accumulation of Triton X-100-
insoluble endogenous tau recognised by PG5 antibody (green) was detected by HCI in up to 
12% of total cells. Soluble proteins were extracted by 1% Triton X-100 during fixation of the 
cells. Cell nuclei were stained by DAPI (blue). Scale bar 50 μm. (B) Quantification of (A). Data 
shown are mean ± SEM (n=2). 
 
Confocal microscopy showed that treatment with TgP301S (0N4R) sarkosyl-insoluble seed 
resulted in punctate, intracellular PG5-positive tau inclusions in cells. These inclusions were 
absent in unseeded cells, in which the phosphorylated tau recognized by antibody PG5 (tau 
pS409) was extracted by 1% Triton X-100 during fixation; similar images were obtained with anti 
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pS202/pT205-tau antibody AT8 (Figure 3.8 A) and anti-nitrated Y29-tau antibody nY29 (Figure 
3.8 B). These epitopes are associated with filamentous tau as they are present in PHFs. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Confocal imaging assay shows modifications at epitopes associated with 
PHFs. pS409 (PG5) - positive tau inclusions (green) in inducible HEK T-REx cells expressing 
human 1N4R P301S tau, following exposure to TgP301S mouse-derived sarkosyl-insoluble 
material for 3 h followed by 3 days of growth. (A) Colocalization with anti pS202/pT205 tau 
antibody AT8 (red) is shown. (B) Colocalization with anti nY29 tau antibody (red) is shown. 
Scale bar 40 μm. 
 
Confocal microscopy experiments comparing the effect of 1 minute treatment with 0.0125% 
trypsin at room temperature following TgP301S seed treatment revealed that the inoculated 
TgP301S seed was truly internalized (Figure 3.9). 
 
 
  
    Hoechst (nuclei)                 PG5                            nY29                         Overlay 
S
e
e
d
e
d
 
U
n
s
e
e
d
e
d
 
   Hoechst (nuclei)                PG5                             AT8                        Overlay 
S
e
e
d
e
d
 
U
n
s
e
e
d
e
d
 
59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Confocal imaging in absence vs presence of trypsin shows that the 
inoculated TgP301S seed is truly internalized. Confocal imaging showing PG5-positive tau 
inclusions (tau pS409, green) in HEK T-REx inducible cells expressing P301S 0N4R tau 
following inoculation with sarkosyl-insoluble TgP301S tau mouse seed for 3 hours, followed by 
0 days of grows (A) or 3 days of growth (B). Total tau was visualised with CP27 antibody (red) 
and the nucleus was visualised with Hoechst (blue). Cells were treated with or without 0.0125% 
trypsin after seeding. Scale bar 20 μm. 
 
An anti-1N tau antibody was also employed to confirm the endogenous nature of tau 
aggregates by confocal microscopy (Figure 3.10). 
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Figure 3.10: Accumulation of endogenous aggregated tau 3 days post-seeding. pS409-
positive tau inclusions (PG5, green) in inducible HEK T-REx cells expressing human 1N4R 
P301S tau, following exposure to TgP301S mouse-derived sarkosyl-insoluble material for 3 h 
followed by 3 days of growth. Total tau was visualised with an antibody specific for 1N tau (red). 
Scale bar 20 μm.  
 
In summary, after incubation of HEK T-REx P301S 1N4R tau inducible cells with TgP301S tau 
seed for 3 hours, followed by 3 days of growth, accumulation of Triton X-100-insoluble 
endogenous tau was detected by HCI in about 12% of total cells, accompanied by appreciable 
accumulation of insoluble tau detected by western blot and Alphascreen. 
 
Taken together, these different readouts showed that the sarkosyl-insoluble, native TgP301S 
tau preparation entered HEK T-REx P301S 1N4R tau-expressing inducible cells and recruited 
endogenous tau to form intracellular tau fibrils. Upon seed treatment, a dose dependent 
increase in levels of insoluble AT8-positive tau was observed.  
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3.5 Discussion on HEK T-REx P301S tau inducible cell-based assay 
Aggregation has been well studied in vitro using diverse disease-associated recombinant 
proteins and proceeds by nucleated growth polymerization, a process that can be accelerated 
by addition of preformed aggregates or seeds. Recent studies have indicated that aggregation 
of Aβ42, polyQ peptides, tau and α-synuclein can be induced experimentally by exogenous 
seeds (Clavaguera et al. 2009, Meyer-Luehmann et al. 2006b, Yang et al. 2002, Yang et al. 
2002, Ren et al. 2009, Li et al. 2008, Desplats et al. 2009). Several publications have now 
demonstrated high efficiency recruitment of soluble tau into authentic NFT-like aggregates in 
cultured cells, providing unequivocal evidence for the seeding phenomenon in cell models of 
tauopathies (Guo, Lee 2011, Frost, Jacks & Diamond 2009). In this work, the induction and 
formation of intracellular aggregates in cell culture presents important differences from these 
previous studies: 
1) We converted a transient cell system into an inducible one, expressing human mutated tau 
upon addition of tetracycline to the cell media, which increased the robustness of the assay by 
reducing variability in tau expression, compared to a transient system which relies on 
transfection reagents. 
2) Recombinant aggregated tau (full length or microtubule binding region, MTBR) has been 
shown to enter cells and recruit endogenous soluble tau into fibrillar tau (Guo, Lee 2011, Frost, 
Jacks & Diamond 2009, Kfoury et al. 2012, Falcon et al. 2015, Wu et al. 2013). Here we used 
native tau seed as opposed to recombinant pre-formed fibrils; the sarkosyl-insoluble TgP301S 
tau extract we introduced into cells contains a heterogeneous mixture of fibrillar species with 
varying dimensions. We have previously characterized the biophysical properties of these 
seeding species, showing that sarkosyl-insoluble tau from the brains of TgP301S transgenic 
mice exhibits increased seeding potency than sarkosyl-insoluble aggregates of recombinant 
P301S tau (Falcon et al. 2015). Other groups have used native seeds in non-neuronal cells. 
When Wu et al incubated HeLa cells with sarkosyl extracted, in vivo-derived tau filaments from 
aged  rTg4510 mice for 12 h, these were not taken up by cells, likely due to their excessive size; 
only recombinant oligomers and short fibrils were taken up by their cell system (Wu et al. 2013). 
Santa-Maria et al showed for the first time that HEK-293T and SHSY5Y cells overexpressing 
GFP-tagged tau, treated with isolated fractions of human AD-derived PHFs for 24 h developed 
intracellular GFP-tau aggregates resembling aggresomes, but the signal window of their assay 
was poor, as PHF-treated cells displayed a 3-fold increase in the content of sarkosyl-insoluble 
GFP-Tau as compared with non-treated cells (Santa-Maria et al. 2012). Sanders et al. 2014 
produced human brain homogenates from distinct tauopathies (AD, CBD, AGD), and 
transduced IP’ed or crude homogenate into the monoclonal Tet Off-tau RD-YFP HEK293 cell 
line, used for its relatively high tau RD expression and greater seeding efficacy, and observed a 
unique inclusion morphology produced by each tauopathy; caveats here were the expression of 
RD as opposed to full-length tau, and the use of Lipofectamine to deliver seeds into the cells as 
opposed to spontaneous uptake (Sanders et al. 2014.). 
3) The use of protein delivery reagents to enhance introduction of seed into cells has been 
shown to provide better efficiency of tau seed entry (Guo, Lee 2011), but we opted for a 
reagent-free inoculation of seed to avoid confounds in characterising the uptake mechanism 
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and produce a more physiological experimental setting. Indeed, the authors found that protein 
delivery reagent improved the efficiency of tau pre-formed fibrils entry (from 10% aggregate-
bearing cells in absence of reagent to 35% aggregate-bearing cells when seeding in presence 
of reagent) but they concluded that tau pre-formed fibrils alone are sufficient to recruit 
endogenous tau into fibrils, and they chose to conduct mechanistic studies on spontaneous 
uptake of ppfs, in absence of protein delivery reagent. 
4) Rather than expressing endogenous tau tagged with a fluorescent protein, which may impair 
the conformational change required for efficient tau fibril assembly, our system employs 
untagged tau so that recruitment of endogenous tau is presumably facilitated; despite 
widespread use of tagged tau constructs in the literature, i.e. FRET biosensor HEK293T cell line 
(“tau biosensor cells”) stably expressing tau repeat domain (RD) fused to either CFP or YFP 
(Holmes et al. 2014), internal work at Eli Lilly showed greater seeding efficiency in rat cortical 
neurons expressing endogenously cleavable tau-GFP constructs, as opposed to stable ones. 
Additionally, our seeding tau is a distinct isoform from our endogenous tau, in order to 
demonstrate that the intracellular inclusions in our system are composed of recruited, 
phosphorylated endogenous tau, rather than simply the original tau seed. 
5) It has been shown that the MT-binding repeats of tau are both necessary and sufficient for 
tau aggregation into straight and paired-helical filaments (von Bergen et al. 2000, Gamblin, 
Berry & Binder 2003), and the repeat domain alone has a higher fibrillogenic tendency than full-
length tau (Wille et al. 1992); our model exclusively employs full-length tau, both endogenously 
and as exogenous seed, providing a more biologically relevant system; recent data also 
highlighted the fact that a rapid propensity to aggregation in vitro, as observed for the K18 
fragment, does not correlate with ability to seed aggregation in cells, as the latter seems to 
depend on the secondary structure produced by the aggregates (Stohr et al. 2017); since full-
length tau aggregates may display greater structural heterogeneity and complexity than short 
fragments, they may offer more opportunities for interactions with tau protein in cells.  
 
An obvious limitation of cell models of tauopathies, including ours, is their clear temporal 
discrepancy with neurodegenerative processes in humans, which typically occur only after 
much longer incubation times. A couple of factors are worth considering: first, the rate-limiting 
step of protein aggregation is the formation of small assemblies of misfolded proteins, or seeds 
(nucleation phase)(Friedhoff et al. 1998a, Wood et al. 1999); this nucleation phase is 
accelerated in our cell model by addition of exogenous seeds, and similarly in animal models 
where misfolded proteins are directly delivered into the brain, and aggregation is observed 
within weeks or months; but in aged brains, where misfolded proteins are no longer efficiently 
cleared by the proteolytic machinery, a slow accumulation of tau seeds in neurons over 
decades only eventually reaches a critical concentration to initiate a cascade of recruitment and 
aggregation of soluble tau, initiating a self-perpetuating process of tangle formation; secondly, 
seeded fibrillization is a concentration-dependent process, and our HEK Trex P301S tau 
inducible cells overexpress tau, carrying a disease-causing mutation that further promote 
aggregation, similarly to animal models of mutant tau overexpression, whereas the incubation 
time is much longer in human tauopathies and other neurodegenerative diseases, where the 
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disease-associated proteins are not usually upregulated. It will be important to demonstrate 
robust propagation of templated pathology in non-overexpressing and non-transgenic in vitro 
and in vivo models which may mimic better the slow progression of tauopathies, however for 
practical reasons such models will always be an accelerated version of the human diseases. 
 
Another limitation of our cell model is the absence of detectable cell death (see chapter 6); 
however, cell death was observed when concentrations of tetracycline higher than 1 μg/ml were 
used to induce tau expression. Other groups similarly reported no obvious cellular toxicity after 
induction of tau aggregates in cultured cells or tau transgenic mice (Guo, Lee 2014, Clavaguera 
et al. 2014., Iba et al. 2013, Guo, Lee 2011, Guo, Lee 2013), but there are examples of reported 
cytotoxicity in cell models. In one publication, HEK-293 cells stably or inducibly overexpressing 
the longest human tau isoform (htau40) were incubated with varying concentrations of Congo 
red for 7 days to drive aggregation; viability was detected by ToPro-3 uptake, a fluorescent 
DNA-intercalating dye taken up by dead but not live cells (Vogelsberg-Ragaglia et al. 2000); 
tetracycline-inducible cells were treated with or without 10 μM Congo red for up to 4 days (to 
avoid underestimation of dead cells because of media change); tau overexpression and 
aggregation induced by Congo red caused a 5.9-fold increase in ToPro-3 fluorescence intensity, 
compared with non-tau expressing cells grown in the absence of Congo red; in this system, tau 
aggregation did not cause acute toxicity, but decreased cell viability in a time dependent 
manner, reaching statistical significance by 4 days in culture (Bandyopadhyay et al. 2007). 
Another publication used N2a inducible Tet-on cells with overexpressed mutant tau 4-repeat 
domain, harboring the FTDP-17 mutation K280 (“pro-aggregant” TauRDΔK280) (Wang et al. 
2007, Khlistunova et al. 2006), where TauRDΔK280 forms aggregates and causes toxicity. 
Inhibition of autophagy increased the number of aggregates and exacerbated cytotoxicity 
(Wang et al. 2009). Activation of autophagy by trehalose reduced endogenous tau, suppressed 
tau aggregation and reduced cytotoxicity measured by LDH assay in medium; upon trehalose 
treatment the cytotoxicity induced by TauRDΔK expression (~24%) dropped back to baseline 
(~10%) (Kruger et al. 2012). Elevated levels of tau cause aggregation and toxicity in neurons 
(Morris et al. 2011), but HEK-293 cells have been shown to tolerate high-level tau 
overexpression without serious toxicity (Li, Yin & Kuret 2004). Cell toxicity may also be 
dependent on the tau conformers used to confer seeding or produced from seeding: Sanders et 
al. generated a monoclonal HEK293 cell line that stably expresses the tau repeat domain fused 
to YFP (RD-YFP); after induction of aggregation with recombinant fibrils, they selected clonal 
lines that indefinitely propagate reproducible and unique aggregate structures from one 
generation to the next. The clones showed a variety of inclusion morphology and size, 
sedimentation profile, seeding capacity, protease digestion patterns, subcellular localization, as 
well as cell toxicity; in particular, different clones showed different degrees of cell death as 
measured by DAPI stain and LDH release, with some clones eliciting cytotoxicity unly upon RD 
expression (Sanders et al. 2014.). Overall, the occurrence of cell death in a particular cell model 
seems to depend on tau expression levels and tau strains present in that particular model. The 
lack of cytotoxicity in our and other models could also be explained by the very nature of 
seeded fibrillization, whereby addition of exogenous seeds bypasses the slow nucleation phase, 
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characterised by oligomers/pre-fibrils, which are believed to be more toxic than mature fibrils 
(Cowan, Mudher 2013, Alonso et al. 2006, Lasagna-Reeves et al. 2012, Maeda et al. 2007). 
 
Our cell based assay also merits further characterisation to corroborate its relevance as a model 
for tauopathy; for instance, in our publication (Falcon et al. 2015) we have shown by electron 
microscopy that endogenous tau aggregates formed following seeding are fibrillar, but we have 
not fully characterised their morphology in term of twist periodicity, flexibility and width of the 
filaments, to assess their fidelity to the ones observed in human tauopathies; furthermore, we 
have not estimated tau intracellular concentrations in our cell model, and compared them to 
physiological tau concentrations in human brains.  
In summary, we have established a novel, simple and yet highly reproducible and robust cellular 
system of tau aggregation. Within the limitation of using non-neuronal cells, our model still 
provides a system to dissect the mechanisms underlying the propagation of tau protein 
misfolding. In particular, we used this system to investigate some of the unresolved questions in 
the field, in particular what mechanisms allow tau uptake and release, and what factors 
influence seeding efficiency. 
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4. CHARACTERISATION OF SEED UPTAKE 
 
Here, we wanted to dissect the mechanisms of TgP301S seed uptake in our inducible cell 
model; we explored the effect of temperature and transfection reagents on seed uptake. To 
investigate whether endocytosis is the main mechanism of tau uptake in this model, we 
explored the effect of different endocytosis modulators during seeding. Next, we investigated 
colocalization between tau seed and endocytic markers (EEA1, CD63) by immunofluorescence. 
Finally, following the incidental observation of tunnelling nanotubes (TNTs) in our cell model, we 
characterised them by confocal microscopy and explored the effect of the F-actin-
depolymerising compound latrunculin A on tau intercellular propagation.   
 
4.1 Tau seed uptake is enhanced by transfection reagents 
Protein delivery/transfection reagents were not used during endocytosis studies as not only 
could they have affected the analysis, but they were also not required as we have shown that 
sarkosyl-insoluble TgP301S tau seed can be taken up spontaneously in the absence of protein 
delivery reagents. Consistent with published literature on the uptake of pre-formed tau fibrils in 
cell-based models (Guo, Lee 2011), we found that transfection reagents like Lipofectamine 
2000 increased the amount of Triton X-100-insoluble tau in TgP301S seed-treated cells in a 
dose-dependent manner, without inducing accumulation of insoluble tau in unseeded cells (from 
~10% cells containing PG5-positive aggregates in absence of Lipofectamine up to ~40% in 
presence of Lipofectamine) (Figure 4.1). 
 
Figure 4.1: Lipofectamine 2000 increases the amount of Triton X-100-insoluble tau in 
TgP301S seed-treated cells. High content imaging assay showing the % of cells containing 
PG5-positive tau inclusions in HEK T-REx P301S 1N4R tau inducible cells expressing P301S 
0N4R tau following 3 hour inoculation with sarkosyl-insoluble TgP301S tau mouse seed in 
presence of transfection reagents. Seeding was followed by 3 days growth. Data shown are 
mean ± SEM (n=2). Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, 
****p<0.0001, compared with “no reagent” control. 
 
In the case of Lipofectamine, a transfection reagent for DNA transfections, the positive surface 
charge of the liposomes mediates the interaction of the nucleic acid and the cell membrane, 
allowing for fusion of the liposome/nucleic acid (“transfection complex”) with the negatively 
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charged cell membrane. The transfection complex is thought to enter the cell through 
endocytosis, whereby a localized region of the cellular membrane uptakes the DNA/liposome 
complex by forming a membrane bound/intracellular vesicle. Once inside the cell, the complex 
must escape the endosomal pathway, diffuse through the cytoplasm, and enter the nucleus for 
gene expression. It is plausible that the same process also applies to protein delivery. 
Therefore, increased intracellular tau aggregate formation by transfection aid reagents is likely 
due to enhanced internalization of TgP301S seed. Taken together, these results show that 
spontaneous TgP301S seed entry seems to occur at least in part through endocytosis, which 
can be potentiated by Lipofectamine 2000. For all the remaining experiments we opted for a 
transfection reagent-free inoculation of seed to avoid confounds in characterising the uptake 
mechanism and produce a more physiological experimental setting. 
 
4.2 Time course of seeding and post-seeding phase 
To examine the progression of TgP301S seed-induced endogenous tau aggregation, we 
dissected the experimental protocol into a “seeding” phase followed by a “post-seeding growth” 
phase, and performed a time course of both phases, monitoring the extent of tau aggregation by 
imaging and biochemical assays. We measured seed-induced 1N4R P301S tau aggregation in 
HEK T-REx P301S 1N4R tau inducible cells after different lengths of seed incubation at 37°C 
(10, 30, 60 or 180 minutes), followed by 3 days growth, and after 3 hours of seed incubation at 
37°C, followed by different lengths of growth (0, 1, 2 or 3 days). The TgP301S seed was taken 
up in a time-dependent manner. Both WB (Figure 4.2) and AS (Figure 4.3) showed a difference 
in the extent of aggregation induced by 10 minutes vs 30 minutes vs 3 h incubation with seed, 
indicating a time-dependent internalization of TgP301S seed (from 0.2 up to 1 Alphascreen 
units). The seed-induced aggregation did not increase between the “30 minute seeding” and “60 
minute seeding” timepoints, but it did increase further in the “180 minutes seeding” timepoint, 
suggesting a slow but continuous uptake of TgP301S seed. Similarly to the seeding phase, 
extending the growth phase up to 3 days led to increasing accumulation of intracellular 
aggregates (from 0 up to 1 Alphascreen units). 3 hour incubation with TgP301S tau seed at 
37°C followed by 3 days growth resulted in the highest incidence of aggregates. Accumulation 
of AT8-positive insoluble tau aggregates failed to occur when sarkosyl-insoluble tau generated 
from wt C57Bl6 mice was inoculated into cells (WT seed). 
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Figure 4.2: Time dependent internalisation and accumulation of aggregated tau in seeded 
HEK T-REx P301S tau inducible cells. Legend on the next page. 
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Figure 4.2: Time dependent internalisation and accumulation of aggregated tau in seeded 
HEK T-REx P301S tau inducible cells. (A) Western blot with total tau antibody DA9 and tau 
pS202/pT205 antibody (AT8) of the insoluble fraction from HEK T-REx inducible cells 
expressing P301S 1N4R tau, inoculated with TgP301S mouse sarkosyl-insoluble extract of WT 
mouse sarkosyl-insoluble extract. For a time course of the seeding phase, cells were seeded for 
10, 30, 60 or 180 minutes, followed by 3 days growth. For a time course of the post-seeding 
phase, cells were seeded for 3 hours followed by 0, 1, 2 or 3 days growth.  Residual seed was 
removed by 0.0125% trypsin for 1 minute at room temperature after seeding. (B) Corresponding 
densitometry analysis. Data shown are mean ± SEM (n=3). 
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Figure 4.3: Time dependent internalisation and accumulation of aggregated tau in seeded 
HEK T-REx P301S tau inducible cells. Alphascreen assays showing levels of total tau 
(capture with DA9, detect with TG5 antibodies) and pS202/pT205 tau (capture with AT8, detect 
with DA9 antibodies) in the same samples shown in figure 4.2. Data shown are mean ± SEM 
(n=3).  
 
Alphascreen data for total tau did not mirror the corresponding WB data; this discrepancy may 
be due intrinsic differences between the two assays, i.e. samples are boiled in presence of 7-
13% LDS (lithium dodecyl sulphate) for WB, whereas for Alphascreen they are not denatured; 
samples are probed with a single antibody (DA9) for WB, whereas for Alphascreen they are 
recognised by an antibody pair (DA9-TG5).  
 
High-content image analysis showed a difference in the extent of aggregation induced by 3 
hours vs 1 hour vs 30 minutes vs 10 minutes of incubation with TgP301S seed (from ~1.5% up 
to ~12% aggregate-bearing cells) indicating a time-dependent internalization (Figure 4.4). 1 day 
after seed inoculation, focal inclusions were not frequent, and Triton X-100-insoluble tau was 
found in about 6% of total cells; 2 days after seeding, about 8% of the cells showed PG5 
immunoreactivity, and 3 days after seed treatment, about 12% of total cells were presenting 
PG5-positive Triton X-100-insoluble tau inclusions. As a control, cells were treated with either 
Optimem alone or with sarkosyl-insoluble tau extract generated from wt C57Bl6 mice; under 
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these conditions, phosphorylated tau recognized by antibody PG5 (tau pS409) was completely 
soluble and extracted by 1% Triton X-100 during fixation. 
 
 
Figure 4.4: Time dependent internalisation and accumulation of aggregated tau in seeded 
HEK T-REx P301S tau inducible cells. High content imaging assay showing the % of cells 
containing PG5-positive tau inclusions in HEK T-REx P301S 1N4R tau inducible cells 
expressing P301S 1N4R tau following inoculation with TgP301S mouse sarkosyl-insoluble  
extract or WT mouse sarkosyl-insoluble extract for 10, 30, 60 or 180 minutes, followed by 3 
days growth, or inoculation for 3 hours followed by 1, 2 or 3 days growth. Residual seed was 
removed by 0.0125% trypsin for 1 minute at room temperature after seeding. Data shown are 
mean ± SEM (n=2). Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, 
****p<0.0001, compared with WT seed control. 
 
Observation by confocal microscopy of cells inoculated with mutant TgP301S tau aggregates 
for 3 hours and grown for increasing lengths of time showed that internalized aggregates 
increased in size over time (Figure 4.5). The time course post-seeding showed that 1 day after 
the incubation with TgP301S seed, a small percentage of cells started showing accumulations 
of Triton X-100-insoluble tau (PG5); 2 days post-seeding, more cells developed aggregates, 
and 3 days post-seeding, PG5-positive aggregates were more frequently seen. Quantification 
was not preformed on confocal images as the % of cells with PG5-positive aggregates was 
measured by high-content imaging assay. 
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Figure 4.5: Confocal imaging shows time-dependent development of Triton X-100-
insoluble tau aggregates.  PG5-positive tau inclusions (tau pS409, green) in HEK T-REx 
inducible cells expressing P301S 1N4R tau following inoculation with TgP301S sarkosyl-
insoluble extract for 10, 30, 60, 180 minutes, followed by 3 days growth, or inoculation for 3 
hours followed by 0, 1, 2, 3 days growth. Total tau was visualised with CP27 antibody (red) and 
the nucleus was visualised with Hoechst (blue). Soluble proteins were extracted by 1% Triton X-
100 during fixing. Scale bar 20 μm. 
 
Both biochemical and imaging readouts suggest that seed internalisation and formation of 
endogenous aggregates after seeding are time-dependent processes. 
 
4.3 Spontaneous seed uptake occurs by endocytosis as it is sensitive to temperature 
To further investigate whether seed uptake is mediated by endocytosis, we incubated HEK T-
REx P301S 1N4R tau inducible cells with sarkosyl-insoluble TgP301S tau seed for 3 hours at 
either 37°C or 4°C to block endocytosis, a temperature-dependent mechanism (Guo, Lee 2011). 
As an indirect readout of seed entry, we quantified insoluble endogenous tau aggregates 
produced by the cells 3 days after seeding. 
 
By high-content imaging, TgP301S sarkosyl-insoluble tau seed incubation at 37°C for 3 hours 
followed by an additional 3-day incubation resulted in ~8% of total cells containing PG5-positive 
Triton X-100-insoluble tau, whereas 3 hours of seed incubation at 4 °C followed by exactly the 
same treatment resulted in a significant reduction of cells containing tau aggregates (~3%), 
suggesting that tau seed uptake is a temperature-dependent process (Figure 4.6 A). A 3 hour 
treatment with tau seed at 37°C but not at 4°C, followed by 3 days growth, resulted in 
detectable Triton X-100-insoluble aggregates. Minimal aggregation was observed with 3 hours 
of seed treatment at 4°C, followed by 3 days growth. Quantification from Alphascreen and 
western blot experiments reproduced a significant reduction  (~50%) in aggregate-bearing cells 
when 3-hour seeding was performed at 4°C instead of 37°C (Figure 4.6 B, C).  
10 min + 3 days 30 min + 3 days 60 min + 3 days 
3 h + 0 days 3 h + 1 day 3 h + 2 days 3 h + 3 days 
pS409-tau (PG5)(green), total tau (CP27)(red), Hoechst (nuclei)(blue) 
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Figure 4.6: Seed uptake is a temperature-dependent process. (A) High-content imaging 
assay showing the % of cells containing PG5-positive tau inclusions in HEK T-REx inducible 
cells expressing P301S 1N4R tau following 3 hour inoculation with TgP301S mouse sarkosyl-
insoluble extract at 37˚C vs 4˚C, and 3 days growth. Data shown are mean ± SEM (n=2). 
Statistical analysis: t test comparing 37˚C vs 4˚C. (B) Alphascreen assays showing levels of 
total tau (DA9-TG5 antibodies) or hyperphosphorylated tau (pS202/pT205-tau, AT8-DA9 
antibodies; pS409-tau, PG5-DA9 antibodies) in the insoluble fraction of HEK T-REx inducible 
cells expressing P301S 1N4R tau following 3 hour inoculation with TgP301S mouse sarkosyl-
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insoluble extract at 37˚C vs 4˚C, and 3 days growth. Statistical analysis: t test comparing 37˚C 
vs 4˚C. (C) Western blot with total tau antibody (DA9) and tau pS202/pT205 antibody (AT8) on 
the same samples. Data shown are mean ± SEM (n=2).  
 
4.4 Endocytosis inhibitors reduce seed-induced tau aggregation by impairing 
spontaneous seed uptake 
Having shown that sarkosyl-insoluble TgP301S tau extract efficiently penetrates inside cells, we 
explored this phenomenon further by systematically examining which of the various endocytic 
pathways contributed to the uptake of mutant tau aggregates. HEK T-REx P301S 1N4R tau 
inducible cells were incubated with TgP301S seed, without transfection reagent, and in the 
presence of concentration of compounds known to inhibit specific endocytic pathways (Munch, 
O'Brien & Bertolotti 2011); cells were further grown for 3 days, fixed and examined by high-
content imaging assay to measure the % of aggregate-bearing cells (Figure 4.7). 
 
To determine whether tau seed penetrates inside the cells via an active process, cells were 
exposed to sodium azide and 2-deoxyglucose (Munch, O'Brien & Bertolotti 2011) to deplete 
cellular ATP prior to the exposure to aggregates. ATP-depletion reduced the % of cells with 
aggregation by 30% at 10 μM (Figure 4.7 A). To determine whether tau seed penetrates inside 
the cells via a dynamin-dependent mechanism, cells were exposed to dynasore (Munch, 
O'Brien & Bertolotti 2011) prior to and during the exposure to aggregates. This treatment did not 
affect seed uptake, apart from a 30% reduction at 1 mM (Figure 4.7 B).  To determine whether 
tau seed penetrates inside the cells via a clathrin-dependent mechanism, cells were exposed to 
chlorpromazine (Munch, O'Brien & Bertolotti 2011) prior to and during the exposure to 
aggregates. The highest concentrations 30 μM, 10 μM reduced tau uptake by 30% (Figure 4.7 
C). To determine whether tau seed penetrates inside the cells via macropinocytosis, cells were 
exposed to 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) (Munch, O'Brien & Bertolotti 2011) to inhibit 
Na+/H+ transport prior to and during the exposure to aggregates. This treatment attenuated the 
internalization of seed by 50% at the highest concentrations 100 μM, 33 μM (Figure 4.7 D). 
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A      B  
                                      
C      D 
 
Figure 4.7: Endocytosis inhibitors reduce tau aggregates uptake. High content imaging 
assay showing the % of cells containing PG5-positive tau inclusions in HEK T-REx inducible 
cells expressing P301S 1N4R tau, inoculated with TgP301S mouse seed sarkosyl-insoluble 
extract for 2-3 hours in conditions of (A) ATP-depletion (sodium azide and 2-deoxyglucose were 
added 2.5 h prior to and during exposure to aggregates); (B) dynamin inhibition (dynasore was 
added 30 minutes prior to and during exposure to aggregates); (C) clathrin inhibition 
(chlorpromazin was added 30 minutes prior to and during exposure to aggregates); (D) 
macropinosomes inhibition (EIPA was added 30 minutes prior to and during exposure to 
aggregates). Seeding was followed by 3 days growth.  Data shown are mean ± SEM (n=2). 
Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, 
compared with untreated control. 
    ATP depletion
(NaN3 + 2-deoxy-D-glucose)
during seeding
%
 o
f 
P
G
5
-p
o
s
it
iv
e
 c
e
ll
s
un
se
ed
ed
se
ed
ed
 
un
se
ed
ed
 +
 1
0m
M
se
ed
ed
 +
 1
0m
M
se
ed
ed
 +
 3
m
M
se
ed
ed
 +
 1
m
M
se
ed
ed
 +
 0
.3
m
M
se
ed
ed
 +
 0
.1
m
M
0
5
10
15
**
***
***
*
        Dynamin inhibition
(dynasore)
during seeding
%
 o
f 
P
G
5
-p
o
s
it
iv
e
 c
e
ll
s
un
se
ed
ed
se
ed
ed
 
un
se
ed
ed
 +
 1
00
uM
se
ed
ed
 +
 1
00
0u
M
se
ed
ed
 +
 3
00
uM
se
ed
ed
 +
 1
00
uM
se
ed
ed
 +
 3
0u
M
se
ed
ed
 +
 1
0u
M
se
ed
ed
 +
 3
uM
se
ed
ed
 +
 1
uM
0
5
10
15 *
        Clathrin inhibition
(chlorpromazine)
during seeding
%
 o
f 
P
G
5
-p
o
s
it
iv
e
 c
e
ll
s
un
se
ed
ed
se
ed
ed
 
un
se
ed
ed
 +
 1
0u
M
se
ed
ed
 +
 3
0u
M
se
ed
ed
 +
 1
0u
M
se
ed
ed
 +
 3
uM
se
ed
ed
 +
 1
uM
se
ed
ed
 +
 0
.3
uM
se
ed
ed
 +
 0
.1
uM
0
5
10
15
20
**
***
Macropinocytosis inhibition
(EIPA)
during seeding
%
 o
f 
P
G
5
-p
o
s
it
iv
e
 c
e
ll
s
un
se
ed
ed
se
ed
ed
un
se
ed
ed
 +
  3
uM
se
ed
ed
 +
 1
00
uM
se
ed
ed
 +
 3
3u
M
se
ed
ed
 +
 1
1u
M
se
ed
ed
 +
 3
uM
se
ed
ed
 +
 1
uM
se
ed
ed
 +
 0
.4
uM
se
ed
ed
 +
  0
.1
uM
0
5
10
15
*
*
75 
 
 
To further dissect the uptake mechanism and allow a more direct measure of seed uptake, we 
repeated the treatment with EIPA during seeding, but fixing the cells straight after seeding, as 
opposed to allowing further 3 days of growth. Again, in this experimental system, EIPA 
treatment markedly attenuated the internalization of seed by 50% at the highest concentrations 
100 μM, 33 μM (Figure 4.8). 
 
Figure 4.8: Tau aggregates enter cells by macropinocytosis. High content imaging assay 
showing the % of cells containing PG5-positive tau inclusions in HEK T-REx inducible cells 
expressing P301S 1N4R tau, inoculated with TgP301S mouse sarkosyl-insoluble extract for 3 
hours in conditions of macropinocytosis inhibition (EIPA was added 30 minutes prior to and 
during exposure to aggregates). Cells were fixed straight after seeding. Data shown are mean ± 
SEM (n=2). Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, 
****p<0.0001, compared with untreated control. 
 
4.5 Tau aggregates are transferred along the endosome/lysosome pathway 
Dysfunction of the endosomal-lysosomal pathway causes the earliest known neuronal 
pathology in AD and is promoted by genetic factors that cause early-onset AD or increase risk 
of late-onset AD. The earliest disease-specific pathologic change in sporadic AD – appearing 
before beta-amyloid is deposited in the neocortex, and before the appearance of NFTs – is the 
enlargement of Rab5- and Rab7-positive neuronal endosomes, which reflects a pathological 
acceleration of endocytosis (Nixon, Yang 2011).  
 
To determine whether aggregates were processed via the endocytic pathway, cells were 
inoculated with mutant tau aggregates for various periods of time (from 10 minutes to 24 hours), 
then fixed with 4% PFA/0.1% Triton X-100 and stained for tau (PG5 antibody), EEA1 (early 
endosome marker, (Filimonenko et al. 2007) (Figure 4.9 A) and CD63 (late endosome marker, 
(Kobayashi et al. 2000) (Figure 4.9 B). 
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Figure 4.9: Tau aggregates colocalize with markers of the endocytic pathway. Confocal 
micrographs of cells after inoculation with TgP301S tau aggregates in a time-course fashion 
before trypsinization to remove residual seed, fixation with 4% PFA and permeabilization with 
0.1% Triton X-100. Nuclei were stained with Hoechst (blue). Tau aggregates were 
immunostained with PG5 antibody (green). (A) Early endosomes were immunostained with a 
16 h 
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6 h 
Seeded 
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Unseeded 
10 min 
30 min 
1 h 
Seeded Unseeded 
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specific antibody (EEA1, red). (B) Late endosomes were immunostained with a specific 
antibody (CD63, red). Scale bar 20 μm. 
The colocalization of TgP301S seed with early endosomal marker EEA1 and late endosomal 
marker CD63 was evident at 16 and 24 hours after inoculation, indicating that tau seeds can be 
internalized into endocytic vesicles, and possibly escape the endocytic compartment to seed 
aggregation of the endogenous protein. 
 
4.6 Discussion on seed uptake in HEK T-REx P301S tau inducible cells 
This study reveals that aggregates of the FTDP17-causing P301S tau mutant penetrate inside 
P301S tau-expressing cells and trigger aggregation of the endogenous mutant protein. By high-
content imaging assay, as little as 10 minute incubation with TgP301S seed led to detectable 
accumulation of Triton X-100-insoluble PG5-positive tau; the presence of tau inclusions after 
such a short incubation with seed is suggestive that internalization of minute quantities of seed 
is sufficient to induce recruitment of endogenous tau into inclusions, even in the absence of any 
transfection reagent. Substantial aggregation of soluble tau can be induced by spontaneous 
uptake of TgP301S seed, which seems to occur via endocytic pathways that are temperature-, 
time- and ATP-dependent, can be potentiated by transfection reagents and impaired by 
pharmacological agents. No complete abolition of seed uptake was observed when blocking 
endocytosis by seeding at 4˚C; this suggests that seed entry may not occur exclusively by 
endocytosis; another possible explanation for the small number of cells with tau aggregates still 
detected after 4 °C incubation with seed could be due to the ongoing internalization of residual 
membrane-associated fibrils during the post-seeding phase. 
 
Fluid-phase endocytosis is a low efficiency, non-specific process that involves the bulk uptake 
of solutes in exact proportion to their concentration in the extracellular fluid. Alternative 
processes are absorptive endocytosis, where molecules are bound to the cell surface and 
concentrated before internalization, and receptor-mediated endocytosis, where molecules bind 
to cell surface receptors and become concentrated before internalization. Depending on the 
composition of the coat, the size of the membrane-bound, intracellular vesicles, and the fate of 
the internalized cargo, endocytosis can occur by macropinocytosis, caveolar endocytosis, 
clathrin-mediated endocytosis, and clathrin/caveole-independent endocytosis (Khalil et al. 
2006).  
 
We used the dynamin inhibitor dynasore and the clathrin inhibitor chlorpromazine to probe the 
clathrin-mediated pathways, since dynamin proteins are GTPases that are essential for budding 
of clathrin vesicles from the plasma membrane (Urrutia et al. 1997). Dynasore reduced tau 
uptake only at 1 mM; other groups did not observe tau uptake inhibition by dynasore, but their 
experimental settings were different: Holmes et al used dynasore at lower concentration (80 
μM) in a different cell line (Holmes et al. 2013.); Munch et al used dynasore at lower 
concentration (100 μM) in a different cell line, to inhibit SOD1 uptake and not tau (Munch, 
O'Brien & Bertolotti 2011)); Wu et al pre-treated cells with 80 μM dynasore to probe for 
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dynamin-specific endocytosis and 30 μM Pitstop 2B to probe for clathrin-specific endocytosis, 
but their data suggested a dynamin-dependent, clathrin-independent mechanism (Wu et al. 
2013); Calafate et al. treated their mammalian-neuronal mixed culture cell system with 0.3, 1, 
3 μM of both dynasore and the more specific dynamin inhibitor JNJ (Gordon et al. 2013) and 
reported a reduction, but not complete abrogation of tau pathology propagation at 1, 3 μM, 
suggesting that other routes are contributing to this process (Calafate et al. 2016). 
Chlorpromazine reduced tau uptake at 30 μM, and again other groups that did not see effect of 
chlorpromazine used it at lower concentrations (5 μM) in a different cell line, to inhibit SOD1 
uptake and not tau (Munch, O'Brien & Bertolotti 2011). In summary, we only saw inhibitory 
effects of dynasore and chlorpromazine at high concentrations, which could elicit non-specific 
effects, but we cannot exclude that the clathrin-dependent pathway plays a role in tau 
aggregates uptake. 
Wu et al. reported that exogenously added recombinant (heparin-induced) tau low-MW 
aggregates (dimers/trimers) and small fibrils (40-250 nm), but not monomeric tau or long fibrils, 
are internalized via bulk endocytosis in neurons at the somatodendritic compartment or the 
axon terminals, and transported anterogradely and retrogradely; the internalized aggregates are 
transported in endosomal vesicles and later trafficked through the endosomal pathway to the 
lysosomes: 6 hours post-addition, internalised tau aggregates co-localised with dextran, marker 
of bulk endocytosis, and later (12 hours) they co-localised with endolysosomal markers (Rab5, 
a GTPase that is enriched in early endosomes; lysosomal-associated membrane protein 1 
(LAMP1); substrate DQ-BSQ) in neurons and HeLa cells (Wu et al. 2013). We used specific 
antibodies for EEA1, marker for early endosomes, and CD63, marker of lysosomes, to further 
interrogate the endocytic pathway, and we observed colocalisation with tau seeds from 16 h 
onwards; moreover, in our recent publication, we observed co-localization of TgP301S tau 
aggregates and recombinant P301S tau aggregates with dextran after 1 hour as shown by 
immunofluorescence with HT7 antibody (Falcon et al. 2015); for a thorough investigation, other 
markers should also be investigated (Rab5 for early endosomes, Lamp1, DB-BSQ for 
lysosomes) (Wu et al. 2013); using higher doses of tau seeds, as well as quantitatively 
measuring the dyes colocalisation, could potentially allow us to determine whether 
colocalisation with endocytosis markers occurs at earlier timepoints. 
Macropinocytosis is the actin-driven invagination of the cell membrane to form large endocytic 
vesicles of irregular shape and size, which then travel into the cytosol and fuse with endosomes 
and lysosomes. Macropinosomes are large vesicles characterised by a diameter of up to 2.5 µm 
(Khalil et al. 2006). The dose-dependent effect on seed uptake we observed with EIPA in our 
system is not conclusive, but it is suggestive that macropinocytosis is the prevalent mechanism 
of tau uptake. The following are further experiments we could carry out to confirm this: 1) 
Estimate the size of the endocytic vesicles containing tau aggregates by confocal microscopy to 
confirm whether they had a diameter consistent with macropinosomes (> 1 μm), and larger than 
other endocytic vesicles (Holmes et al. 2013.); 2) Macropinocytosis is an actin-dependent 
process which requires actin rearrangement to create lamellipodia-like membrane protrusions; 
cells could be stained with fluorescently-tagged phalloidin to label filamentous actin to show its 
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engulfment of tau inclusions (Holmes et al. 2013.); 3) HIV-derived transactivator of transcription 
(TAT) peptide is a known substrate of macropinocytosis; cells could be co-treated with 
fluorescently-labelled TAT and tau seeds to show their co-localisation (Holmes et al. 2013.). In 
our recent publication (Falcon et al. 2015) we also showed that native TgP301S tau aggregates 
enter cells through the same mechanism as recombinant P301S tau aggregates, consistent with 
macropinocytosis, as it inhibited by 100 μM EIPA. Therefore, like SOD1 aggregates (Munch, 
O'Brien & Bertolotti 2011), PrP
sc
 (Magalhaes et al. 2005) several viruses (Mercer, Helenius 
2009), recombinant tau (Holmes et al. 2013., Frost, Jacks & Diamond 2009, Falcon et al. 2015) 
and perhaps other prion-like aggregates, we have observed that native TgP301S tau 
aggregates can hijack macropinocytosis to penetrate into the cytosol of host cells.  
 
There is now in vitro and in vivo evidence that pathological tau can transfer inter-cellularly and 
transmit a misfolded state to cytosolic soluble tau (Hasegawa, Nonaka & Masuda-Suzukake 
2017). Here, we established a cell model that allowed us to study the mechanisms of tau uptake 
and will allow us to assess therapeutic strategies with a potential to affect disease progression. 
Further studies will be required to fully describe the tau species involved in cellular uptake and 
determine the best molecular targets to prevent internalisation of tau misfolded seeds. 
 
4.7 Nanotubes in cell culture: a potential mechanism of tau transmission? 
Tunneling nanotubes (TNTs), a cell-to-cell communication between animal cells based on the 
formation of thin membrane channels, were first reported in cultures of rat pheochromocytoma 
(PC12) cells (Rustom et al. 2004); similar TNT-like connections were subsequently identified for 
several permanent cell lines and primary cultures (Gerdes, Bukoreshtliev & Barroso 2007). 
Typical TNTs connecting PC12 cells have a 50–200 nm diameter, can stretch to lengths up to 
several cell diameters, interconnecting cells at their nearest distance (Rustom et al. 2004, 
Hodneland et al. 2006) and appear to be floating in the medium without contact to the 
substratum, unlike other cellular protrusions. Structurally, F-actin is the prominent cytoskeleton 
component of TNTs between PC12 cells, but no microtubules are present. At the ultra-structural 
level, the TNTs surface membrane is shown to connect seamlessly with the plasma membranes 
of the connected cells. TNTs structural integrity is sensitive to mechanical and chemical stress, 
as well as prolonged light exposure (Gurke, Barroso & Gerdes 2008). 
 
Thin tau-positive channels interconnecting cells were visualised by confocal microscopy in both 
TgP301S-seeded and unseeded cells in our inducible cell model; to ascertain that such 
structures were bona fide TNTs, their architecture was explored further: by immunofluorescence 
they appeared to be tau- and F-actin-positive (Figure 4.10), and a z-stack showed that they 
were stretched between interconnected cells attached at their nearest distance and did not 
contact the culture surface (Figure 4.11). 
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Figure 4.10: Confocal imaging shows tau-positive TNTs in cell culture. Confocal imaging 
showing TNTs in HEK T-REx P301S 0N4R tau inducible cells following inoculation with 
sarkosyl-insoluble P301S tau mouse seed for 3 hours, followed by 3 days growth. (A) Total tau 
was visualised with CP27 antibody (red), pS409-tau with PG5 antibody (green) and the nucleus 
with Hoechst (blue). (B) Total tau was visualised with CP27 antibody (red), early endosomes 
with EEA1 antibody (green) and the nucleus with Hoechst (blue. (C) Total tau was visualised 
with CP27 antibody (red), F-actin with phalloidin-AlexaFluor488 (green) and the nucleus with 
Hoechst (blue). TNTs positively stained for pS409-tau (PG5), total tau (CP27), and F-actin 
(phalloidin-AF488). Scale bar 40 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Confocal imaging shows tau-positive TNTs in cell culture. Confocal imaging 
showing an x-z section (A) and an x-y section (B) of a TNT in HEK T-REx P301S 1N4R tau 
A                                                B                                                 C 
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inducible cells following inoculation with sarkosyl-insoluble P301S tau mouse seed for 3 hours, 
followed by 3 days growth. Total tau was visualised with CP27 antibody (red), pS409-tau with 
PG5 antibody (green) and the nucleus with Hoechst (blue). Z-stack taken with a 40X objective, 
0.5 μm slices, 1024x1024 pixels. Scale bar (A) 5 μm (B) 40 μm. 
 
TNTs were shown to mediate membrane continuity between connected cells and facilitate the 
intercellular transport of cargo: organelles, cytoplasmic molecules, membrane components 
(Gerdes, Bukoreshtliev & Barroso 2007), mitochondria (Koyanagi et al. 2005) and pathogens 
like viruses and bacteria have been shown to exploit cellular protrusions to transfer from cell to 
cell (Cudmore et al. 1996, Favoreel et al. 2006, Onfelt et al. 2004, Onfelt et al. 2006). TNTs can 
also form between neuronal cells and prions have been reported to traffic through these 
structures between infected and non-infected cells (Gousset, Zurzolo 2009). Once delivered to 
the target cells, the transferred endocytic vesicles fuse with their counterparts (Rustom et al. 
2004); this may provide a way to integrate signalling information and coordinate cell behaviour 
by dissemination from a single cell to a larger community (Gurke, Barroso & Gerdes 2008). 
 
Actin polymerization is a key event for TNT formation (Gerdes, Bukoreshtliev & Barroso 2007) 
and actin-depolymerizing drugs have been shown to abolish TNTs formation (Rustom et al. 
2004); therefore, to determine whether tau aggregates could be trafficked across cells via TNTs, 
HEK T-REx P301S 1N4R tau inducible cells were exposed to latrunculin A (Gousset, Zurzolo 
2009) for up to 3 days to cause actin depolymerisation following exposure to sarkosyl-insoluble 
0N4R P301S tau aggregates. Increasing doses of latrunculin A did not result in less frequent 
phospho-tau (PG5-positive) aggregates in the cell culture as detected by HCI assay (Figure 
4.12).  
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Figure 4.12: Actin depolymerization agent latrunculin A post-seeding does not affect tau 
aggregation. HCI assay measuring PG5-positive tau inclusions in HEK T-REx P301S 1N4R tau 
inducible cells inoculated with sarkosyl-insoluble P301S 0N4R tau seed for 3 hours, followed by 
incubation with actin depolymerization agent latrunculin A (added straight after seeding for 1-2-3 
days). Data shown are mean ± SEM (n=2). Statistical analysis: one-way ANOVA with Dunnett’s 
post hoc test. *p<0.05, ****p<0.0001, compared with untreated control. 
 
With a view of studying the mechanisms of tau transfer, our lab also generated and optimized a 
co-culture HEK cell system that robustly develops intracellular tau aggregates following addition 
of exogenous mutant tau. Briefly, sarkosyl-insoluble tau extracted from tgP301S mice was used 
to trigger aggregation in HEK T-rex P301S tau inducible cells, which were then co-cultured with 
HEK cells stably expressing GFP and transiently transfected with P301S tau. 
Immunofluorescence readout showed that exogenous seeds efficiently enter cells and trigger 
aggregation of endogenous protein, resulting in the time-dependent accumulation of insoluble 
tau fibrils, which are transferred from donor to acceptor cells (Cavallini et al. 2014.). We then 
employed latrunculin A to examine the transfer mechanisms of mutant tau aggregates in our co-
culture system. TgP301S seed was used to trigger aggregation in HEK T-REx P301S tau 
inducible cells, which were then co-cultured with HEK GFP-expressing P301S tau-transfected 
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cells for 3 days, in presence of latrunculin A, before being fixed and analysed by 
immunofluorescence. Latrunculin A inhibited transfer of aggregates from donor to acceptor cells 
in a dose-dependent manner (from 12% donor cells containing PG5-positive aggregates in 
absence of treatment, to 4% at the highest concentration of Latrunculin A)  (Figure 4.13). 
 
Figure 4.13: Actin depolymerization agent latrunculin A affects transfer of aggregates in 
a co-culture setting. HCI assay measuring PG5-positive tau inclusions in GFP-positive 
acceptor cells co-cultured with TgP301S-seeded donor cells for 3 days, in presence of actin 
depolymerization agent latrunculin A. Data shown are mean ± SEM (n=2). Statistical analysis: 
one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, compared with untreated 
control. 
 
4.8 Discussion on nanotubes in HEK T-REx P301S tau inducible cells 
We incidentally observed tunnelling nanotubes (TNTs) in our cell model, and described their 
main features by confocal microscopy. Since it has been shown that tunnelling nanotubes can 
form between neuronal cells and prions appear to traffic through these structures between 
infected and non-infected cells (Gousset, Zurzolo 2009), we asked whether nanotubes could 
allow cell-to-cell propagation of tau aggregates. Since all the TNTs we observed were tau-
positive, it is possible that tau, together with F-actin, is a specific constitutive marker of TNTs. 
We therefore explored the effect of the F-actin-depolymerising compound latrunculin A (Rustom 
et al. 2004) post-seeding in a bid to disrupt intercellular propagation of tau aggregate via TNTs. 
One of the reasons why latrunculin A did not seem to affect tau transfer between HEK T-REx 
P301S tau inducible cells might lie in the dynamic nature of TNT-like structures, leading to only 
transient bridges with variable lifetimes, ranging from a few minutes up to several hours; or 
TNTs could be playing a minor role among multiple mechanisms of tau transmission, and their 
relative contribution may be difficult to measure; another possibility is that the aggregates 
intercellular transfer is not efficiently modelled by our mammalian cell inducible system, and 
may mainly occur from mother to daughter cells during cell division. Nevertheless, in a co-
culture setting, latrunculin A induced dose-dependent inhibition of aggregate transfer from donor 
to acceptor cells at 1-2 days in co-culture. The extent of the effect we observed suggests that 
disrupting the actin cytoskeleton with latrunculin A may have an impact not necessarily only on 
nanotubes, but possibly on other actin-dependent mechanisms of tau release and uptake, 
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therefore further experiments should focus on dissecting these mechanisms and study the 
effect of latrunculin A on tau extracellular concentration in co-culture media.  
 
In summary, our cell model allowed us to characterise TNTs and formulate the hypothesis that 
they may be a mean of tau propagation between cells. Since the pharmacological modulation of 
these structures suggested that actin-dependent processes are involved in tau intercellular 
transfer in our cell model, further experiments should employ pharmacological and genetic 
modulators to further dissect these mechanisms; ultimately, whether TNTs facilitate the 
intercellular spread of pathological tau will also have to be confirmed in vivo in tauopathy brains. 
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5. CHARACTERISATION OF NATIVE VS RECOMBINANT SEED 
 
In this section we focus on investigating the tau species that constitute seeds; some of the work 
presented below has been included in recent publications. In Falcon et al. 2015 we described 
the development of a cell model to understand the relationship between tau conformation 
/phosphorylation state and seeding ability. Using both recombinant and native tau aggregates, 
we provided evidence that despite being taken up by cells to the same degree, native tau 
aggregates have a higher seeding potency than recombinant tau aggregate; the latter though 
can acquire the conformation and seeding potency of the former by templated assembly, 
demonstrating for the first time that conformation and not phosphorylation determines the 
seeding potency of tau aggregates (Falcon et al. 2015). In Jackson et al. 2016 we characterized 
by sucrose gradient and immunodepletion the native tau species responsible for seeding and 
pathology spreading in TgP301S mice. Tau species that were aggregated, AT8-, and nY29-
positive with structure ranging from ring-like to small fibrils of 179–250 nm were able to seed tau 
aggregation in our inducible cell model and initiate trans-synaptic spreading in TgP301S mice in 
vivo, indicating that short fibrils are the most potent species capable of seeding tau pathology 
(Jackson et al. 2016).   
 
5.1 Sarkosyl extraction enriches for seed-competent tau 
Having characterised the mechanisms of TgP301S seed uptake in our cell model, we then 
wanted to compare this transgenic-derived seed to a recombinant, heparin-aggregated seed. 
The sarkosyl-insoluble (SI) fraction and the total lysate (TL) from the brains of TgP301S tau 
mice were compared (Falcon et al. 2015). Tau levels were normalized and the levels of MC1 
(conformationally changed) and AT8 (pS202/pT205) -positive tau determined by Alphascreen 
assays. Sarkosyl treatment enriched for MC1- and AT8-positive tau relative to the total brain 
lysate (~130- and ~100-fold, respectively, taking into account that the sarkosyl-insoluble pellet 
was resuspended in 1:10 of the volume of the total lysate) (Figure 5.1 A). We next compared 
the seeding abilities of these preparations in our inducible cell model. While sarkosyl-insoluble 
TgP301S tau at 45 ng/ml led to the accumulation of sarkosyl-insoluble AT8-positive tau, the 
total brain lysate failed to seed at this concentration (Figure 5.1 B).  
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Figure 5.1: Sarkosyl insoluble fraction is enriched for seed-competent tau. (A) 
Alphascreen assays showing the levels of DA9 (phosphorylation-independent)-, MC1 
(conformationally changed) - and AT8 (pS202/pT205) -positive tau in the total lysate and the 
sarkosyl-insoluble fraction from TgP301S tau mice brains. The results are the means ± SEM 
(n=3). The levels of AT8- and MC1-positive tau are expressed relative to total tau levels. 
Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, 
compared with total tau. (B) Western blot showing DA9- and AT8-positive tau in the sarkosyl-
insoluble fraction of HEK 293T cells expressing P301S 1N4R tau, following the addition of either 
total lysate (TL) or sarkosyl-insoluble (SI) material [normalized for DA9-positive tau] for 3 h, 
followed by 3 days of incubation. 
 
5.2 Reduced seeding following tau immunodepletion  
We next used several biochemical techniques to dissect the molecular characteristics of native 
tau protein conformers from TgP301S tau mice brain lysates. As part of the characterisation of 
seed-competent tau in the TgP301S transgenic model, we assessed the seeding abilities of 
brain lysates from symptomatic TgP301S tau mice following immunodepletion with a number of 
anti-tau antibodies (both phosphorylation-independent and phosphorylation-dependent). 
Immunodepletion of TgP301S total lysates was performed using DA9, AT8, PG5, PHF1, and 
total IgG as isotype control. WB was carried out to quantify the extent of depletion of DA9- and 
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AT8-positive species (Figure 5.2). Immunodepletion with AT8, PG5, or PHF1 only significantly 
reduced 64k Da aggregate-derived AT8-positive tau (AT8 (-96%) > PHF1 (-75%)> DA9 (-72%) 
> PG5 (-70%) relative to control IgG) without reducing total tau (DA9) levels, whereas 
immunodepletion with DA9 removed DA9 reactivity and reduced the amount of 64 kDa AT8-
positive tau. Since DA9 reduced the amount of 64 kDa AT8-positive tau without completely 
removing it, it is likely that this pan-tau antibody preferentially recognises soluble tau and it is 
not able to remove all tau species. Depletion with IgG isotype control did not significantly reduce 
DA9 or AT8 levels. 
 
 
  
 
 
 
 
 
 
 
 
 
 
B 
 
Figure 5.2: Immunodepletion with tau antibodies significantly reduces 64kDa aggregate-
derived AT8-positive tau in TgP301S mice brain lysates. (A) WB with AT8 or DA9 antibodies  
of brain lysates from symptomatic TgP301S tau mice following immunodepletion with 
phosphorylation-independent anti-tau antibody DA9 or phosphorylation-dependent antibodies 
AT8, PG5, and PHF1 or IgG1 isotype control. A representative blot from 3 separate 
experiments is shown, each with 3 replicates per condition. GAPDH was used as the loading 
control. Immunodepletion reduced levels of the 64 kDa AT8-positive band by all antibodies to 
varying degrees (AT8 > PHF1 > DA9 > PG5); only DA9 significantly reduced the 55 kDa tau 
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species. (B) Quantification of (A). The quantification results are the mean ± SEM (n=3); 64 kDa 
band quantified for AT8 blot; sum of 64 and 55 kDa bands quantified for DA9 blot. Statistical 
analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, compared with 
IgG1 isotype control. 
 
We then tested the seeding ability of the immunodepleted samples in HEK T-REx P301S 1N4R 
tau inducible cells. Immunodepletion with anti-tau antibodies, but not control IgG, reduced the 
seeding ability of TgP301S tau brain lysates in a manner proportional to the reduction of the 64  
kDa aggregate-derived AT8-positive tau observed in the samples (AT8 (-75%) > PHF1 (-30%) >  
DA9 (-32%) > PG5 (-50%), relative to control IgG) (Figure 5.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
Figure 5.3: Immunodepletion with tau antibodies reduces the seeding ability of TgP301S 
mice brain lysates. (A) WB with anti-tau antibodies DA9 and AT8 of the insoluble fraction 
extracted from HEK T-REx P301S tau inducible cells following seeding with immunodepleted 
TgP301S total lysate samples. Positive control was sarkosyl-extracted tau from symptomatic 
TgP301S mice (“TgP301S seed”). A representative blot from 3 separate experiments is shown. 
(B) Quantification of (A). Results are the means ± SEM (n=3); 68 kDa band quantified for AT8 
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blot; sum of 68 and 59 kDa bands quantified for DA9. Statistical analysis: one-way ANOVA with 
Dunnett’s post hoc test. *p<0.05, ****p<0.0001, compared with IgG1 isotype control. 
 
There was also a strong positive correlation (R
2
 = 0.85, p <0.0001) between the levels of 64 
kDa AT8-positive tau present in the TgP301S brain lysates after immunodepletion (AT8 input) 
and the levels of seeded aggregation observed in cells following incubation with each 
immunodepleted brain lysate, as measured by AT8-positive insoluble tau (AT8 output). No 
correlation was observed between the levels of total, DA9-positive tau (comprising soluble and 
insoluble tau) in brain lysates (DA9 input) and the levels of seeded aggregation (AT8 output) 
(Figure 5.4). 
 
Figure 5.4: Seeding efficiency correlates with level of 64 kDa hyperphosphorylated tau. 
The levels of 64 kDa, AT8-positive tau in the TgP301S brain lysate (AT8 input) correlated with 
its seeding ability in cells (AT8 output) measured by WB. No correlation was observed with 
DA9-positive tau as the input. Linear regression was performed to determine the relationships 
between input and output tau. 
 
To determine overlap of species being identified by different antibodies, we performed 
immunodepletion of TgP301S brain lysates with a combination of phospho-tau antibodies AT8 
and PHF1, and compared it with immunodepletion with either AT8 alone or PHF1 alone; 
unconjugated Sepharose beads (no antibody) were used as control. WB showed that the 
pairing of AT8 and PHF1 did not result in any additional species being depleted (Figure 5.5). 
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Figure 5.5: Double immunodepletion with phospo-tau antibodies does not remove 
additional species. (A) WB of AT8-tau and total tau remaining following immunodepletion of 
TgP301S mouse brain lysate with AT8 alone (AT8 + no Ab), PHF1 alone (PHF1 + no Ab) or 
AT8 and PHF1 together (AT8+PHF1). No-antibody Sepharose beads (no Ab) were used as 
control. When the antibodies were used alone, an equal volume of unconjugated beads was 
added, so that the beads volume would be the same in each condition. A representative blot 
from 2 separate experiments is shown. (B) Quantification of (A). Results are the means ± SEM 
(n=2). Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, 
compared with no-antibody control. 
 
Similarly, when the immunodepleted lysates were tested for seeding in HEK T-REx P301S 
1N4R tau inducible cells, the seeding ability of the doubly immunodepleted lysate was 
comparable to lysate immunodepleted by single antibody AT8 or PHF1 (Figure 5.6). 
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Figure 5.6: Double immunodepletion with phospo-tau antibodies does not remove 
additional species. (A) WB with anti-tau antibodies DA9 and AT8 of the insoluble fraction 
extracted from HEK T-REx P301S tau inducible cells following seeding with TgP301S total 
lysate samples immunodepleted with a combination of AT8 and PHF1 antibodies. Positive 
control was sarkosyl-extracted tau from symptomatic TgP301S mice (“TgP301S seed”). A 
representative blot from 2 separate experiments is shown. (B) Quantification of (A). Results are 
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the means ± SEM (n=2); 68 kDa band quantified for AT8 blot; sum of 68 and 59 kDa bands 
quantified for DA9. Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, 
****p<0.0001, compared to “no antibody control” or “no seeding control”. 
 
5.3 Discussion on characterisation of seed-competent tau 
We compared the total lysate from the brains of TgP301S tau mice with the sarkosly-insoluble 
fraction extracted from the lysate itself, and showed that the sarkosyl-insoluble fraction was 
enriched for MC1- (conformationally changed) and AT8- (pS202/pT205) positive tau and had a  
seeding activity superior to the total lysate, when the two preparations were normalised for total 
tau; this indicates that sarkosyl treatment enriches for seed-competent tau. Conversely, we 
showed in immunodepletion experiments that a reduction of AT8-positive tau reduces the 
amount of seed-competent tau in total lysate from the brains of TgP301S mice. We performed 
the immunodepletions of all the antibodies at the same concentration, as we wanted to rank the 
antibodies that would preferentially remove or reduce the 64 kDa seeding-competent species. 
Total tau antibody DA9 removed and reduced the 64 kDa AT8-positive tau as well as total tau 
immunoreactivity in the TgP301S lysate, whereas antibodies that recognise 
pathological/phosphorylated tau (AT8, PG5, and PHF1) did not reduce total tau levels but 
significantly reduced the 64 kDa AT8-positive tau in the TgP301S lysate. Despite being a pan-
tau antibody, DA9 was not the most effective antibody at reducing seed-competent tau, 
suggesting that it may not be able to recognise all forms of tau and it may preferentially 
recognise soluble tau species. This is corroborated by further data that we published (Jackson 
et al. 2016): in a native-PAGE of sucrose gradient fractions derived from TgP301S brain lysate 
and blotted with DA9 (total tau), AT8 (pS202/pT205-tau), nY29 (nitrated Y29-tau) and PHF1 
(pS396-tau),  we showed that DA9 recognises small tau species in the low-density sucrose 
fractions that are not labelled by AT8, nY29 or PHF1 antibodies; conversely, DA9 did not 
recognise small oligomeric species (~400 kDa) that were AT8- and nY29-positive. Also, 
preliminary experiments showed that the immunodepletion was dose-dependent, but even 
higher concentrations of DA9 did not completely suppress the 64 kDa species. Taken together, 
the results suggest that pan-tau antibody DA9 does not recognise all forms of tau equally and 
therefore does not remove all tau species from the TgP301S lysate. 
We observed a strong positive correlation between the reduction of the 64 kDa AT8-positive tau 
in the TgP301S lysate and the reduction of the seeding potency of the lysate; no correlation was 
observed between the reduction of total tau immunoreactivity in the TgP301S lysate and the 
reduction of the seeding potency; this confirms that seeding is conferred by AT8-positive tau 
species and is not just the result of the mere addition of tau protein to the cells. The reduction of 
AT8-positive tau in the TgP301S lysates by the different antibodies tended to be more 
conspicuous than their corresponding reduction of the seeding ability of the TgP301S lysate 
(compare AT8 (-96%) > PHF1 (-75%)> DA9 (-72%) > PG5 (-70%) immunodepletion relative to 
control IgG, vs AT8 (-75%) > PHF1 (-30%) > DA9 (-32%) > PG5 (-50%) seeding reduction 
relative to control IgG); for instance, although AT8 nearly completely abolished the AT8 
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immunoreactivity of the TgP301S lysate (-96%), it only partially suppressed the seeding ability 
of the immunodepleted lysate (-75%); this may indicate that AT8-positive tau species may be 
the main species responsible for seeding but possibly not the only ones. Further studies should 
elucidate the characteristics of seed-competent tau in more details, i.e. immunodepletion 
experiments with a wider range of antibodies, targeting different epitopes and including 
conformational and C- and N-terminus antibodies should help identify the most efficient 
therapeutic antibody. We and others (Guo & Lee, 2011) have shown that small amounts of tau 
seeds are sufficient to induce robust endogenous tau fibrillization in cell models; furthermore, 
Guo et al. investigated the turnover of tau aggregates in cells and highlighted the need to fully 
remove seed-competent species: they generated a monoclonal QBI-293 cell line with 
doxycycline-regulated inducible expression of GFP-tagged 2N4R human tau carrying the P301L 
mutation; after transduction with recombinant Myc-K18/P301L pre-formed fibrils, followed by 
single cell cloning, they generated monoclonal cell lines with persistent tau inclusions that were 
faithfully transmitted through mitosis; they selected a clone where 95% cells maintained tau 
aggregates even after more than 100 days of passaging in culture; in this system, tau 
aggregates can be gradually removed from cells when soluble tau expression is turned off for 7 
days, however, the presence of even minuscule amounts of residual aggregates remaining after 
clearance is sufficient to rapidly reinstate tau aggregation once tau expression is restored (Guo 
et al. 2016). This suggests that a tau immunotherapy approach would require a total 
suppression of seed-competent tau species, to prevent small residual seeds from perpetuating 
the recruitment and aggregation of monomer. This may be further challenged by the existence 
of different pathological tau strains, as an antibody may not be able to form high-affinity 
complexes with all the strains present in a given diseased brain; rather than targeting highly-
specific epitopes, antibodies targeting shared conformation of multiple strains may have better 
chances of therapeutic success. 
 
Our results with a combination of AT8 and PHF1 antibodies did not show enhanced 
immunodepletion compared to using single antibodies, suggesting that a combination of these 
antibodies would not offer a therapeutic advantage over single administration, possibly due to 
the fact that AT8 and PHF1 antibodies target similar tau species. However, in principle, a multi-
epitope strategy could be beneficial to reach complete clearance of seed-competent tau; this 
could be a combination of different monoclonal antibodies targeting different species, or a 
polyclonal antibody. A polyclonal antibody strategy has been tried for targeting beta-amyloid in 
AD, however high regulatory hurdles for approval of studies with polyclonal antibodies have so 
far limited their numbers. Intravenous immunoglobulin (IVIG) products are prepared from 
plasma immunoglobulins from large numbers of healthy donors. Before being trialled for AD, 
they had been used to treat a range of autoimmune, infectious, and idiopathic disorders 
(Scheinfeld 2017). Commercially available IVIGs from healthy and diseased donors contain 
naturally occurring autoantibodies against beta-amyloid (Dodel et al. 2002), however their 
concentration is reduced in patients with AD (Du et al. 2001, Weksler et al. 2002, Britschgi et al. 
2009, Pul, Dodel & Stangel 2011). This provided the rationale for the use of IVIGs in AD trials, 
until negative results were reported in phase III IVIG studies in 2013 and since then, efforts 
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towards IVIGs as a treatment for AD have been reduced (Loeffler 2013). A downside of 
polyclonal immunotherapy with IVIGs is that these preparations differ in their concentrations of 
antibodies to beta-amyloid (Safavi et al. 2016, Balakrishnan et al. 2010) and tau protein (Smith 
et al. 2013) therefore their efficacy as AD therapy would be difficult to standardise. Most 
approaches currently in pre-clinical or clinical phases use single monoclonal tau antibodies. 
 
Open questions in the tau propagation field are what species of tau constitute a seed, and what 
are the minimal requirements for tau to be seed-competent. In a recent publication (Jackson et 
al. 2016) we used several biochemical techniques to dissect the molecular characteristics of 
native tau protein conformers from TgP301S tau mice and showed that seed-competent tau 
species comprise small fibrils capable of seeding tau pathology in cell and animal models. In 
particular we found that sucrose gradient fractions from TgP301S brain lysates seeded cellular 
tau aggregation only when large (>10 mer) aggregated, hyperphosphorylated (AT8- and AT100-
positive), misfolded (MC1-positive) and nitrated (nY29-positive) tau was present. Sucrose 
fractions containing small, oligomeric (<6 mer) tau were unable to seed. Immunodepletion of the 
large aggregated AT8-positive tau strongly reduced seeding, and the seeding ability of 
TgP301S brain lysates correlated with the levels of AT8-positive tau; moreover, fractions 
containing these species initiated the formation and spreading of filamentous tau pathology in 
vivo, whereas fractions containing tau monomers and small oligomeric assemblies did not. By 
electron microscopy, seed-competent sucrose gradient fractions contained aggregated tau 
species ranging from ring-like structures to small filaments.  
 
In summary, our cell model allowed us to characterise by sucrose gradient and 
immunodepletion the native tau species responsible for seeding and pathology spreading in 
TgP301S mice (Jackson et al. 2016), providing us with a powerful tool to investigate the tau 
species that constitute seeds in a tauopathy model. Results obtained in cells were replicated in 
our in vivo model of tau propagation (Ahmed et al. 2014), showing the potential of our cell 
system as a good surrogate for in vivo studies. Future experiments should aim at further 
elucidating the properties of seed-competent tau species to better tailor therapeutic strategies.  
 
 
5.4 Recombinant tau seeded with native tau aggregates acquires the same seeding 
potency as native tau aggregates 
We previously showed (Falcon et al. 2015) that when comparing sarkosyl-insoluble 0N4R tau 
aggregates from the TgP301S tau mice brains to sarkosyl-insoluble, heparin-assembled full-
length recombinant P301S 0N4R tau, native tau aggregates have a higher seeding potency 
than recombinant tau aggregates in our inducible cell model. After measuring ThioT binding, 
equating filament length by sonication and normalizing tau concentration by immunoblotting, we 
assessed the seeding potencies of the two preparations in the cell-based assay. Approximately 
50 times more synthetic P301S tau seed than TgP301S tau seed was needed to produce 
equivalent amounts of sarkosyl-insoluble tau from expressed protein in cells. 
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To examine the effect of aggregate conformation on seeding potency and to control for the 
presence of heterologous components in the TgP301S aggregates, we seeded recombinant 
P301S tau in the absence of heparin with 5% (v/v) sarkosyl-insoluble fraction from P301S mice 
brains. We monitored aggregation of recombinant P301S tau by ThioT binding over time (Figure 
5.7). 
 
 
Figure 5.7: Aggregation of seeded recombinant tau. Aggregation of soluble recombinant 
P301S tau in the presence of 5% (v/v) sarkosyl-insoluble fraction from P301S mice brains, and 
in absence of heparin, as measured by Thioflavin T binding over time. RFU: Relative 
Fluorescence Units.  
 
When normalised for total tau levels and filament length, the recombinant tau aggregates 
seeded by aggregated TgP301S tau in the absence of heparin were equally potent to 
aggregated TgP301S tau in our seeding assay (Figure 5.8).  
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Figure 5.8: Recombinant tau seeded with native tau aggregates acquires the same 
seeding potency as native tau aggregates. (A) Western blots with anti-tau antibodies DA9 
(phosphorylation-independent) and AT8 (pS202/pT205) of the insoluble fraction from inducible 
HEK293T cells expressing P301S 1N4R tau seeded for 3 h with either  TgP301S tau 
aggregates, or equivalent concentration of recombinant P301S tau seeded with 5% (v/v) 
TgP301S tau aggregates, or equivalent concentration of  heparin-assembled recombinant 
P301S tau aggregates, or the 5% (v/v) TgP301S tau aggregate component alone, followed by 3 
days incubation. (B) Quantification of (A). Seeding with TgP301S tau aggregates and 
recombinant P301S tau seeded with (5%v/v) TgP301S tau aggregates were not significantly 
different. Statistical analysis: t test.  The values are the means ± SEM (n=3).  
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5.5 Discussion on seeding potency of native and recombinant seeds 
Some of the work described above has been included in a recent publication (Falcon et al. 
2015) where we described the development of a cell model to understand the relationship 
between tau conformation /phosphorylation state and seeding ability.   
 
Using our cell-based assay, we first compared the seeding activity of the sarkosyl-insoluble 
fraction from TgP301S tau mice brain with that of total brain lysate. The sarkosyl-insoluble 
fraction, which was enriched in aggregated and AT8-positive tau, had a greater seeding activity 
than the lysate, when normalized for total tau. This indicates that the tau species required for 
seeding are likely to be sarkosyl-insoluble.  We then used our cell-based assay to compare the 
seeding activity of the sarkosyl-insoluble fraction from TgP301S tau mouse brain with that of 
sarkosyl-insoluble P301S recombinant tau. We used sonication and electron microscopy to 
ensure equal filament length between the two preparations and we observed that, similarly to 
synthetic prions (Kim et al. 2010, Tanaka et al. 2006, Legname et al. 2006, Legname et al. 
2005), α-synuclein aggregates (Luk et al. 2012) and A assemblies (Meyer-Luehmann et al. 
2006a, Stöhr et al. 2012), synthetic tau aggregates had a greatly reduced seeding activity 
compared to sarkosyl-insoluble tau from P301S tau mouse brain; both preparations entered 
cells through a mechanism consistent with macropinocytosis, demonstrating that the difference 
in their seeding activity is unlikely to be the result of different uptake mechanisms. 
 
We showed that synthetic tau aggregates were more resistant to disaggregation by guanidine 
hydrochloride and digestion by proteinase K than tau aggregates from TgP301S tau mouse 
brain, consistent with the hypothesis that more stable aggregates possess lower seeding 
activity. Also, low concentrations of guanidine hydrochloride enhanced exposure of the HT7 
antibody epitope on tau aggregates from P301S mice brain but not on synthetic tau aggregates, 
suggesting a different molecular organization of the two types of preparations. Our findings are 
in agreement with a study showing that tau filaments produced by incubating recombinant 
human tau with heparin were more stable than paired helical filaments from AD brain (Morozova 
et al. 2013). Structural differences among the two preparations could be further confirmed by an 
array of techniques like trypsin digestion, electron microscopy, Congo red stain, thermostability, 
native gel, circular dichroism.  
 
Since we used heparin to form synthetic aggregates, which has been shown to compact the 
repeats and induce dimerisation of tau, with filaments growing through monomer addition 
(Ramachandran, Udgaonkar 2011, Elbaum-Garfinkle, Rhoades 2012), we postulated that 
heparin-induced synthetic tau aggregates have distinct conformations to that of brain-derived 
native tau aggregates. To demonstrate this hypothesis, we produced synthetic tau filaments 
seeded with TgP301S tau aggregates, and showed that they have a resistance to 
disaggregation by guanidine hydrochloride similar to P301S tau seeds. Importantly, in our 
inducible cell assay, synthetic tau aggregates seeded by aggregated TgP301S tau in the 
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absence of heparin acquired the seeding potency of brain-derived P301S tau seeds, in 
agreement with the prion hypothesis (Prusiner 2013).  
 
Cumulative data from this thesis and from our publications (Falcon et al. 2015, Jackson et al. 
2016) show that the seeding activity of tau from TgP301S mouse brain correlates with AT8 
phosphorylation. AT8 recognises tau phosphorylated at both Ser202 and Thr205 and is one of 
the most common antibodies presently used for AD diagnostics, as it recognises AD-derived 
tau; AT8 stains hyperphosphorylated tau in late-stage human AD brain as well as in cell and 
animal models (Biernat et al. 1992, Goedert et al. 1995, Braak et al. 2006). However, in Falcon 
et al. 2015, we compared the seeding potency of TgP301S brain-derived tau seeds and 
recombinant P301S tau seeds, and noted that a major difference is that the former are 
hyperphosphorylated, whereas the latter are unphosphorylated. We tested whether 
phosphorylation could account for the superior seeding potency of TgP301S tau seeds, by 
producing hyperphosphorylated recombinant P301S tau aggregates in vitro. Sequential 
phosphorylation of recombinant P301S tau with PKA and SAPK4, in the presence of heparin 
produced 64 kDa tau hyperphosphorylated at epitopes characteristic of pathological tau (S422, 
the AT8 epitope (pS202/pT205) and the AT100 epitope (pS212/pT214/pT217)) (Goedert et al. 
1997). Hyperphosphorylation was retained following purification of sarkosyl-insoluble tau 
(Yoshida et al. 2006). When we tested the seeding ability of the preparations, TgP301S tau 
aggregates were still more potent seeds than phosphorylated recombinant P301S tau 
aggregates, which retained the same potency as unphosphorylated recombinant P301S 
aggregates; in conclusion, hyperphosphorylation did not increase the seeding potency of 
recombinant tau aggregates. Moreover, hyperphosphorylated and unphosphorylated heparin-
assembled recombinant P301S tau aggregates had similar stability to guanidine hydrochloride 
and proteinase K digestion, hinting that they had a similar conformation. Taken together, our 
data support the conclusion that phosphorylation at the AT8 epitope is a marker for pathological 
tau, but is not the main driver of the seeding potency of tau aggregates; conformation 
determines the seeding potency of tau seeds (Falcon et al. 2015). Although our findings apply 
to tau carrying the P301S mutation, similar observations were made by Guo et al. for WT tau 
(Guo et al. 2016). Abnormal phosphorylation has been believed to be the trigger of tau 
deposition, but a more recent hypothesis is that phosphorylation may occur after its aggregation 
(Hasegawa et al. 2017). Further work should explore the effect of other post-translational 
modifications on tau seeding ability, as they may have a more crucial role than phosphorylation.  
 
In summary, using both recombinant and native tau aggregates, our cell model allowed us to 
demonstrate for the first time that, despite being taken up by cells to the same degree, native 
tau aggregates have a higher seeding potency than recombinant tau aggregate; the latter 
though can acquire the conformation and seeding potency of the former by seeded assembly, 
demonstrating that conformation and not phosphorylation determines the seeding potency of 
tau aggregates. Our work supports the hypothesis that conformationally distinct tau strains 
exist, and might be associated with individual tauopathies (Clavaguera et al. 2013, Frost, 
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Diamond 2010). In the future, it will be important to characterise tau conformations in human 
brains diagnosed with tauopathies, and determine whether the different diseases can be 
defined by aggregate structures, as this could aid drug design and creation of PET ligands 
specific to human tauopathies; further research should also examine whether there are genetic 
or environmental factors that promote particular tau conformations, and whether these could 
constitute therapeutic targets for tauopathies. 
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6. CHARACTERISATION OF TAU SPECIES IN CONDITIONED MEDIA 
 
Here we focused on tau release by characterising the tau species in conditioned media from 
unseeded vs seeded HEK T-REx P301S 1N4R tau inducible cells, to investigate the presence 
of post-translational modifications (phosphorylation, truncation,..) aggregation state, size and 
encapsulation in vesicles of extracellular tau; we also collected and concentrated the 
conditioned media to test its ability to seed endogenous tau aggregation in naïve induced cells. 
 
6.1 Seed-competent species are present in conditioned media from cell culture 
(biochemical assay in presence and absence of Lipofectamine) 
Conditioned media experiments were carried out in our cell model to investigate the tau species 
involved in intercellular transfer. HEK-T-REx-293 P301S inducible cells were seeded with 
TgP301S mice derived brain extract, in presence or absence of Lipofectamine, and the seed 
was removed after 3 h. Cells were treated with 0.0125% trypsin for 1 min at RT to remove 
residual seed. Conditioned medium was collected at different timepoints after seeding (0-1-2-3 
days post seeding) and assayed by Alphascreen to normalise the samples for total tau levels, 
before being added to a new population of HEK-T-REx-293 P301S inducible cells, in absence of 
transfection reagents. The transfer of conditioned medium from seeded cells was sufficient to 
induce tau aggregation in the second population of cells, as detected by western blot of 
insoluble fraction derived from total lysates (Figure 6.1). Media from unseeded cells failed to 
cause accumulation of insoluble tau in the second population of cells, whereas media from cells 
seeded in absence of Lipofectamine could induce accumulation of insoluble tau in recipient 
cells, albeit to a much lower extent than media from cells seeded in presence of the delivery 
reagent. Lipofectamine produced a greater accumulation of insoluble tau in the second 
population of cells, but this was accompanied by increased cytotoxicity (up to 15%), as 
measured by LDH assay (Figure 6.2). Therefore, the increase in the levels of seed-competent 
tau in the media caused by Lipofectamine is potentially being caused by release of tau from 
dead cells or leakage of tau from the cell membrane.  
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Figure 6.1: Conditioned media from seeded TgP301S tau inducible cells contains seed-
competent tau species. (A) Western blot with total tau antibody (DA9) and pS202/pT205 
antibody (AT8) in insoluble fraction of HEK T-REx P301S tau inducible cells treated with 
conditioned media from cells seeded with P301S mouse brain-derived tau extract shows 
accumulation of insoluble tau. Sequential extraction (fractionation) was performed. (B) 
Quantification of blots. The values are the means ± SEM (n=2). 
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Figure 6.2: Lipofectamine induces tau release from cell death as shown by LDH assay. 
LDH assay in conditioned media samples from cells seeded with P301S mouse brain-derived 
tau extract and collected 0-1-2-3 days post seeding shows negligible levels of cell death 
measured in the media, apart from samples from cells seeded in presence of Lipofectamine 
2000. The values are the means ± SEM (n=2). 
 
6.2 Seed-competent species are present in conditioned media from cell culture (imaging 
assay in absence of Lipofectamine) 
To investigate the tau species involved in intercellular transfer and minimise the spill of 
intracellular tau into the media due to Lipofectamine-induced cell death, conditioned media was 
collected after seeding HEK-T-REx-293 P301S inducible cells with P301S mice derived brain 
extract, in absence of transfection reagents, at different timepoints (0-1-2-3 days post seeding). 
Cells were treated with 0.0125% trypsin for 1 min at RT to remove residual seed. The media 
was concentrated and assayed by Alphascreen for total tau (DA9-TG5, to normalise the 
samples for total tau levels), pS202/pT205-tau, conformational changed tau (MC1-DA9) and 
pT181-tau (AT270-TG5) (Figure 6.3). Total tau, MC1-positive tau and pT181-tau were present 
in a time dependent manner in media from both unseeded and seeded. Total tau increased up 
to 30 units in media collected 3 days post-seeding; MC1-tau increased up to 0.3 units in media 
collected 3 days post-seeding; pT181-tau increased up to 1 unit in media collected 3 days post-
seeding. On the other hand, AT8-positive tau was present in a time dependent manner only in 
media from seeded cells. Media from cells that were induced, seeded and grown for the longest 
period (3 days) contained the highest amount of AT8-tau (0.1 unit), followed by the Induced-
Seeded-Grown 2 days (0.06 units) and the Induced-Seeded-Grown 1 day (0.02 units) samples. 
Samples which were either not seeded or not induced showed no presence of AT8-tau.  
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Figure 6.3: AT8-positive tau is present in media from seeded TgP301S tau inducible cells. 
Alphascreen assay in conditioned media samples from cells seeded with TgP301S mouse 
brain-derived tau extract and collected 0-1-2-3 days post seeding. Statistical analysis: one-way 
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ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001 compared with controls 
(Uninduced, seeded, 3 days). The values are the means ± SEM (n=2). 
Conditioned media samples, matched for total tau levels using Alphascreen, were added to a 
new population of HEK-T-REx-293 P301S inducible cells, in absence of transfection reagents. 
The transfer of conditioned medium from seeded cells was sufficient to induce tau aggregation 
in the second population of cells, where insoluble tau was extracted by 1% Triton X-100; cells 
were analysed by high-content imaging assay (measuring tau aggregation as ratio “PG5 total 
intensity / Hoechst total area” or “MC1 total intensity / Hoechst total area”) (Figure 6.4) and 
confocal imaging (Figure 6.5). Seeding in the imaging assay 96-well format required lower 
volumes of media sample than the ones required for the 6-well biochemical assay, allowing us 
to perform a minimal dilution of the media samples, and therefore see a bigger seeding effect 
than the one seen by biochemical assay. We found that media from seeded cells could induce 
accumulation of PG5-and MC1-positive, insoluble tau in recipient cells, proportional to the 
amount of AT8-tau measured by Alphascreen in the media. Media from unseeded cells failed to 
cause accumulation of insoluble tau in the second population of cells.  
 
 
 
Figure 6.4:  Conditioned media from seeded TgP301S tau inducible cells induces seeding 
in a new population of cells. HCI assay using PG5 antibody (pS409-tau) (upper panel) and 
MC1 antibody (lower panel) in HEK T-REx P301S tau inducible cells treated with conditioned 
media from cells seeded with TgP301S mouse brain-derived tau extract shows accumulation of 
abundant Triton X-100-insoluble tau. Statistical analysis: one-way ANOVA with Dunnett’s post 
hoc test. *p<0.05, ****p<0.0001, compared with unseeded controls. The values are the means ± 
SEM (n=2). 
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Figure 6.5: Conditioned media from seeded TgP301S tau inducible cells induces seeding 
in a new population of cells. Confocal imaging assay using PG5 antibody (pS409-tau) and 
MC1 antibody (conformationally-changed tau) in HEK T-REx P301S tau inducible cells treated 
with conditioned media from cells seeded with TgP301S mouse brain-derived tau extract shows 
accumulation of abundant Triton X-100-insoluble tau. Scale bar 50 μm. 
 
A strong positive correlation (R
2
 =0.9156) was observed between the levels of AT8-positive tau 
present in conditioned media samples (input) and the levels of seeded aggregation observed in 
the cells, as measured by the levels of PG5-positive Triton X-100-insoluble tau following 
seeding with each conditioned media sample (output). No correlation (R
2
 = 0.02624) was 
present between the levels of total tau in conditioned media samples measured by Alphascreen 
(input) and the levels of seeded aggregation in cells (output) (Figure 6.6).  
  
Unseeded cells 
Hoechst 
(nuclei)(blue) 
Cells seeded with conditioned media from cells induced, seeded and grown 3 days  
pS409-tau 
(PG5)(green) 
Misfolded tau 
(MC1)(red) 
Overlay 
106 
 
 
 
 
Figure 6.6: Positive correlation between levels of AT8-positive tau in conditioned media 
(input) and levels of aggregation in seeded cells (output). Correlation and linear regression 
were performed to determine relationships between input and output tau in the cell-based 
seeding assay. The levels of AT8-positive tau in conditioned media measured by Alphascreen 
assay correlated with the seeding ability measured by HCI assay (r
2
 = 0.9156). No correlation 
was observed with total tau as the input (r
2
 = 0.02624). 
 
The presence of tau in the extracellular medium may result from either active secretion or 
neuronal cell death. Therefore we tried to minimize cell death during the course of the 
experiment to investigate whether tau can be released from intact cells. In addition, we 
controlled for cell damage induced by tau expression and/or seeding in our culture conditions. 
All the conditioned media samples subject to analysis were assessed for LDH activity, a 
normally cytoplasmic enzyme, while the corresponding cells were assessed by Trypan blue cell 
count. We observed that while tau was progressively secreted in the extracellular medium, LDH 
activity or Trypan blue stain did not change according to the same pattern as tau; the LDH 
assay showed no significant difference in cytotoxicity across media samples, as did the cell 
death count by Trypan blue assay, both measuring up to 10% cytotoxicity across samples 
(Figure 6.7).  
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Figure 6.7: Seed-competent tau species in conditioned media do not derive from cell 
death. (Upper panel) LDH assay in conditioned media samples from cells seeded with 
TgP301S mouse brain-derived tau extract and collected 0-1-2-3 days post seeding shows 
negligible levels of cell death measured in the media. (Lower panel) Trypan blue cell death 
assay in cells seeded with TgP301S mouse brain-derived tau extract and collected 0-1-2-3 days 
post seeding shows that levels of cell death are consistent across samples. Media from 1% 
Triton X-100-treated cells was used as high control. The values are the means ± SEM (n=2). 
 
In summary, we showed that conditioned media collected from seeded cells is able to induce 
seeding in naïve cells, confirming the presence of extracellular seed-competent tau species. 
Similarly to what we observed for TgP301S lysate, the seeding ability of the conditioned media 
correlated to its levels of AT8-positive tau. 
 
6.3 Discussion on extracellular tau in HEK T-REx P301S tau inducible cells 
Several prior studies investigated tau release in various cell culture systems, such as 
overexpression models (Kim, Lee & Hall 2010a, Kim et al. 2010, Chai, Dage & Citron 2012, 
Plouffe et al. 2012, Simon et al. 2012), untransfected cells (Chai, Dage & Citron 2012, Karch, 
Jeng & Goate 2012, Bright et al. 2015) or primary cortical rodent neurons (Karch, Jeng & Goate 
2012, Pooler et al. 2013, Kanmert et al. 2015) and found that tau detected in cell medium is 
released by an unconventional secretion mechanism, but none of them used a seeded cell 
model of tau aggregation. Here, we investigated the presence of extracellular tau in conditioned 
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media from our well established cell-based model of seeded tau aggregation (Falcon et al. 
2015). HEK T-REx P301S 1N4R tau inducible cells were initially seeded with sarkosyl-insoluble 
TgP301S tau via reagent-free inoculation (to avoid any confound in characterising tau species 
present in media) in order to collect and concentrate the derived conditioned media, and 
ultimately test its ability to seed endogenous tau aggregation in naïve induced cells. We found 
that only conditioned media from seeded cells, containing AT8+ve tau, induced seeding in a 
new population of cells. Controlling for cell death is critical for the interpretation of the very low 
level of tau release that we are investigating; we measured accumulation of tau in the absence 
of increased LDH activity in the medium, ruling out unspecific release based on cell death. We 
did not apply any detergent treatment of the conditioned media, yet tau was readily detectable, 
suggesting the presence of released free-floating tau species. Our findings are in agreement 
with other groups, which have reported endogenous tau to be released free in a 
dephosphorylated full-length form (Pooler et al. 2013) or as N-terminally truncated fragments 
(Bright et al. 2015, Kanmert et al. 2015). Total tau levels measured by Alphascreen in media 
from induced, unseeded cells were higher (32 units) than in media from induced, seeded cells 
(22 units) at the same time point; the reason for this is unknown and was not observed for other 
tau epitopes measured by Alphascreen (MC1-tau, pT181-tau) and it is not attributable to tau 
release from cytotoxicity, as shown by LDH and Trypan blue assays (Figure 6.7). Since seeding 
seems to have a specific effect of reducing total tau release, but increasing AT8-positive tau 
release, further studies should be carried out to establish the specific effect of seed-competent 
species on tau release. 
 
Our data suggests that tau transfers via the extracellular medium, however we have not yet 
confirmed this by showing modulation of tau release; for instance, we have not investigated 
whether beta-amyloid or small molecules can influence the levels and forms of tau released 
from cells. Also, we collected the media at different timepoints after seeding cells with a single 
concentration of TgP301S seed; in future experiments, we could collect media at a fixed 
timepoint after seeding with a range of concentrations of TgP301S seed. An alternative 
experiment to prove that the cell-to-cell transfer depends on release of aggregates in the 
extracellular space, rather than on cell-to-cell contacts, would be to show its dependency from 
culture media volume; for instance, efficiency of SOD1 aggregates transfer between co-cultured 
cells dramatically decreased when increasing the volume of the cell culture media, thereby 
diluting the transferring species (Munch, O'Brien & Bertolotti 2011). In future studies, we would 
also need to develop orthogonal methods to identify more rigorously the tau species detected in 
media; for this, we would need high-sensitive assays, i.e. Simoa (Single Molecule Array), 
differentiating between full-length tau, mid-region-bearing fragments, and C- and N-terminal 
fragments; future experiments should also aim at collecting conditioned media from seeded 
cells and subject it to immunodepletion or immunoprecipitation with different antibodies, to 
define the molecular identity of extracellular tau.  
In summary, our cell model allowed us to measure extracellular tau species and characterise 
their ability to seed naïve cells. Importantly, the transcellular spread of tau by extracellular 
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release provides a molecular basis for tau immunotherapies targeting extracellular species. 
Further studies are needed to investigate whether secretion of misfolded tau into the 
extracellular space is a factor contributing to disease progression, whether it can be blocked by 
antibodies or small molecules, and whether tau conformation plays a role in the propagation of 
the tau lesions. Given that tau has been shown to exist in different conformational states 
(strains) with varying degrees of neurotoxicity and seeding properties, it is plausible that 
effective immunotherapy strategies will have to be conformation-specific, and possibly targeting 
multiple amyloidogenic proteins, at various levels of the disease progression. 
  
110 
 
7. DEVELOPMENT OF NEURONAL MODELS OF TAU AGGREGATION 
 
After developing a useful non-neuronal model for studying the pathogenesis of tauopathies, we 
wanted to replicate our findings in neurons, the cell type most relevant for neurodegenerative 
tauopathies. We also wanted to employ a neuronal model to be able to investigate the 
mechanisms of neuron-to-neuron propagation, and the role of synaptic transmission on tau 
propagation, which are still unanswered questions. We created a neuronal model recapitulating 
the main features of seeded tau pathology, using hippocampal neurons from TgP301S mice 
expressing 0N4R P301S tau, or rat cortical neurons expressing 1N4R P301S tau.  
 
7.1 Development of a tau aggregation model in TgP301S mouse hippocampal neurons 
Having found that TgP301S and recombinant P301S seeds can spontaneously enter non-
neuronal cells and recruit normal tau into pathological accumulations, we wanted to replicate 
this phenomenon in a cell type more relevant for tauopathies. Primary hippocampal neurons 
dissociated from P301S and C57Bl6 mouse embryos were seeded at DIV7 with sarkosyl-
insoluble tau extracted from TgP301S mice (“TgP301S seed”) or C57Bl6 mice (“WT seed”), 
containing equivalent amounts of total tau, according to 3 different seeding paradigms: seeds 
added for 3 hours, then replaced with fresh media; seeds added for 6 hours, then replaced with 
fresh media; seeds added and not removed (but cultures were half-fed at DIV11, 4 days post 
seeding). Neurons were cultured until DIV14, then fixed, stained and imaged by high-content 
imaging assay measuring tau aggregation as ratio “AT8 total intensity / Hoechst total area”. 
Addition of TgP301S seed to neurons at DIV7, without any transduction reagent, led to robust 
accumulation of AT8-phosphorylated tau that resisted Triton X-100 extraction at 7 days post-
seeding (AT8/Hoechst ratio ~10), whereas addition of WT seed did not cause significant 
increase in AT8-positive tau compared to unseeded cells (AT8/Hoechst ratio ~4) (Figure 7.1 A). 
The amount of AT8-positive tau inclusions induced in WT neurons by both TgP301S and WT 
seeds was highly limited compared to that observed in TgP301S neurons, most likely due to 
lack of overexpression of mutated tau; only when the TgP301S seed was left on and not 
removed, WT neurons showed phosphorylated tau recognized by AT8 that remained Triton X-
100-insoluble, suggesting the detection of residual seed rather than bona fide intracellular 
endogenous tau aggregates (AT8/Hoechst ratio ~2) (Figure 7.1 B).  
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Figure 7.1: Triton X-100-insoluble tau accumulation in TgP301S primary hippocampal 
neurons after incubation with TgP301S seed, but not WT seed. Neurons were 
immunostained with phospho-tau mAb AT8 with 1% Triton X-100 extraction during fixing. 
Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, 
compared to unseeded controls. (A) Hippocampal TgP301S neurons treated with TgP301S 
seed and WT seed. (B) Hippocampal WT neurons treated with TgP301S seed and WT seed. 
The values are the means ± SEM (n=2).  
 
Since our readout signal (AT8 Total intensity/Hoechst total area) will not discriminate between 
exogenously added TgP301S seed and genuine intracellular aggregates of overexpressed 
P301S tau resulting from seeding, Figure 7.2 shows the seeding assay in TgP301S neurons 
corrected for the presence of residual TgP301S seed, (by subtracting the values of AT8 Total 
intensity/Hoechst total area measured in WT neurons from the ones measured in TgP301S 
neurons in the corresponding conditions); a time-dependent and dose-dependent seeding 
pattern is clearly observed. 
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Figure 7.2: Triton X-100-insoluble tau accumulation in TgP301S primary hippocampal 
neurons after incubation with TgP301S seed is dose-and time-dependent. Hippocampal 
TgP301S neurons treated with TgP301S seed (signal corrected for the presence of residual 
seed). Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, ****p<0.0001, 
compared to unseeded controls. The values are the means ± SEM (n=2). 
 
In the same experiment, aggregates in TgP301S neurons treated with TgP301S seed, but not 
WT seed, were intensely labelled by disease-specific conformational antibody MC1, indicating 
that the aggregates acquired a pathological conformation (Figure 7.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Triton X-100-insoluble tau accumulation in TgP301S primary hippocampal 
neurons after incubation with TgP301S seed, but not WT seed. Confocal imaging showing 
punctate accumulations of Triton X-100-insoluble tau in the neurites of TgP301S neurons after 3 
h, 6 h or prolonged incubation (seed left on, half media change 4 days post-seeding) with 
TgP301S seed, but not WT seed. Neurons were immunostained with MC1 antibody 
(conformational changed tau, red) and CP27 antibody (total human tau, green) with 1% Triton 
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X-100 extraction during fixing. Scale bar 100 μm. Data shown is representative of 2 
independent experiments. 
 
Both TgP301S and WT seeds were also tested in non-Tg primary neurons for their ability to 
seed endogenous tau fibrillization without overexpressed human mutant tau; confocal imaging 
showed no tau aggregate formation upon TgP301S or WT seed treatment in non-transgenic 
neurons after 3h, 6h or prolonged incubation with seeds; both seeds demonstrated no seeding 
efficiency in this system, where only residual TgP301S seed was detected in the “seed left on” 
paradigm. Since CP27 antibody recognizes human tau only, endogenous mouse tau in C57Bl6 
neurons displayed no immunoreactivity with this antibody (Figure 7.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Confocal imaging shows no tau aggregates formation upon TgP301S or WT 
seed treatment in non-transgenic neurons. Neurons were immunostained with MC1 antibody 
(conformational changed tau, red) and CP27 antibody (total human tau, green) with 1% Triton 
X-100 extraction during fixing. Scale bar 100 μm. Data shown is representative of 2 
independent experiments. 
 
In summary, this neuronal system relies on spontaneous uptake of native forms of tau 
aggregates and potentially provides a tool for understanding the mechanisms of tau 
dysfunction. However, due to poor viability of the cultures, we decided to create a more reliable 
neuronal model using rat neurons, generally deemed more robust than mice neurons. 
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7.2 Development of a tau aggregation model in rat cortical neurons 
Primary rat cortical neurons (RCNs) overexpressing TgP301S 1N4R tau by lentiviral infection 
were treated for 24 h with TgP301S 0N4R tau seed at DIV8, and cultured until DIV15 (Figure 
7.5).  
 
 
 
 
 
 
 
 
Figure 7.5: Schematic representation of the cell-based seeded tau aggregation assay in 
rat cortical neurons. Untransfected neurons were used as a control for absence of tau 
expression. Neurons treated with buffer were used as control for absence of seeding. 
 
Biochemical analysis (western blot and Alphascreen) of sarkosyl extracts from cell lysates after 
15 days revealed that the internalized tau seed initiated accumulation of sarkosyl-insoluble, 
AT8-positive aggregates, only in neurons overexpressing human P301S 1N4R tau, and not in 
uninfected neurons (Figure 7.6); AT8-tau was measured by AT8-DA9 Alphascreen to be 0.2 
units when the highest seed concentration was used; aggregated tau was measured by MC1-
MC1 Alphascreen to be 1.5 units when the highest seed concentration was used; total human 
tau was measured by DA9-CP27 Alphascreen to be 0.1 units when the highest seed 
concentration was used. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6: Dose-dependent accumulation of tau aggregates in seeded RCNs expressing 
P301S tau. Legend on the next page. 
 
 
 
  
42 days in culture
qPCR
ICC Western blot
1 7 14 28DIV
qPCR qPCR qPCR
ICC
ICC
qPCR
Cells plated
Plate RCN at 150 k/well 
(6-well plate) 
+ AAV transduction  
at 80 k MOI 
42 days in culture
qPCR
ICC Western blot
1 7 14 28DIV
qPCR qPCR qPCR
ICC
ICC
qPCR
Cells plated
Seed for 24 h with  
TgP301S seed 
+ collect media 
42 days in culture
qPCR
ICC Western blot
1 7 14 28DIV
qPCR qPCR qPCR
ICC
ICC
qPCR
Cells plated
Harvest cells 
+ collect media 
DIV 0 DIV 8 DIV 15 
 
AS, WB  
(intracell 
tau)  
LDH, 
ELISA, 
Simoa 
(extracell 
tau) 
0
 n
g
/m
l 
- Input seed (0N4R) 
- HyperP(1N4R) 
Tau: 
TgP301S  
seed: -     -    +    +    +    +    +    + 
-     -    -     -     -     -     -     - 
6
0
 n
g
/m
l 
2
0
0
 n
g
/m
l 
0
 n
g
/m
l 
6
0
0
 n
g
/m
l 
In
p
u
t 
s
e
e
d
 
AT8 (pS202/pT205 tau) 
HT7 (total tau) 
A 
-     -    +    +    +    +    +    + 
+    +   +    +    +    +    +    + 
6
0
 n
g
/m
l 
2
0
0
 n
g
/m
l 
6
0
0
 n
g
/m
l 
- Input seed (0N4R) 
- HyperP(1N4R) 
115 
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Figure 7.6: Dose-dependent accumulation of tau aggregates in seeded RCNs expressing 
P301S tau. WB (A) and Alphascreen (B) of sarkosyl-insoluble human tau accumulation in rat 
cortical neurons virally transduced with human P301S 1N4R tau, after 24 h incubation with 
TgP301S 0N4R tau seed. Blots were probed with AT8 antibody, and human tau-specific 
antibody HT7. Statistical analysis: one-way ANOVA with Dunnett’s post hoc test. *p<0.05, 
****p<0.0001, compared to uninfected, unseeded controls. The values are the means ± SEM 
(n=2).  
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Extended seeding time was also tested; primary rat cortical neurons (RCNs) overexpressing 
TgP301S 1N4R tau by lentiviral infection were treated with TgP301S 0N4R tau seed at DIV8, 
and cultured until DIV15. Seed was not deliberately removed, but media was half-changed at 
DIV11, 3 days after seeding. Imaging analysis after 15 days revealed that the internalized tau 
seed initiated accumulation of MC1- and PG5-positive aggregates, only in neurons 
overexpressing human P301S 1N4R tau, and not in uninfected neurons or neurons expressing 
WT 1N4R tau (Figure 7.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7:  Accumulation of tau aggregates in seeded RCNs expressing P301S tau. 
Legend on the next page. 
 
 
 
GFP-P2A-Tau P301S, 
unseeded 
GFP-P2A-Tau P301S, 
TgP301S seed 
GFP-P2A-Tau WT,  
TgP301S seed 
A 
Misfolded tau (MC1)(red), total tau (CP27)(green), Hoechst (nuclei)(blue) 
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7:  Accumulation of tau aggregates in seeded RCNs expressing P301S tau. 
Confocal imaging showing tau aggregates formed upon TgP301S seed treatment in rat cortical 
neurons expressing P301S 1N4R human tau, but not WT 1N4R tau, after prolonged incubation 
with tgP01S 0N4R tau seed (seed not removed). Neurons were immunostained with (A) MC1 
antibody (conformational changed tau, red) or (B) PG5 antibody (pS409-tau, red) and CP27 
antibody (total human tau, green) with 0.1% Triton X-100 extraction during fixing. Scale bar 20 
μm. Data shown is representative of 2 independent experiments. 
 
In summary, this overexpression neuronal system relies on spontaneous uptake of native forms 
of tau aggregates; behaving similarly to the HEK T-REx P301S tau inducible cell model, it 
provides a valuable tool for understanding the mechanisms of tau dysfunction and for screening 
therapeutics for the treatment of tauopathies.   
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7.3 Discussion on neuronal cell-based assay 
After developing a useful non-neuronal model for studying the pathogenesis of tauopathies, we 
wanted to replicate our findings in neurons, the cell type most relevant for neurodegenerative 
tauopathies. We also wanted to employ a neuronal model to be able to investigate the 
mechanisms of neuron-to-neuron propagation, and the role of synaptic transmission on tau 
propagation, which are still unanswered questions. Guo and Lee (Guo, Lee 2013) demonstrated 
that synthetic tau fibrils triggered robust aggregation of otherwise soluble endogenous tau into 
NFT-like inclusions in primary neurons dissociated from embryonic hippocampus of PS19 
transgenic mice, which express human 1N4R P301S tau. We used a similar system of primary 
hippocampal neurons overexpressing human mutant tau and showed that transgenic mice-
derived exogenous aggregates time-dependently recruit endogenous tau into aggregates. 
Importantly, seed-induced tau aggregation did not occur in non-tg neurons in the absence of 
overexpression. Consistent with Guo and Lee (Guo, Lee 2013), who found that mutant tau pre-
formed fibrils resulted in dramatically more abundant pathology than wt tau pre-formed fibrils in 
PS19 neurons overexpressing mutant tau, we also found that tau aggregates only formed upon 
TgP301S seed treatment in TgP301S hippocampal neurons, and not in the other conditions, in 
the timeframe of our assay (up to 1 week post-seeding). Similarly, rat cortical neurons 
overexpressing P310S tau, but not WT tau, also showed tau aggregation upon seeding with 
TgP301S seed.  
Non-neuronal cell lines have the advantage of low cost and unlimited proliferation, allowing 
screening of large numbers of compounds, but their response to genetic modifications or drug 
treatments may be different from neurons, so the translatability from mammalian cells to 
neuronal cells is not always guaranteed. High cost and relatively long cultivation periods of 
iPSC-derived neurons preclude them from use for primary screening of tau therapeutics. On the 
other hand, our RCN neuronal model is amenable to high-throughput screening (high content 
imaging assay in 96-well format) and could serve as a more relevant biological tool to confirm 
hits from a primary aggregation inhibition assay.  
However, neuronal cultures also have their limitations, as other in vitro techniques can be a 
more reliable representation of the in vivo environment. For instance, organotypic 
hippocampal slices are explants of hippocampal tissue that can be maintained in culture for 
months, and present a more naturalistic synaptic organization than routine culture dissociated 
neurons methods. Basic advantages of slices over cultured cells is the preservation of the 3-
dimension tissue architecture, presence of multiple cell types, glial-neuronal interaction, 
synapses network connectivity and long term viability, while the in vitro nature of the slices 
enables direct control of the environment, direct access for various imaging, biochemical and 
electrophysiology assays, easy gene manipulation and precise pharmacological intervention; 
overall, slice cultures are an ex vivo model that bridges cell culture and in vivo models, and 
could offer a more accurate representation of the in vivo environment than cell cultures. 
Another limitation of our neuronal cell model is that it is characterised by tau overexpression, 
coupled to a mutation that further enhance tau fibrillization propensity (P301S). However, 
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upregulation of tau is not a cause of AD or the majority of neurodegenerative diseases in 
humans, where the disease-associated proteins are not usually up-regulated; moreover, 
tauopathies are mostly sporadic, and mutations on the tau gene (MAPT) are only present in rare 
cases of frontotemporal dementia dementia with parkinsonism associated with chromosome 17 
(FTDP-17) (Hutton et al. 1998, Rizzu et al. 1999, Goedert, Jakes 2005, Spillantini, Bird & Ghetti 
1998); recent data has shown that the heterogeneity of tauopathies can be attributed to different 
tau strains (Clavaguera et al. 2013), therefore our neuronal system is strictly applicable to 
modelling a specific form of tauopathy. In an effort to better recapitulate AD pathology, we are 
currently developing a seeded neuronal model that expresses WT tau, using non-transgenic tau 
seed derived from human AD brain. 
In summary, we created a neuronal model recapitulating the main features of seeded tau 
pathology, using a rat cortical overexpression system that relies on spontaneous uptake of 
native forms of tau aggregates; behaving similarly to the HEK T-REx P301S tau inducible cell 
model, our neuronal cell-based assay provides a valuable tool for understanding the 
mechanisms of tau dysfunction and a platform for screening therapeutics for the treatment of 
tauopathies. Further work should aim at improving existing models or establishing new cellular 
models that are physiologically and pathologically relevant, good surrogate for in vivo studies 
and also highly suitable for screening of drug candidates, to expedite the development of 
therapeutics.  
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8. DISCUSSION 
We have established a HEK T-REx cell culture model where the inducible expression of mutant 
tau, accompanied by the introduction of aggregated mutant tau extracted from transgenic 
mouse brain, leads to endogenous tau aggregation and filament assembly, suggesting a 
seeding process as a likely mechanism underlying NFT formation. We found that substantial 
aggregation of soluble tau into Triton X-100-insoluble tau can be induced by spontaneous 
uptake of mutant tau aggregates, which are internalised through an endocytic mechanism that 
is temperature-, time- and ATP-dependent, can be potentiated by transfection reagents and 
impaired by pharmacological agents inhibiting macropinocytosis, suggesting a potential 
mechanism for the propagation of tau pathology in tauopathy brains (Figure 8.1). We also found 
that seed-competent tau species are sarkosly-insoluble, tagged by AT8 and MC1 antibodies, 
and are present in conditioned media from seeded cells. Finally, we established a more 
physiologically relevant model of seeded tau aggregation in rat cortical neurons.  
 
 
 
 
 
 
 
 
 
Figure 8.1: Potential mechanisms mediating cell-to-cell transmission of tau aggregates. 
Exocytosis from a donor cell followed by endocytosis by a recipient cell is one possible route for 
tau transfer between cells. Tau aggregates can be released into the extracellular space as free-
floating seeds or via membrane-bound vesicles. Tunneling nanotubes, which have been shown 
to transport both organelles and proteins such as prions between cells, remains an unexplored 
possible mechanism for cell-to-cell transfer of tau seeds. Internalized seeds then nucleate the 
fibrillization of native monomers in the cytoplasm of the recipient cell.  
 
8.1 Discussion on seed uptake 
Macropinocytosis is the actin-driven invagination of the cell membrane to form large endocytic 
vesicles of irregular shape and size, which then travel into the cytosol and fuse with endosomes 
and lysosomes. Macropinosomes are large vesicles characterised by a diameter of up to 2.5 µm 
(Khalil et al. 2006). In our HEK Trex P301S tau inducible cells, seed uptake occurs via 
macropinocytosis, the prevalent mechanisms reported for tau uptake. In our recent publication 
(Falcon et al. 2015) we also showed that native TgP301S tau aggregates enter cells through the 
same mechanism as recombinant P301S tau aggregates, consistent with macropinocytosis. 
Therefore, like SOD1 aggregates (Munch, O'Brien & Bertolotti 2011), PrP
sc
 (Magalhaes et al. 
2005) several viruses (Mercer, Helenius 2009), recombinant tau (Holmes et al. 2013., Frost, 
Jacks & Diamond 2009, Falcon et al. 2015) and perhaps other prion-like aggregates, we have 
observed that native TgP301S tau aggregates can hijack macropinocytosis to penetrate into the 
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cytosol of host cells. This implies that tau aggregates released from neurons or from “ghost 
tangles” are possibly using this mechanism to access neighbouring healthy neurons and trigger 
fibrillization of soluble tau in tauopathy brains. Internalised seeds may escape from 
macropinosomes by disrupting the vesicle membrane, and seed aggregation in the cytosol; this 
is plausible, since tau oligomers have been shown to cause destabilisation of the lipid bilayer of 
membranes (Flach et al. 2012); moreover, macropinosomes have been reported to be relatively 
“leaky” and lacking physical structure compared to other endosomes (Holmes et al. 2013., Flach 
et al. 2012, Conner, Schmid 2003) and a number of bacteria and viruses have been reported to 
exit macropinosomes and reach the cytosol (Conner, Schmid 2003), as well as SOD1 
aggregates (Zeineddine et al. 2015). Aggresomes, stress-induced perinuclear inclusion bodies 
that form in response to the presence of a high load of abnormal cytosolic protein (Johnston, 
Ward & Kopito 1998), have also been proposed to be the site of seeded aggregation in the 
cytosol. Santa-Maria et al. demonstrated that mammalian cells internalize AD patient-derived 
paired helical filaments (PHFs) by an endocytic mechanism, and the induced tau aggregates  
co-localized with the aggresome markers γ-tubulin and vimentin, supporting the idea that 
endocytosed tau fibrils can exit the vesicular lumen to access the cytosol and seed aggregation 
of cytosolic tau monomer (Santa-Maria et al. 2012). One way to show the release of internalised 
seeds from macropinosomes would be to test whether the internalized aggregates are 
ubiquitinated; looking at different time points after inoculation, labelling the internalised seeds 
with a polyubiquitin antibody would suggest a cytosolic location. 
 
In our analysis in HEK Trex P301S tau inducible cells, both monomeric and aggregated tau 
enter cells by a mechanism consistent with macropinocytosis with equal efficiency, however 
monomeric tau lacks seeding ability (Falcon et al. 2015).  However, this finding may be cell-
specific, since it has been reported that, unlike oligomers and short fibrils, soluble monomeric 
tau was not internalised in HeLa cells and mouse primary neurons (Wu et al. 2013).  
Neurons express cell surface receptor complexes that have been shown to facilitate binding of 
viruses and activation of macropinocytosis: heparan sulfate proteoglycans (HSPGs), RAGE, 
CD36, integrins and receptor tyrosine kinases such as EphA2 and EphA4 (Yerbury 2016); 
heparan sulphate proteoglycans allow heparin-induced recombinant tau fibrils in neural cell 
lines and primary neurons alike (Holmes et al. 2013.). If macropinocytosis is to become a 
therapeutic target, it will be important to further characterise the neuron-specific machinery of 
cell surface proteins that are responsible for the binding and uptake of tau seeds, and avoid 
general blocking of all macropinocytosis in the brain, including microglial and astrocytic 
macropinocytosis. Calafate et al. developed a cell-to-neuron co-culture model where tau 
pathology propagates from clonal HEK293 donor cells to hippocampal neuron acceptor cells. To 
create this system, a polyclonal HEK293 cell line inducibly expressing  GFP-tagged human 
mutant 2N4R P301L tau (‘‘clone 1’’) was treated with recombinant preformed synthetic HA-
K18P301L fibrils (Guo, Lee 2011); sub-clones were isolated and assessed for the ability to 
stably produce tau aggregates throughout cellular generations, without addition of exogenous 
pre-formed fibrils; ‘‘clone 2’’ was chosen for its robustness in constitutively showing AT8-positive 
tau aggregates; finally, “clone 2” cells were co-cultured with hippocampal neurons (DIV7) 
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expressing human mutant P301L 2N4R Tau, not GFP-tagged. In this model, they showed that 
non-synaptic mechanisms were mediating baseline propagation, in absence of synaptic 
contacts; when synaptic contacts between donor and acceptor cells were induced by 
expression of synaptogenic adhesion proteins, propagation was enhanced above the baseline 
conditions, showing that both synaptic and non-synaptic mechanisms may contribute to tau 
pathology spreading. Their cell-to-neuron model presents the advantage of not requiring 
addition of exogenous tau seeds and allows screening for pre- and post-synaptic agents that 
may be involved in tau propagation, such as adhesion molecules, membrane receptors, and 
other synaptic machinery proteins. Synapses seem to be actively participating in cell-to-cell tau 
transmission, but tau has also been identified as causal factor in synaptic loss in AD, where 
synaptic degeneration correlated with cognitive decline (Selkoe 2002, Spires-Jones, Hyman 
2014, Lu et al. 2013, Serrano-Pozo et al. 2011); more studies are needed to shed light on the 
link between these two processes, and determine whether synaptic rescue therapies will 
ultimately be beneficial or detrimental (Calafate et al. 2015). Blocking tau uptake via 
immunotherapy has been proved promising in animal models, but still to be determined is 
whether any receptors contribute to tau transmission, whether any cofactors facilitate tau 
uptake, and whether different uptake mechanisms apply to different neuron populations. 
Recently, McEwan et al.  (McEwan et al. 2017) published a study that unveils a possible 
mechanism of action of tau therapeutic antibodies, involving Tripartite motif protein 21 
(TRIM21), a cytoplasmic receptor that recognizes the Fc region of antibodies, binds to antibody-
coated pathogens internalised by cells, and promotes their degradation by the proteasome and 
the unfoldase valosin-containing protein (VCP). They found that after cultured neurons took up 
tau aggregates complexed with anti-tau antibodies, the complexes bound to TRIM21, which 
acts as a tag for the proteasome degradation pathway. Of course this may be just one of 
multiple mechanisms of protein clearance by tau immunotherapies, i.e. blocking tau uptake, and 
the mechanism of action may be antibody-dependent; also, TRIM21 expression is higher in 
microglia and astrocytes, therefore the TRIM21 clearance pathway may be exploited by glial 
cells more than neurons; further research should investigate the role of TRIM21 in vivo, and 
whether the TRIM21-dependent immune response may work towards clearance of other protein 
aggregates like huntingtin and α-synuclein. 
 
8.2 Discussion on nanotubes  
It has been shown that tunnelling nanotubes can form between neuronal cells and prions 
appear to traffic through these structures between infected and non-infected cells (Gousset, 
Zurzolo 2009); in our HEK cell co-culture model, we used latrunculin A to verify whether 
nanotubes could allow cell-to-cell propagation of tau aggregates. The extent of the effect we 
observed suggests that disrupting the actin cytoskeleton with latrunculin A may have an impact 
not necessarily only on nanotubes, but possibly on other actin-dependent mechanisms of tau 
release and uptake, therefore further experiments should focus on dissecting these 
mechanisms and study the effect of latrunculin A on tau extracellular concentration, in co-
culture media. Other compounds with an opposite effect to latrunculin A could be used to 
observe modulation of the actin cytoskeleton: several actin polymerising agents (phalloidin, 
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jasplakinolide, cytochalasin) are available and have been used in cell models to study the actin-
dependent exocytosis of lytic granues by cytotoxic T lymphocytes (Lyubchenko, Georjeana & 
Zweifacht 2003). A recent paper similarly showed that TNTs may be involved in the prion-like 
propagation of tau assemblies, and tau facilitates their formation (Tardivel et al. 2016). In two 
different cellular models (CAD neuronal cells and rat primary embryonic cortical neurons), 
exogenous recombinant tau species (both monomers and fibrils) induced formation of TNTs, 
which subsequently facilitated the intercellular spread of pathological tau fibrils. Their data also 
suggests that tau might be transported into TNTs via actin, as tau progressively induced 
formation of long and thick F-actin structures, which were absent in absence of tau. Several in 
vitro models have implicated TNTs in the transport of many pathological proteins and pathogens 
(Rustom et al. 2004), however to date there have been no reports of TNTs in tauopathy brains, 
and only two reports of TNTs in vivo: in an animal model (for myeloid cells in corneas of wild 
type and transgenic mice)  (Chinnery, Pearlman & McMenamin 2008), and in humans (for 
human mesothelioma cells) (Lou et al. 2012), therefore the relevance of this tau transmission 
mechanism in vivo remains to be confirmed. 
 
8.3 Discussion on seeding properties 
In our recent publication (Falcon et al. 2015) we used our cell-based assay to compare the 
seeding activity of sarkosyl-insoluble TgP301S tau with P301S recombinant tau. We observed 
that, similarly to synthetic prions (Kim et al. 2010, Tanaka et al. 2006, Legname et al. 2006, 
Legname et al. 2005), α-synuclein aggregates (Luk et al. 2012) and A assemblies (Meyer-
Luehmann et al. 2006a, Stöhr et al. 2012), synthetic tau aggregates had a greatly reduced 
seeding activity compared to sarkosyl-insoluble tau from TgP301S tau mouse brain; importantly, 
in our inducible cell assay, synthetic tau aggregates seeded by aggregated TgP301S tau in the 
absence of heparin acquired the seeding potency of brain-derived TgP301S tau seeds. In 
agreement with our findings, Guo et al. (Guo et al. 2016) established a mouse model of 
sporadic tauopathies and found that intracerebral inoculation of tau fibrils purified from AD 
brains, but not synthetic tau fibrils, resulted in the formation of abundant tau inclusions in 
anatomically connected brain regions in nontransgenic mice. Parallel with our findings, they 
found that human brain–derived tau fibrils are superior to synthetic tau fibrils in seeding 
physiological levels of WT tau in vivo (Guo et al. 2016). Recombinant human tau seeded by AD-
tau produced unique conformational features, distinct from synthetic tau fibrils, which could 
underlie the differential potency in seeding physiological levels of tau to aggregate. Other 
disease-associated proteins, including prion, Aβ, and α-syn, similarly show different potency 
between synthetic- and brain-derived protein aggregates (Guo et al. 2016). The reasons for this 
phenomen could be: 
a) The effect of post-translational modifications that are found in vivo but are absent in 
recombinant tau. Although we and others (Guo et al. 2016) showed that 
phosphorylation of tau does not contribute to its seeding efficiency, the effect of other 
post-translational modifications such acetylation, glycosylation, ubiquitination, glycation, 
prolyl-isomerization, polyamination, oxidation, nitration, and sumoylation should be 
explored in future studies. 
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b) The pathogenic tau strains produced in vivo in human brain may be the result of 
selection processes that cannot be recreated in vitro; tau conformers that are kinetically 
favoured, more resistant to degradation, and more readily transmitted than other 
conformers are more likely to be created in diseased brain, and not during in vitro 
fibrillization. Similarly, the complexity of the cellular environment and the presence of 
particular cofactors may generate particular pathogenic tau strains in the diseased brain 
that cannot be created in vitro (Guo et al. 2016). 
c) Heparin is widely used as inducer of tau fibrillization in vitro, but was also shown to 
interfere with propagation of the AD-tau conformation (Morozova et al. 2013). 
d) Synthetic aggregates are usually produced from a single isoform of tau, whereas brain-
derived aggregates will typically contain a mixture of isoforms, whose interaction may 
result in conformations not observed in vitro. 
In summary, using both recombinant and native tau aggregates, we provided evidence that 
despite being taken up by cells to the same degree, native tau aggregates have a higher 
seeding potency than recombinant tau aggregates; the latter though can acquire the 
conformation and seeding potency of the former by seeded assembly, demonstrating that 
conformation and not phosphorylation determines the seeding potency of tau aggregates. Our 
work supports the idea that distinct conformers of assembled tau exist, reminiscent of prion 
strains; their heterogeneity may explain the variety of human tauopathies, including genetic 
tauopathies like FTDP-17T, where different MAPT mutations produce different filament 
morphologies (Crowther, Goedert 2000) and the selective neuronal vulnerability of different 
tauopathies, with different aberrant conformers initiating disease processes in different brain 
cells, from where they spread to connected regions (Goedert 2015).  
 
In future experiments, the comparison between native and recombinant seeds could be 
expanded to include brain extracts from different human tauopathies to characterise their 
seeding properties, possibly using antibodies and structural biology techniques to determine 
structures and conformational epitopes specific to individual diseases, and confirm the 
hypothesis that conformationally distinct tau strains might be associated with individual 
tauopathies (Clavaguera et al. 2013, Frost, Diamond 2010). Indeed a study found that 
inoculation of transgenic human tau mice with brain homogenates from patients with different 
tauopathies recapitulates certain pathological features of the diseases (Clavaguera et al. 2013); 
similarly, another group isolated a number of tau clones from HEK293 cells, injected into 
TgP301S (PS19) mouse brains and observed strain-specific patterns of tau pathology (Kaufman 
et al. 2016); this understanding could help facilitate therapeutic strategies tailored towards the 
underlying protein pathology. Similarly, at ADPD 2017 conference, J. Steen from Harvard 
Medical School, Boston, USA presented data from a mass spectroscopy-based technique 
called FLEXITau; while previously the authors applied this technique  to map tau post-
translational modifications (PTMs) in AD brain (Mair et al. 2016), more recently FLEXITau 
enabled the comprehensive, unbiased, robust and highly sensitive identification and 
quantification of tau PTMs in 4 different tauopathies; analyzing 129 postmortem brain samples 
from AD, PSP, CBD, PiD, and aged-matched controls, they discovered and quantified 74 PTMs, 
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over 60% of which have not previously been described in human tau; they found that each 
disease had its own distinctive pattern of tau PTMs (phosphorylation, acetylation, ubiquitination, 
and fragmentation); combining the FLEXITau signatures with computational analysis, they 
developed a classifier for tauopathies that correctly identified disease type with an accuracy of 
94% for AD, 96% for CBD, 92% for PiD and 82% for PSP samples. The technique holds 
promise for a number of applications, including patient stratification, identification of therapeutic 
epitopes that should be targeted in each disease  (the authors are currently generating disease-
specific antibodies in collaboration with P. Davies, Manhasset, NY), screening of small 
compounds, and in vivo diagnostic biomarker for tau derived from peripheral fluids.  
 
In additional experiments, recombinant P301S tau seeded with TgP301S tau could 
subsequently be used to seed a new generation of P301S recombinant tau, and the process 
could carry on along a number of generations, to see whether the conformation acquired by 
recombinant tau is stable and is maintained along several seeding generations. Tau post-
translational modifications like cleavage, acetylation and O-GlcNac-ilation could be explored as 
potential factors that affect tau seeding potency. It will also be important to thoroughly 
characterise the seed-competent tau conformation using stability assays, conformational 
antibodies and small molecules, with a view to developing diagnostic tests and therapies. A 
similar potency comparison between transgenic and recombinant seeds could also be carried 
out for other known amylodogenic proteins, i.e. a-synuclein. 
 
8.4 Discussion on seed competent species 
Our findings indicate that a range of filamentous tau aggregates are the major species that 
underlie the spreading of tau pathology in the P301S transgenic model (Jackson et al. 2016). A 
recent paper reported that a tau trimer was the minimal particle size that could seed intracellular 
tau aggregation (Mirbaha et al. 2015), whereas our data shows that such small (low-n) 
oligomeric tau assemblies in brain extracts from TgP301S mice are not seed competent; it is 
important to note that Mirbaha et al. used different techniques and different brain material: they 
separated tau protein from one AD and one age-matched control brain using size-exclusion 
chromatography; their seeding assay in biosensor cells measures dimerization of tau repeats 
(K18) with the P301S mutation, rather than aggregation of full-length tau (Holmes et al. 2014); 
they did not confirm tau seeding and propagation in an in vivo model; consistent with our 
findings, they observed more efficient seeding of intracellular tau with assemblies larger than 
trimers, suggesting that although trimers can propagate, only larger tau species may have the 
structural complexity to produce bona fide tau strains, and it is possible that trimers have to 
convert to larger assemblies before being able to seed aggregation in cells. Another publication 
(Wu et al. 2013)  showed that low molecular weight tau assemblies (~10–40 nm, consistent with 
dimers and trimers) and short tau filaments (~40–250 nm) were taken up by primary neurons 
from the extracellular space and transported through axonal terminals; however the authors 
only examined the internalisation of these tau assemblies and not their seeding ability. It is clear 
that many factors such as tau mutations, tau isoforms, seed preparation (i.e. sonication of 
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seeds), source of seeds, can influence the ability of tau to conformationally template; a lack of 
standardization of techniques and materials is a possible explanation for differences in seeding 
efficiency observed between different studies. 
 
Our immunodepletion experiments support the idea that antibody-mediated removal of 
pathological forms of tau may block propagation. Various tau antibodies directed against distinct 
epitopes have been tested in vitro and in vivo, including N-terminal antibodies (Yanamandra et 
al. 2013a, Umeda et al. 2015), phospho-specific antibodies, (Collin et al. 2014, Chai et al. 2011, 
D'Abramo, Acker & Davies 2011, Sankaranarayanan et al. 2015, Boutajangout et al. 2011, 
Castillo et al. 2012) and conformation-dependent antibodies. (Chai et al. 2011, Castillo et al. 
2012). Despite some promising results in tau-transgenic mice that showed improvement of 
cognitive impairments and tau neuropathology, determining which antibody / epitope can most 
efficiently and selectively remove tau species involved in AD pathogenesis is still in progress. 
Recently, Nobuhara et al. tested the effects of a panel of tau antibodies on neuronal uptake and 
aggregation in vitro, to identify the best target epitopes (Nobuhara et al. 2017). 
Immunodepletion was performed on brain extract from aged Tg4510 mice and postmortem AD 
brain which were added to a cell-based FRET assay (Holmes et al. 2014). Similar to our results, 
they found that antibodies reduced tau uptake to different extents: a C-terminal tau antibody had 
little effect, whereas N-terminal and mid-domain antibodies successfully prevented uptake of tau 
species, with the most efficient also blocking neuron-to-neuron spreading of tau in a three-
chamber microfluidic device, even after uptake had begun. They found that phosphorylation-
dependent antibodies 40E8 (pS202/pT205-tau) and p396 (pS396-tau)) also reduced tau uptake 
despite removing less total tau by immunodepletion, suggesting that most of the tau taken up by 
neurons is phosphorylated at these three sites. Despite low immunoprecipitation efficiency, 
40E8 and p396 reduced neuronal uptake of Tg4510 extract by 40% and 80% respectively, and 
neuronal uptake of AD extract by 65% and 53% respectively, suggesting that the blocking 
efficiency is relative to the extract used. Even though we used antibodies against the same 
epitopes (AT8 for pS202/pT205-tau and PHF1 for pS396-tau), substantial differences in the 
materials and assays used preclude a direct comparison with our data. Taken together, our and 
their results imply that the efficacy of antibodies in blocking uptake and seeding of tau derived 
from tau-transgenic mouse and the human AD brain is epitope-dependent. Moreover, the 
blocking efficiency of certain antibodies may be dependent on the distinct pool of pathological 
forms of tau present in each individual diseased brain, which renders tau immunotherapy 
approaches particularly challenging. 
 
8.5 Discussion on extracellular tau 
The transynaptic pathway has been implicated in the spreading of tau pathology from neuron to 
neuron (de Calignon et al. 2012, Liu et al. 2012, Gomez-Ramos et al. 2008), but (Maphis et al. 
2015) showed that reactive microglia drives tau pathology in a cell-autonomous manner in tau 
transgenic mice, suggesting that glial cells could also have a role in tau spreading; the authors 
created a mouse model of tauopathy (hTauCx3cr1-/-mice) where deficiency of the microglial 
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fractalkine receptor (CX3CR1) caused elevated microglia activation, acceleration of tau 
pathology and memory impairment (Bhaskar et al. 2010); in an age-based study in 2-, 6-, 12- 
and 24-month old hTauCx3cr1-/- mice, they observed a spatio-temporal correlation between 
CD45+ microglial activation and  spread of tau pathology in anatomically connected regions of 
the hippocampus; purified microglia from hTauCx3cr1-/- mice brain induced tau 
hyperphosphorylation and a pre-tangle phenotype when inoculated in the brains of non-
transgenic mice; all together, the data suggests that reactive microglia drives tau pathology and 
correlate with its spread in a transgenic mouse model. Tau has also been shown to be 
internalized by glial cells in vitro and in vivo and to colocalise with microglia in postmortem AD 
brains (Bolos et al. 2015); also, depletion of microglia dramatically suppresses tau propagation 
from the entorhinal cortex to the dentate gyrus in a mouse model (Asai et al. 2015); in particular, 
inhibition of exosome synthesis reduces tau propagation, highlighting secretion of exosomes as 
a mechanism by which microglia spread tau, and suggesting microglia as a potential therapeutic 
target to enhance clearance of extracellular tau in neurodegenerative diseases. 
 
The presence of tau and α-synuclein in human cerebrospinal fluid has been reported (Tapiola et 
al. 2009, Mollenhauer et al. 2013, van Dijk et al. 2014), and thanks to microdialysis techniques, 
measurable levels of tau and α-synuclein were found in the interstitial fluid of healthy mice, 
suggesting a constitutive efflux from healthy neurons (Emmanouilidou et al. 2011); the release 
of tau monomer in particular is increased by neuronal activity (Pooler et al. 2013, Yamada et al. 
2014). A recent publication (Wu et al. 2016) used optogenetic and chemogenetic approaches to 
show that increased neuronal activity stimulates the release of tau in vitro and enhances tau 
pathology in vivo; in particular, human iPSC neurons, primary mouse neurons expressing 
endogenous tau and neurons overexpressing mutant hTau (rTg4510 line) were stimulated with 
picrotoxin, a noncompetitive channel blocker for the GABA receptor chloride channels, which 
increased tau in the media by 150–210%, without causing cell death; since amyloid β is known 
to cause neuron excitability, this data could explain how amyloid pathology catalyzes tau 
propagation. Also (Croft et al. 2017) investigated tau release from organotypic brain slice 
cultures prepared from wild-type and 3xTg-AD mice (Oddo et al. 2003a, Oddo et al. 2003b): 
stimulation of neuronal activity with KCl increased tau release from wild-type slices, whereas tau 
release from 3xTg-AD slices could not be further stimulated with KCl, possibly due to saturation 
of synaptic activity caused by overexpression and changes in the subcellular distribution of tau 
in this model; future experiments should aim at determining whether tau released from 3xTg-AD 
slices is aberrantly phosphorylated, cleaved, vescicle-associated or free-floating, compared to 
tau from wild-type slices, and to be relevant for AD and the majority of human tauopathies these 
findings should be replicated in a mouse model that expresses wild-type human tau rather than 
P301L FTDP-tau. 
 
Exosomes have been implicated in the propagation of PrPSc (Vella et al. 2007), and non-fibrillar 
(monomeric or oligomeric) α-synuclein and tau have also been shown to be secreted into the 
cell culture medium by exosomes  (Simon et al. 2012, Emmanouilidou et al. 2010, Danzer et al. 
2012, Saman et al. 2012, Wang et al. 2017) but others found no evidence for tau in exosomes 
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(Karch, Jeng & Goate 2012), with one study showing that an antibody against tau repeat 
domain (RD) affected tau intercellular propagation in HEK293 cells transfected with tau 
RD(ΔK280), with no effect on intracellular aggregation of tau, suggesting that tau aggregates 
are not encapsulated into a membrane when released into the extracellular space (Kfoury et al. 
2012) and can be trapped outside the cells by an antibody. Ectosomes, plasma membrane-
derived vesicles, have been shown to account for a small proportion of endogenous tau 
released under basal conditions  (Dujardin et al. 2014), but in cell models where tau was 
exogenously expressed or in a highly phosphorylated misfolded state, a small proportion of 
released tau was associated with MVB-derived vesicles, the exosomes (Plouffe et al. 2012, 
Simon et al. 2012, Saman et al. 2012). Discrepancies in findings from different groups raise 
several questions about a universal mechanism of tau release; within a complex biological 
system, the release of tau protein may be a combination of each of the possible release 
mechanisms, which makes tau release a difficult therapeutic target; most likely physiological 
species of soluble tau are released from healthy neurons via a distinct mechanism from 
pathological tau, since studies in models of tau overexpression tend to claim vesicular release 
of tau, whereas at physiological tau expression levels, non-vesicular release is mostly observed; 
therefore, the effect of tau overexpression in in vitro systems should be taken into account, as it 
will affect the localisation and post-translational modifications of tau, and consequently its 
release. Also, the impact of disease-relevant tau mutations on tau release needs investigating, 
as conflicting findings have been reported: in vitro, expression of P301S tau in human 
neuroblastoma cells decreases tau release (Karch, Jeng & Goate 2012), whereas in vivo, mice 
expressing human P301S tau show 5-fold higher tau levels in the brain and in interstitial fluid 
compared with wild-type littermates (Yamada et al. 2011). Overall, findings from different groups 
suggest that different mechanisms may govern the release of functionally distinct pools of tau: 
in the healthy brain, physiological tau may contribute to neuronal signalling, whereas 
pathological tau may drive spread of pathology and disease progression within diseased brain. 
Blocking tau release as therapeutic target poses the challenge of selectively targeting abnormal 
tau release, and since it may be beneficial for the cell to reduce the intracellular tau burden, its 
blockade could even be detrimental.  
 
While the intracellular role of tau in microtubule stabilization and axonal transport is well 
established, the role of extracellular tau is still being elucidated. Since tau pathology in AD and 
other tauopathies propagates following a stereotypically defined pattern, it could be mediated by 
the spreading of tau seeds from cell to cell. Studies in cell culture models have shown 
intercellular transfer of tau (Guo, Lee 2014, Holmes et al. 2013., Guo, Lee 2011, Frost, Jacks & 
Diamond 2009, Kfoury et al. 2012, Wu et al. 2013, Santa-Maria et al. 2012), and numerous 
groups replicated these findings for α-synuclein (Desplats et al. 2009, Hansen C et al. 2011, 
Freundt et al. 2012, Lee et al. 2010, Luk et al. 2009, Volpicelli-Daley et al. 2011), SOD1 
(Munch, O'Brien & Bertolotti 2011), huntingtin (Ren et al. 2009) and TDP-43 (Furukawa Y et al. 
2011). Further studies are needed to investigate whether secretion of misfolded tau into the 
extracellular space is a factor contributing to disease progression, and whether tau 
conformation plays a role in the propagation of the tau lesions. We are currently looking at the 
129 
 
effect of the ionophore ionomycin on tau levels in media from RCN overexpressing TgP301S 
0N4R tau. We are planning to collect conditioned media from seeded HEK P301S tau inducible 
cells or RCNs and test its ability to produce aggregation in a new population of RCNs. 
Exosomal fractions could be extracted according to published protocols (Saman et al. 2012) 
from our cell models of tau aggregation and probed for tau. Another open question in the field is 
whether synaptic activity plays a role in transcellular propagation of tau; using microfluidic 
chambers, (Calafate et al. 2015) demonstrated that blocking either synaptic connectivity or 
synaptic activity blocked tau aggregation in the downstream chamber, supporting a trans-
synaptic pathway for conveying tau between cells. We will use our RCNs neuronal model in 
microfluidic chambers to create two fluidically isolated microenvironments and allow delivery of 
exogenous seeds to one cell population, without them crossing over to the other cell population, 
hence avoiding the confound of detecting residual seeds in the conditioned media. Moreover, 
with a view of studying the mechanisms of tau transfer, our lab has generated and optimized a 
co-culture HEK cell system that robustly develops intracellular tau aggregates following addition 
of exogenous mutant tau and provides mechanistic insights into NFT pathogenesis and 
propagation (Cavallini et al. 2014.). 
 
8.6 Discussion on neuronal model of tau aggregation 
Consistent with Guo and Lee (Guo, Lee 2013), who found that mutant tau pre-formed fibrils 
resulted in dramatically more abundant pathology than wt tau pre-formed fibrils in PS19 neurons 
overexpressing mutant tau, we also found that tau aggregates only formed upon TgP301S seed 
treatment in TgP301S hippocampal neurons, and not in the other conditions, in the timeframe of 
our assay (up to 1 week post-seeding). Similarly, rat cortical neurons overexpressing P310S 
tau, but not WT tau, also showed tau aggregation upon seeding with TgP301S seed. The 
causes of the asymmetrical seeding observed, which has also been reported in non-neuronal 
models (Clavaguera et al. 2014.), are likely to be due to conformational and isoform disparities 
between WT and mutant tau. Similarly, P301L tau seeds promoted fibrillization of P301L tau but 
not WT tau, whereas R406W tau seeds supported fibrillization of both R406W and WT tau, as 
did WT tau seeds, as measured by electron microscopy in an in vitro aggregation system of 
recombinant tau in the presence of heparin (Aoyagi, Hasegawa & Tamaoka 2007). The 
substructures of these seeds were shown to be different by proteolytic analysis; these results 
correlate with the patterns of tau depositions in FTDP-17 brains with these mutations: only 
P301L mutant tau is deposited in FTDP-17 with P301L mutation, whereas both WT and R406W 
tau are deposited in FTDP-17 with R406W mutation. A seeding barrier between 3R- and 4R-tau 
has been reported (Dinkel et al. 2011): in developing non-transgenic neurons the predominantly 
expressed isoform is 3R-tau, which has lower propensity to aggregate than 4R-tau (Dotti, 
Banker & Binder 1987, Ferreira et al. 1997, Zhong et al. 2012), and it is not efficiently recruited 
by the seed-derived 4R-tau. Similarly, a seeding barrier has been previously reported for prion 
disorders, for which incubation times and infectivity depend on the correspondence between the 
amino acid sequence, and consequently the conformation, of the infectious prion and that of the 
host prion protein (Scott et al. 1993). More studies are needed to determine the effect of tau 
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isoforms and tau mutations on seeding efficiency, and whether these seed barriers observed 
could explain the diversity of human tauopathies.  
We know in AD misfolded, hyperphosphorylated tau first accumulates in the locus coeruleus, 
from where it appears to spread to entorhinal cortex, hippocampus and neocortex. This 
differential distribution underlies the Braak stages of tau pathology (Braak, Braak 1991, Braak, 
Del Tredici 2011b). Stereotypical temporospatial spreading of tau pathology has also been 
described in argyrophilic grain disease (AGD) (Saito et al. 2004). Transmission and spreading 
of tau pathology can be shown experimentally (Goedert, Clavaguera & Tolnay 2010). Thus, 
brain extracts from mice transgenic for human mutant P301S tau with abundant silver-positive 
tau  inclusions, when injected into the brains of ALZ17 mice expressing human wild-type tau 
(lacking tau inclusions), induced the slow assembly of wild-type tau into silver-positive 
inclusions.  Moreover this tau pathology was observed to spread to neighbouring brain regions 
(Clavaguera et al. 2009). Aggregated recombinant tau was also sufficient to convert soluble tau 
into aggregates (Clavaguera et al. 2013, Iba et al. 2013). As previously stated, infusion of 
TgP301S tau extracts from the hindbrain of symptomatic mice into the hippocampus and 
overlying cerebral cortex of non-symptomatic mice transgenic for human P301S tau, induced 
the formation of tau inclusions in the hippocampus, which spread rapidly (2-4 weeks) to 
synaptically connected brain regions (Ahmed et al. 2014), which suggests that tau—or a 
particular species of tau, such as hyperphosphorylated tau, misfolded tau, or a fragment of 
tau—may have been released at the synapses. The induction and spreading of tau pathology 
through synapses has also been demonstrated following the restricted expression of human 
mutant tau in transgenic mice (de Calignon et al. 2012, Liu et al. 2012) and in cultured 
hippocampal neurons expressing human mutant tau (Calafate et al. 2015). If human tau protein 
propagates to synaptically connected brain regions, an in vitro neuronal model would allow us to 
investigate whether a neuronal tau receptor or a surface protein allows tau release and 
internalisation, and whether this processes can be modulated. Pharmacological, enzymatic, and 
genetic manipulations have already been used to implicate heparan sulphate proteoglycans 
(HSPGs) as key receptors for recombinant full-length and repeat domain tau fibrils in neural cell 
lines and primary neurons alike (Holmes et al. 2013.).  
 
As well as confirming the above findings in our own neuronal model, we could also explore the 
colocalization of tau and synaptic markers by immunofluorescence (synapsin1, marker of 
synaptic vesicles (de Calignon et al. 2012), postsynaptic density protein 95 (PSD95), 
postsynaptic marker (de Calignon et al. 2012) and see whether modulation of synaptic 
transmission affects tau propagation in a neuronal model (Calafate et al. 2015). Tau presence 
at the synapses could be due to tau missorting from the axonal (physiological) to the 
somatodendritic compartment, where it correlates with loss of microtubules and reduced spine 
number (Zempel et al. 2013); a microtubule polymerisation assay developed in our laboratory 
could then be employed to monitor microtubule stability.  
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A neuronal model is also the best experimental setting to pinpoint the tau species responsible 
for seeding, i.e. by seeding with transgenic mouse or human brain homogenates subjected to 
immunodepletion with tau antibodies or sucrose gradient fractionation. A recent paper 
(Varghese et al. 2016) compared the effect of extracellular PHFs on tau aggregation in mitotic 
cell cultures and post-mitotic neurons, observing aggresome-type tau depositions and impaired 
proteasome degradation in mitotic cells, but not in neuronal cells. It is possible that independent 
mechanisms of propagation of tau pathology also act in our mammalian and neuronal models, 
so we could investigate the role of the ubiquitin-proteasome system and autophagy in both 
models. Their findings also highlight the fact that propagation of tau pathology may follow 
independent mechanisms in mitotic cells such as astrocytes vs post-mitotic cells such as 
neurons. 
 
8.7 Future development of aggregation assays for screening 
Both our mammalian and neuronal cell-based assays could also be part of a drug discovery 
flowscheme. In a target-based approach, they could be used as secondary assays to confirm 
actives from a primary screen. For instance, an in vitro tau fibrillization assay, typically 
monitored by thioflavine T fluorescence, could be used first to interrogate a compound library by 
high throughput screening (HTS). Active compounds meeting the criteria set for selection in the 
HTS could be confirmed in our HEK Trex P301S tau inducible cell-based assay using TgP301S 
seed, deemed more potent than recombinant P301S seed. Alternatively, the HEK Trex P301S 
tau inducible cell-based assay could be used as primary assay for a phenotypic screen to 
identify compounds that affect relevant mechanisms such as tau uptake or tau degradation. In 
both target-based and phenotypic screening strategies, selected potent compounds could then 
be further evaluated in our RCN overexpression cell-based assay, ultimately leading to hit 
declaration. Both the HEK Trex and RCN cell-based assays would require prior optimisation 
and validation; a number of variables should be optimized with regards to SD window, z-factor, 
%CV and effect of tool molecules, until the validation requirements are met: 
- Optimal tau expression (tetracycline dose-response) 
- Optimal seed concentration (seed dose-response) 
- Optimal cell density 
- Optimal detection antibodies (i.e. PG5 vs AT8) 
- Optimal nuclear dyes (i.e. Hoechst vs propidium iodide) 
- Optimal assay volume (i.e. 50 μl/well vs 100 μl/well) 
- Optimal equipment for automation and detection 
- Optimal cell fixatives (i.e. formaldehyde vs Prefer) 
- Time course 
- Effect of trypsinisation 
The validation will assess plate uniformity and result reliability (test-retest) and profile a number 
of tool molecules. Both assays would likely be run in a 96-well plate format with an imaging 
readout for the highest throughput, but selected compounds could also be investigated by 
biochemical assay, to demonstrate the reduction of sarkosyl-insoluble tau. 
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9. CONCLUSIONS 
We sought to establish cellular systems with a significant number of NFT-like aggregates to 
allow investigation of the pathological mechanisms of tau tangle formation as well as tau 
intercellular transmission. In particular, we used our systems to investigate some of the 
unresolved questions in the field, in particular what mechanisms allow tau uptake and release, 
and what factors influence seeding efficiency.   
In summary, we have developed new models of tau aggregation and propagation which not only 
are important tools to gain mechanistic insights into the pathogenesis of tau aggregation, but 
also offer a robust system for identifying therapeutic strategies to prevent propagation and 
spreading of tau pathology.  
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